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Abstract
PTEN, a dual protein and lipid phosphatase, regulates a myriad of cellular functions including PI3K
pathway signaling, cell migration, proliferation, invasion and apoptosis. PTEN mutations often lead to
multiple malignancies, including prostate, breast, endometrial, skin and brain cancers, associated with
hyperactive PI3K signaling. PTEN mutations have also been associated with a variety of other diseases,
classified as PTEN Hamartoma Tumor Syndromes (PHTS). In addition, compromised function or reduced
expression of PTEN due to non-genomic mechanisms are associated with many types of hyperproliferative
diseases, such as restenosis and neoplastic diseases, including melanoma, lung, breast, prostate and
colon cancers. Although PI3K pathway inhibitors are the first line of targeted therapy in these cancers, offtarget effects, toxicities, and chemoresistance persists in the clinic, warranting development of alternative
therapeutic paradigms. Consequently, restoration of PTEN expression and/or function has increasingly
become an attractive option. Cell-based and pre-clinical studies have demonstrated that reintroduction of
PTEN attenuates oncogenic signaling and tumorigenic potential. Unfortunately, restoration methods
involve expression of a gene, mRNA or protein as therapy, which are difficult to implement in the clinic.
My thesis attempts to fill this therapy gap by developing a novel small-molecule compound that can easily
be administered to patients. I have identified small molecules that enhance endogenous PTEN activity and
reduce oncogenic potential of cancer cells. This approach has engendered a novel avenue for PTEN
restoration therapy that will likely serve as an adjunctive treatment for patients with PTEN-related diseases.
To begin to define molecules that can enhance endogenous PTEN activity, I first identified a likely
binding hotspot for small molecules on PTEN between its two core domains, and determined that targeting
of this hotspot via an α-helical peptide can modulate PTEN lipid phosphatase activity. Furthermore, in vitro
biochemical assays determined a lead compound to enhance lipid phosphatase activity. This compound

xvii

suppressed the canonical PI3K signaling cascade and inhibited cell proliferation, migration and cell cycle
progression of A549 lung cancer cells. Computational docking and molecular dynamics simulations
revealed that binding of this small molecule can induce conformational changes in the active site that
enhance binding affinity and orientation of PTEN substrate, PIP3, in the catalytic pocket. Thus, I have
identified and discerned the likely mechanism of the first known small molecule that directly binds and
enhances PTEN enzymatic activity in vitro and asserts its biological functions in cancer cells.
Mutations which compromise PTEN phosphatase activity have been well-studied; however, little
is known about other clinically relevant PTEN mutations which alter its structure and function. Indeed,
PTEN has overlapping clinical significance to tumor suppressor p53 and both molecules form multimers in
vivo. Since select p53 mutant proteins are inactivated via an aggregation mechanism, I hypothesized that
likewise, select clinically relevant PTEN mutations may aggregate and inactivate PTEN function, driving
disease pathogenesis. To this end, I curated 1,523 known PTEN mutations in cancers and PHTS that were
derived from various patient databases and assessed their potential to alter chemical properties, secondary
protein structure, and aggregation propensity. I identified >250 mutations that increase the aggregation
propensity of PTEN wild-type protein and determined that β-sheet structure and increased hydrophobicity
greatly enhanced the potential of PTEN to become aggregation-prone. Validation of aggregation of these
mutants in vivo will aid in the development of small molecule-based therapies that can target specific
aggregation-prone PTEN regions, re-activating endogenous PTEN. In summary, my work implicates small
molecule-based therapy that enhances endogenous PTEN activity as a potentially beneficial alternative or
adjunctive therapy for patients suffering from diseases associated with hyperactive PI3K signaling, either
due to PI3K pathway aberrations or compromised PTEN function.

xviii

Chapter 1: Introduction
Introduction to Phosphatase and Tensin Homolog, PTEN
In 1997, several groups identified human chromosome 10, region q23-24 to be highly
deleted/mutated across various types of cancer [23-25]. It comprised of a gene with an open reading frame,
which was named PTEN (Phosphatase and Tensin Homolog) due to its homology to the superfamily of
PTPs (Protein Tyrosine Phosphatases) and chicken tensin [23-26]. PTEN has DUSP (dual specificity
protein phosphatase) functions, with a preference for highly acidic substrates, which also allows for its
additional function as a lipid phosphatase targeting the PI3K (Phosphatidylinositol 3 Kinase) pathway [2729]. PTEN dephosphorylates PIP3 (phosphatidylinositol-3,4,5-phosphate) and converts it to PIP2
(phosphatidylinositol-4,5-phosphate), thereby modulating the PI3K signaling pathway (Figure 1.1) [27, 28,
30, 31]. Thus, PTEN as a lipid phosphatase inhibits PI3K signaling, reducing activation of downstream
effector kinases AKT (Protein Kinase B/PKB), mTOR (Mammalian Target of Rapamycin), and p70S6K
(p70S6 Kinase) (Figure 1.1) [4, 32]. Apart from its dual phosphatase functions, PTEN also has phosphataseindependent tumor suppressor functions [32, 33].
Compromised PTEN activity is not only associated with cancers, but also with other PTEN-related
diseases, coined PTENopathies. These diseases include PHTS (PTEN Hamartoma Tumor Syndromes), like
CS (Cowden Syndrome), and ASD (Autism Spectrum Disorder) with associated macrocephaly [1, 2, 9, 13].
PTEN knockout mouse models demonstrated its role in embryonic development and disease progression in
multiple organs. PTEN-/- mice are embryonically lethal, whereas PTEN+/- mice develop intestinal polyps,
lymphoma/leukemia, and neoplasia in several organs, including thyroid, prostate, endometrium, and skin
[5, 6, 34]. These phenotypes recapitulate disease progression in humans with PHTS, associated with
multiple cancers. The PTEN-/- mice have brain enlargement due to increased soma size in neurons and

1

Figure 1.1: PTEN Regulates the PI3K Signaling Pathway. Select growth factors via their membrane-bound growth factor
receptors induce phosphorylation and activation of PI3 Kinase. Activated PI3K phosphorylates its substrate, PIP2, generating PIP3.
PIP3, an oncogenic signaling molecule, stimulates the phosphorylation and activation of downstream effector kinases. PTEN
directly antagonizes this pathway by dephosphorylating PIP3 back to PIP2, resulting in suppression of cell growth, cell
proliferation and sensitization to apoptosis.

astrocytes. Additionally, these astrocytes are hyperproliferative [35]. PTEN haploinsufficiency in
stem/progenitor cells increases migration, invasion and decreases susceptibility to apoptosis [36]. Complete
PTEN deletion in stem/progenitor cells also confers increased cell proliferation [37]. Overall, systemic,
organ or cell specific in vivo reduction or loss of PTEN contributes to multiple PTENopathies.
Compromised PTEN function is implicated in many diseases, therefore, I will first review the
various facets of PTEN structure and function to understand how functions can be compromised. I will then
illustrate the widespread inactivation of PTEN in disease, and current attempts in developing effective
therapies and their limitations. Thus, the overall goal of my thesis work is to elucidate mechanisms by
which activation of endogenous intracellular PTEN can be enhanced in a targeted manner in vivo for
therapeutic purpose.

2

PTEN in Cancer
Because PTEN is a highly mutated and/or deleted tumor suppressor protein, its aberrant expression
or compromised function continues to be elucidated in various malignancies (Table 1.1). Although PTEN
mutations are found in virtually all types of sporadic cancers, only endometrial, central nervous system,
skin and prostate cancers are associated with high PTEN mutation propensity in the range of ~14-38% [4].
Table 1.1: Table of Diseases with Compromised PTEN Function.

Disease

References

Cancer
Prostate

[3-6]

Breast

[3, 4, 8]

Endometrial

[4, 8]

Glioma/CNS

[4, 8]

Skin

[4, 5, 8]

Colon

[4, 5, 8]

Lung

[4, 8, 10]

Lymphoma/Leukemia

[6]

Thyroid

[6, 8]

Pancreatic

[4, 8]

Ovarian

[4]

Esophageal

[4]

Urinary Tract

[4]

Stomach

[4, 11]

Liver

[4, 8]
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Table 1.1 (continued).

Disease

References

PTEN Hamartoma Tumor Syndromes
Cowden Syndrome

[1, 2]

Bannayan Riley-Ruvacalba Syndrome

[2, 9]

Lhermitte-Duclos Disease

[12]

Autism Spectrum Disorder

[13]

Other PTEN-related Diseases
Ischemia

[14, 15]

Restenosis

[16]

Alzheimer’s Disease

[17]

Parkinson’s Disease

[18]

Huntington’s Disease

[19, 20]

Metabolic disorders (Diabetes/Obesity)

[21, 22]

Conversely, many cancers demonstrate reduced PTEN expression, which is not attributed to a genomic
aberration. For example, lung cancers have a signature loss of PTEN function or expression despite low
frequency of mutation or allelic deletion [10, 38-44]. In a recent review, it was highlighted that many
cancers such as breast, thyroid, endometrial, colorectal, lung, bladder, liver, pancreatic as well as
melanomas, and gliomas are PTEN deficient due to promoter methylation, loss of heterozygosity or other
unknown mechanisms [8]. Understanding the degree to which PTEN is down-regulated by non-genomic
mechanisms will serve to better understand its role in disease initiation and progression.
The sheer frequency of reduced PTEN expression found across cancers suggests that quantitative
PTEN status may serve as a relevant prognostic marker. Indeed, loss of PTEN is correlated with late stage
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disease and aggressive cancers, while PTEN positive cancers have a more favorable prognosis and higher
survival rates [11, 45-47]. Many of these studies only address PTEN as a prognostic factor in the context
of PTEN-positive and PTEN-negative patient samples; however, recent evidence suggests that the degree
of PTEN function and its expression levels define the type and severity of a disease spectrum. This novel
concept is explored in the following section.

PTEN and the Continuum Model of Tumor Suppression
Since PTEN loss of heterozygosity is more common than bi-allelic inactivation, and heterozygous
PTEN knockout models demonstrate disease phenotypes, PTEN haploinsufficiency is clinically relevant
[5, 6, 34, 48]. The concept of dose-dependent PTEN inactivation was further explored in PTEN hy
(hypomorphic) mouse models, whereby PTEN+/+ = 100% expression, PTENhy/+ = ~80% expression,
PTEN+/- = 50% expression and PTENhy/- = ~30% expression. As PTEN levels decreased, a corresponding
increase in p-AKT (phosphorylated/activated AKT) was observed, as was the development of breast,
uterine and prostate cancers (Figure 1.2) [3]. Interestingly, PTEN

hy/-

mice rescued embryonic lethality,

albeit with incomplete penetrance, indicating that reduction of PTEN expression beyond 50% is lethal in
some cases [3, 49]. This evidence led to the proposal of the continuum model of tumor suppression, which
incorporates haploinsufficiency and quasi-insufficiency as a driver for disease, rather than discrete changes
in expression (i.e. 100%, 50%, 0%) [50]. Furthermore, reduction in PTEN expression has been detected in
patient samples, of which a high proportion of samples lacked DNA/RNA aberrations [51, 52]. Therefore,
loss of heterozygosity due to allelic deletion is not the only factor which dictates PTEN expression levels.
It is thought that regulation of PTEN protein expression can occur through PTMs (post-translational
modifications) which modulate PTEN degradation, localization, structure and function [32, 33, 38, 51]. The
mechanisms of regulation at the genomic and non-genomic levels will be discussed in subsequent sections.
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Figure 1.2: PTEN Follows the Continuum Model of Tumor Suppression. PTEN has been determined to assert its cellular
functions as a haplo- and quasi-insufficient protein, where graded changes in PTEN expression levels along a continuum dictates
disease type and severity in specific tissues. Small decreases in levels of PTEN expression in breast tissue (20% reduction) can
drive breast malignancies, where more severe reduction, such as 50% or 70% reduction are minimally required to drive lung/uterine
and prostate malignancies, respectively.

PTENopathies
In addition to sporadic PTEN mutations found in a wide variety of malignancies, PTEN germline
mutations are associated with PHTS (Table 1.1). The most common PHTS include CS, BRSS (BannayanRiley-Ruvacalba Syndrome), LDD (Lhermitte Duclos-Disease), PS (Proteus Syndrome) and Proteus-like
Syndrome [12, 13, 52]. Irrespective of specific clinical presentations, diagnosed germline mutations in
PTEN are classified as a PHTS. It is thought that up to 85% of patients with CS display PTEN germline
mutations, whereas 60% of BRRS patients, 7-20% of PS patients and ~60% of Proteus-like Syndrome
patients harbor germline PTEN mutations [2, 9, 12]. Occasionally, germline mutations within the canonical
PI3K pathway are observed in patients with these heritable syndromes when there are no detectable PTEN
mutations, highlighting the importance that the PI3K pathway may play in disease initiation and
progression.
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Phenotypically, these diseases are characterized by the presence of hamartomas, or benign tumors
and tissue overgrowth throughout the body, and neurological conditions like ASD or macrocephaly [12].
Also of note are the disease risks associated with these syndromes. For example, patients with PTEN
germline mutations presenting as CS have an increased lifetime risk of developing organ specific cancers,
like breast (85%), thyroid (35%) and endometrial (28%) as compared to the general population [12].
Furthermore, the risk of multiple neoplasia is increased dramatically, with greater than 90% of patients
harboring PTEN germline mutations at risk of developing intestinal polyps [12, 53]. Additionally, it is
suggested that ~10-20% of ASD cases with macrocephaly are positive for PTEN germline mutations [12,
54]. The presence of PTEN germline mutations in these diseases is not surprising, considering that PTEN
heterozygous or conditional PTEN-null homozygous mice recapitulate similar disease phenotypes of
various cancers, neoplastic lesions, metabolic disorders and cognitive impairments [5, 6, 12, 34, 35, 54].
The importance of normal PTEN functions have also been demonstrated in non PTEN-related
diseases like AD (Alzheimer’s Disease), PD (Parkinson’s Disease), HD (Huntington’s Disease), ischemia,
restenosis and select metabolic disorders [14-20, 22] (Table 1.1). Inhibition of PTEN restores cognitive
function in AD mouse models or can serve as a neuroprotective event in PD [17, 18]. Upregulation of PTEN
expression through p53 in medium spiny neurons is neuroprotective in early HD; however, increased PTEN
expression in indirect pathway striatal projection neurons confers decreased long-term potentiation,
resulting in unwanted motor movements [19, 20]. Thus, activation or inhibition of PTEN in specific cells
types in HD models may influence disease progression. Inhibition of PTEN, as observed in mouse models,
may serve as a protective mechanism against ischemic damage in patients [14, 15, 55]. Conversely, in cases
of restenosis, or narrowing of arterial walls by VSMCs (vascular smooth muscle cells), PTEN
overexpression was able to suppress cell proliferation and migration and induce apoptosis in VSMCs [16].
Whole body overexpression of PTEN in mice confers decreased body weight and lipogenesis, increased
energy expenditure, and maintenance of insulin sensitivity throughout ageing, indicating that upregulation
of PTEN may be therapeutic for metabolic disorders like obesity and diabetes [21, 22, 56]. Taken together,
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intended inhibition or upregulation of PTEN may serve as promising disease therapies in the abovementioned diseases associated with aberrant PI3K pathway signaling or PTEN function.

PTEN Structure
The PTEN protein is 403 amino acids in length and is composed of two core domains, the PD
(Phosphatase Domain) and C2D (C2 Domain), which are flanked by flexible N-terminal and C-terminal
tails (Figure 1.3A) [26]. Sequence homology analysis identified regions in PTEN that have high homology
to PTPs and DUSPs, mostly in the active site residues. Additionally, a majority of the PD has high sequence
homology to chicken tensin and bovine auxillin, which aided in naming PTEN [26].

Figure 1.3: PTEN Structure. (A) Representation of full-length PTEN wild-type protein and its four domains. 1) PIP2 Binding
Module (PBM), 2) Phosphatase Domain (PD), 3) C2 Domain (C2D) and 4) the C-terminal tail containing a PDZ Binding Domain
(PDZ-BD). (B) 1D5R PTEN crystal structure, residues 7-353 Δ286-309 with the C-terminal tail added to the crystal structure. The
active site comprised of the P-loop, TI-loop and WPD-loop. PTEN monomers can dimerize using a domain-swapping mechanism,
where each monomer associates at the PDs and the C-tail interacts with the PD of the other monomer.
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A few years after the discovery of PTEN as an important tumor suppressor protein, most of its
structure was determined by X-ray crystallography methods. Since the N- and C-tail regions are highly
intrinsically disordered, crystalizing PTEN with these tail regions remains challenging [57]. Additionally,
the C2D contains a 24 amino acid intrinsically disordered loop which had to be removed to obtain PTEN
crystals [26]. Thus, the solved crystal structure of PTEN comprises of amino acid residues 7-353 Δ286-309
(Figure 1.3B). This truncated PTEN protein structure was determined to have phosphatase activity similar
to that of wild-type PTEN. Structural homology analysis using the PTEN crystal structure revealed that the
PD has structural similarities to the DUSP VHR. The C2D was found to be structurally similar to
Ca2+-dependent C2 Domains, which aids in membrane recruitment for signaling molecules like PI3K and
PKC; however, PTEN does not utilize Ca2+ binding ligands for its membrane recruitment [26]. The
following subsections will cover a detailed overview of PTEN protein domain structures.

The N-terminus
The N-terminus of PTEN has been shown to play a vital role in PTEN lipid phosphatase activity at
the membrane. PTEN residues 6-15 are a proposed PIP2 binding motif which targets PTEN to the
membrane to dephosphorylate substrate PIP3 (Figure 1.3A) [58]. Indeed, several studies have shown that
in Dictyostelium discoideum, PTEN binds PIP2 at the rear of the cell during chemotaxis, modulating
directional sensing [59-61]. Interestingly, PIP2 has been shown to be an allosteric activator of PTEN,
enhancing PTEN phosphatase activity against PIP3 with residues Lys13, Arg14 and Arg15 being important
for this interaction [58, 62-64]. Furthermore, circular dichroism studies identified increased α-helical
content upon PIP2 binding, which enhanced lipid phosphatase activity, confirming that PIP2 does activate
PTEN via an allosteric mechanism [65].
The PTEN N-terminus also contains multiple localization sequences which alter PTEN subcellular
localization. Residues 20-25 (GFDLDL) are suggested to play a role in PTEN cytoplasmic localization, as
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clinically-relevant mutations in these residues cause nuclear import [66]. These mutants retain lipid
phosphatase activity but cannot antagonize PI3K pathway signaling because of their nuclear targeting, thus
they lack growth suppression functions as compared to PTEN wild-type protein. Alternatively, deletion of
residues 13-16 (LRRY) or mutation of Tyr26, Tyr27 and Tyr29 prevent PTEN nuclear accumulation,
indicating that these two small N-terminal regions are likely nuclear localization sequences [67].
Interestingly, clinically relevant PTEN K13E mutant impedes nuclear import by abolishing
monoubiquitination [68]. The role of monoubiquitination in PTEN subcellular localization is covered later
in this chapter. Furthermore, PTEN cytoplasmic and nuclear functions, which are both tumor suppressive
in nature, will be reviewed in the subsequent sections. Lastly, PTEN has been shown to be exported from
the cell in exosomes, likely through monoubiquitination of Lys13 via NEDD4-1 (neural precursor cell
expressed developmentally down-regulated protein 4-1) and Ndfip1 [69]. Decreased p-AKT levels and cell
proliferation was observed in cells which were exosome recipients [69]. Taken together, the N-terminus of
PTEN plays a crucial role in PTEN phosphatase activity and localization.

The Phosphatase Domain
The PTEN PD is comprised of amino acid residues 7-185 and is highly homologous to other PTP
and DUSPs, as it contains conserved active site residues [26]. The active site pocket is made up of three
walls: the P-loop (residues 123-130), the WPD-loop (residues 91-94) and the TI-loop (residues 161-169)
(Figure 1.3B). The P-loop mimics the catalytic motif seen in PTPs and DUSPs, with a sequence
123-HCXXGXXR-130, where X is any amino acid residue [26]. The PTEN active site is distinct from its
other related phosphatases because of a four amino acid residue insertion in the TI-loop (residues 163-166)
which extends the active site, allowing for binding of its bulkier lipid substrate PIP3, in addition to phosphoserine, -threonine and -tyrosine residues. Positively charged residues in the TI-loop are also proposed to
play a role in non-specific binding to the plasma membrane, and may serve as a nuclear exclusion motif
[67, 70]. The shape of the pocket, as well as the overall basic charge of the pocket, due to the presence of
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His123 and Lys125, accommodates protein and lipid substrates. Lys128 and Arg130 attract the negatively
charged substrates [26]. The catalytic mechanism of PTEN will be discussed later.

The C2 Domain
The PTEN C2D lies C-terminal to the PD, from residues 186-351 (Figure 1.3B) [26]. A majority
of this domain is made of β-strands with an orientation that demonstrates structural homology to
Phospholipase Cδ1, Phosphokinase Cδ and Phospholipase A2 [26]. These latter three enzymes bind the
plasma membrane in a Ca2+ dependent manner; however, PTEN lacks the residues necessary for
Ca2+-dependent binding. Instead, the PTEN CBR3 loop and cɑ2 helix have an abundance of charged
residues which associate with phosphatidylserines in the plasma membrane [71]. Mutation of these regions
abrogated membrane binding, and expression in PTEN-null U87MG glioblastoma cells increased
proliferation and contact-independent cell growth, indicating the important contribution of the C2D to
tumor suppressor function [26, 72].
The C2D also modulates PTEN nuclear import utilizing select residues. These residues interact
with MVP (Major Vault Protein), which likely acts as a cytoplasmic-nuclear transporter [26, 72-74].
Furthermore, mutations in amino acids 265-269 (C2D) and residues 160-164 (PD) or 233-237 (C2D)
abrogated PTEN’s interaction with MVP, resulting in nuclear localization defects [73]. Additionally,
clinically relevant K289E PTEN mutant is excluded from the nucleus, likely by preventing
monoubiquitination necessary for nuclear targeting [68]. In contrast, mutation to proposed nuclear
localization sequences in a PTEN 1-375 mutant background, which has enhanced nuclear localization,
increased nuclear accumulation, indicating that these sequences may contribute to PTEN nuclear export
[67]. These regions include R233/R234/K237, K263/M264/L265/K266/K267/K269 in the CBR3 loop, and
K327/N329/K330/K332/ R335 in the cɑ2 helix [67]. Thus, the C2D is necessary for plasma membrane and
nuclear targeting.
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Despite the C2D lacking a catalytic motif, select clinically relevant mutants abolish PTEN lipid
phosphatase activity in vitro and are more susceptible to degradation in cells [75]. Notably, a truncated
PTEN mutant harboring the N-terminus, PD and part of the C2D did not display lipid phosphatase activity,
indicating that the C2D is integral to lipid phosphatase activity [75]. Thus, select C2D mutations likely
affect the conformation of the C2D or multiple PTEN domains, which in turn abolishes lipid phosphatase
activity.

The C-terminus
The PTEN C-terminus is comprised of the PTEN C-tail from residues 351-403, which includes a
PDZ (Post synaptic density protein (PSD95), Drosophila disc large tumor suppressor, (Dlg1), and Zonula
occludens-1 protein (ZO-1)) binding motif from residues 401-403 (Figure 1.3A) [26]. Extensive
computational analysis confirmed that the C-tail is highly intrinsically disordered region (IDR), classifying
PTEN as an IDP (intrinsically disordered protein) [44, 57]. The PTEN C-tail IDR provides structural
plasticity and has high preponderance of MoREs/MoRFs (molecular recognition elements and features) and
SLiMs/ELMs (short linear motifs and Eukaryotic linear motifs), which facilitates PPIs (protein-protein
interactions). For example, approximately 400 PPIs were identified for PTEN and 60% of those interactions
occur at the C-tail, and analyses of the primary/secondary interactome identify these PPIs in a myriad of
signaling pathways [44, 57]. The PDZ binding motif alone facilitates important PPIs which contribute to
PTEN membrane translocation and stability [76, 77]. For example, the PTEN PDZ binding motif interacts
with the PDZ domain in MAGI2/3 (membrane-associated guanylate kinase 2 and 3) to reduce AKT
activation at the plasma membrane [76, 77]. Furthermore, PTEN utilizes its PDZ binding motif to build
higher order PTEN-associated complexes, which have a variety of functions such as cell signaling,
homeostasis, cell polarity and invasion, and neuronal regeneration [78-82]. In addition to the regulatory
roles of these scaffolds, they also contribute to PTEN protein stability [81].
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Participation of PTEN in scaffold structures greatly enhances its stability. Additionally, PTEN
contains two putative PEST sequences within amino acid residues 350-375 and 379-396 [75]. Typically,
these sequences target a protein for proteolytic degradation; however, deletion of these sequences decreases
PTEN expression levels in cells [75]. Thus, partial or whole loss of the C-tail reduces protein stability,
likely by altering folding. Both the PTEN C-tail and PDZ binding motif are subject to PTMs which regulate
intramolecular and intermolecular protein interactions. All PTEN PTMs are covered in later sections and
select PTMs which alter domain interactions will be covered more extensively.

PTEN Dimer Formation
In 2014, PTEN was discovered to exist as a dimer [83]. Notably, the dimeric complex is
catalytically more active than a PTEN monomer; however, heterodimerization between PTEN wild-type
and mutants C124S, G129E, or R130G, which are catalytically dead against phosphoinositides, exerted a
dominant negative effect and suppressed wild-type PTEN activity in the heterodimer [83]. Structural and
computational studies on PTEN dimer formation revealed association of the PDs of two PTEN monomers,
generating a dimer with coplanar membrane binding sites [84]. Furthermore, the membrane binding affinity
of the dimer was greater than that of the monomer [83, 84]. Additional evidence suggested that
phosphorylation inhibited dimer formation, implicating the role of a flexible C-tail in dimer formation [83,
84]. It is proposed that the flexible, unphosphorylated C-tail associates with the C2D of the other monomer,
stabilizing dimer formation through a domain swapping mechanisms [84]. Unphosphorylated PTEN
monomers were also shown to undergo oligomerization; however, the mechanism and structures have not
been defined [83]. Thus, perturbations in PTEN protein structure via mutations or structural modifications
via PTMs can disrupt dimer formation, resulting in loss of enzymatic activity.
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PTEN Isoforms
PTEN has multiple isoforms, which are now considered as a subset of PTEN proteoforms [38].
They arise from alternative translation initiation or alternative splicing, with functions that range from
tumor suppressive to oncogenic. Several non-canonical translation initiation codons exist 5’ upstream to
the canonical AUG start site, which result in the translation of PTEN-L, -M, -N and -O protein products
(Figure 1.4A) [85]. Additionally, alternative splicing of PTEN mRNA generates ten distinct isoforms:
PTEN-delta, PTEN-B, DelE5, DelE6, PTEN-3a, -3b, -3c and PTEN-5a, -5b, -5c (Figure 1.4B) [86, 87].
This section focuses on the structures and functions of these naturally occurring alternative translational
and alternative splice variants.

Figure 1.4: PTEN Proteoforms Comprising of Variants Generated by Alternative Translation and Splicing from the Same
ORF. (A) PTEN has four alternative translational variants (L-O) which are generated from upstream alternative initiation codons.
(B) PTEN has eight alternative splice variants which are truncated forms of PTEN wild-type and are differentially expressed in
disease. The role of these PTEN variants in normal cellular homeostasis and disease is an emerging area of research.
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Alternative Translational Proteoforms
All alternative translational isoforms are N-terminally extended and retain PTEN lipid phosphatase
activity (Figure 1.4A) [85]. While PTEN-L, -M and -N are endogenously expressed in several cell lines,
with PTEN-M being the most abundant, endogenous expression was not detected for PTEN-O [85]. Despite
PTEN-M being the most highly expressed of the alternative translational variants, PTEN-L (also known as
PTEN-Long) has unique structural and functional properties; hence the most well studied. Apart from
PTEN-L retaining the canonical lipid phosphatase activity, it has additional localization functions not found
in PTEN wild-type protein. PTEN-L contains a sequence motif that confers its extracellular secretory
function. Likewise, PTEN-L also has a sequence motif in its N-terminal extension that confers a cell
penetrating function. Indeed, PTEN-L has been shown to be secreted and to re-enter the cells, as shown
both in cell-based assays and in vivo [88]. Additional studies have demonstrated the ability of PTEN-L to
localize to the inner membrane of the mitochondria, maintain mitochondria structure and function, and
synergize with PTEN wild-type to increase cytochrome c oxidase activity, aiding in oxidative
phosphorylation [89]. The cell-penetrating function of PTEN-L, i.e. its N-terminal signaling sequences,
makes it a potent tumor suppressor that can be exploited for tumor suppressor restoration therapy in cancers
with low PTEN expression or compromised function.

Alternative Splice Proteoforms
All ten PTEN splice variants result in a truncated PTEN protein (Figure 1.4B). PTEN-Δ and PTENB include intronic sequences after exons 8 and 5, respectively, resulting in premature truncations only a
few residues after the alternative splice site [87]. Interestingly, PTEN-Δ expression is observed in renal cell
carcinoma, where its expression correlates with extended survival. Stable overexpression of this variant in
renal carcinoma cell lines dampened AKT and MAPK (Mitogen Activated Protein Kinase) signaling and
decreased cell migration capabilities, indicating that PTEN-Δ has similar functions to PTEN wild-type [90].
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While DelE5 lacks part of exon 5, DelE6 lacks all of exon 6 [86]. Variants -3a, -3b, and -3c incorporate
parts of intron 3 immediately 3’ of exon 3, while variants -5a, -5b, and -5c incorporate parts of intron 5
immediately 3’ of exon 5 [86]. Functional assessment of these variants determined that only PTEN-5a
expression was able to decrease p-AKT levels and inhibit cyclin D1 promoter activity. Conversely, PTEN
-5b and -5c overexpression enhanced cyclin D1 promoter activity, indicating a potential oncogenic effect.
In patients with CS and BRRS, PTEN-5b is typically overexpressed and variants -3a and -3b are relatively
under expressed, as compared to controls [91]. Notably, there is high turnover of these variants due to rapid
protein degradation. By virtue of differential expression in various normal tissues, the role of these splice
variants in disease has not been well characterized [86].

PTEN Enzymatic Mechanism
Shortly after the discovery of PTEN as a likely tumor suppressor protein that has homology to
PTPs, PTEN was discovered to dephosphorylate serine, threonine and tyrosine substrates, as well as
phosphoinositide substrates [23, 27, 28, 86]. Although both protein and lipid phosphatase activities of
PTEN are tumor suppressive in nature, the canonical tumor suppressor function of PTEN is through
regulation of the oncogenic PI3K signaling pathway modulated by its lipid phosphatase activity [29]. PTEN
was discovered as a phosphatase for the D3 position of inositol rings, with its preferred substrate as
PI(3,4,5)P3 [28]. However, PTEN can dephosphorylate PI(3)P, PI(3,4)P2, and inositol(1,3,4,5)P4, albeit
with a lesser efficiency [31].
The PTEN catalytic mechanism used to dephosphorylate its protein and lipid substrates is thought
to be the same two step mechanism employed by PTPs. Upon stabilization of the anionic substrate by
positively charged active site residues, like Lys125, Lys128 and Arg130 in the PTEN P-loop, the catalytic
cysteine residue (Cys124 in PTEN) engages in nucleophilic attack on the D3 position phosphate to be
removed [26, 92, 93]. An aspartate residue in the WPD-loop of the PTPs/DUSPs acts as a general acid and
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allows cleavage of the phosphate group from the substrate/leaving group [93]. This general acid is thought
to be Asp92 in PTEN; however, one study has shown that Asp92 is dispensable for phosphatase activity,
implying that a different residue acts as the general acid [26, 94]. This first step creates a phospho-enzyme
intermediate by transferring the phosphate to the thiol group on the cysteine [93]. In the second step, a water
molecular hydrolyzes the phospho-enzyme bond, freeing inorganic phosphate to leave the active site, which
is regenerated for another round of catalysis [93].
Since the main tumor suppressor function of PTEN is through its lipid phosphatase activity, it is
important to recognize that catalysis is affected by plasma membrane binding. Specifically, binding of the
PIP2 binding module to PIP2 orients the active site for PIP3 hydrolysis [63]. As mentioned above, PIP2
binding also acts as an allosteric activator, changing PTEN from a less active Tense (T) state to a more
active Relaxed (R) state [38]. Taken together, combination of a basic active site pocket, which has increased
affinity for highly anionic substrates, combined with allosteric modulation via PIP2 binding at the plasma
membrane confers preferential catalysis of PIP3 substrate.

PTEN Functions
Lipid Phosphatase Dependent Functions
The lipid phosphatase activity of PTEN is the most well-studied of all its functions. PTEN uses its
PIP2 binding module at its N-terminus and its C2D to correctly position itself at the plasma membrane to
dephosphorylate PIP3 [26, 58, 64, 71]. Recent evidence suggests that the diffuse cytoplasmic distribution
of PTEN is attributed to C2D mediated interaction with cytoplasmic endosomes, where PTEN exerts its
lipid phosphatase activity [95]. The following subsections describe a variety of physiological processes that
are regulated by PTEN lipid phosphatase activity.
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Cell Proliferation and Survival
Dephosphorylation of lipid substrate PIP3 to PIP2 directly counteracts the function of class I PI3K
[28]. Growth factor interaction with cognate RTKs (receptor tyrosine kinases) induces RTK dimerization
and recruits PI3K to the membrane where the p85 subunit interacts with the receptor or adaptor substrates
and the catalytic p110 subunit phosphorylates PIP2 [96]. PIP3 generation recruits serine/threonine kinase
AKT to the plasma membrane where its phosphorylated at Thr308 by PDK1, then at Ser473 by mTORC2
for full activation [96, 97]. Activated AKT can phosphorylate TSC2, an inhibitor of RHEB, thereby
allowing RHEB to stimulate mTOR [33, 98]. Alternatively, AKT exerts its kinase activity to inhibit
PRAS40, a negative regulator of mTORC1 [33, 99]. mTORC1 activation subsequently phosphorylates
endpoint pathway effectors kinase p70S6K and 4EBP1 to stimulate protein translation and cell growth
(Figure 1.1) [33, 98, 100]. Interestingly, mTOR kinase, found in both mTOR complexes, can induce cellular
senescence after PTEN loss via phosphorylating and stabilizing p53. Enhancing p53 stability results in
p21Cip1/WAF1 upregulation and renders cells more susceptible to senescence rather than oncogenesis, a
process named PICS (PTEN-loss induced cellular senescence) [33, 98, 100, 101]. Additional AKT
substrates include FOXO proteins, GSK3β (Glycogen Synthase Kinase 3β), BAD, MDM2, p27Kip1, and
p21Cip1/WAF1 to promote cell survival and cell proliferation [33, 100]. Therefore, dephosphorylation of PIP3
by PTEN antagonizes signaling outputs downstream of PI3K [32, 33, 102-104].

Cell Migration, Invasion and Polarity
Regulation of the PIP3 levels and the PI3K pathway plays critical roles in cell migration, invasion
and polarity. PTEN deletion in mouse fibroblasts upregulates the functions of Rac1 and Cdc42 in
modulating the actin cytoskeleton, while reintroduction of PTEN with lipid phosphatase activity inhibited
cell migration [105]. Transcriptional repression of PTEN by BMI-1 enhances cell migration and EMT
(epithelial mesenchymal transition) via the activation of PI3K/AKT/GSK3β/Snail axis [106]. PTEN also
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plays a significant role in both mammalian and Drosophila epithelial morphogenesis and polarity during
organ development by localizing to and maintaining PIP2 levels at the apical plasma membrane [82, 107].
In mammalian cells, PTEN localization recruits Anax2, Cdc42 and aPKC to the apical membrane and PTEN
loss results in improper lumen development [107].

Cell Metabolism
The PI3K/AKT pathway plays a crucial role in insulin-mediated glucose metabolism. Insulin
stimulation activates the pathway and drives lipogenesis and the Warburg effect [32, 33]. Notably, PTEN
loss also conveys similar features. For example, PTEN loss in hepatocytes induces PPARγ and SREBP1C
transcription, likely by loss of regulator MAF1, leading to inflammation, fat deposition and hepatocellular
carcinoma [108, 109]. SREBP target genes promote lipid biosynthesis and its upregulation is dependent on
AKT/mTORC1 signaling [110]. AKT activation also drives the Warburg effect by stimulating GLUT4
plasma membrane translocation for increased glucose uptake, and by upregulating ENTPD5, a regulator of
aerobic glycolysis [111-114]. Interestingly, several studies have generated mice containing additional
copies of the Pten gene, resulting in heightened PTEN expression levels. These mice were found to be
cancer resistant and exhibited an overall tumor suppressive metabolic state, as established by small body
size due to decreased cell proliferation, increased energy expenditure, and decreased lipid synthesis [21,
56]. Thus, one of the tumor suppression function of PTEN is to assert an anti-Warburg effect in cells.

Cancer Stem Cells
PTEN has also been shown to play a role in stem cell maintenance. For example, PTEN deletion in
hematopoietic, neural, skin and intestinal stem cells enhances cell proliferation via progression through the
cell cycle G0/G1 phases [37, 115-118]. In some of these cases, deletion of PTEN alone can contribute to
disease pathology, such as epithelial hyperplasia in the skin, respiratory tract and lungs or formation of
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polyps in the intestine [116, 117, 119, 120]. Hematopoietic cells depleted of PTEN eventually undergo
exhaustion; however, this phenomenon is not observed in neural or skin stem cells, likely because they
share similar cell origins [37, 115, 117]. PTEN deletion in the prostate confers an expansion of Sca1+ cells,
which are associated with prostate stem cells phenotypes [121]. Although the frequency of PTEN
mutations/deletions is low (~10%) in the lung epithelium, PTEN downregulation or phosphorylationmediated inactivation in lung cancers is common [10]. Furthermore, conditional deletion of PTEN in the
lungs displayed an increase in bronchioalveolar stem cells and expansion of neuroepithelial bodies
comprising of pulmonary neuroendocrine cells, considered to harbor stemness properties that may
contribute to tumorigenesis [119, 122-124]. Similar outcomes after PTEN deletion have been observed in
other cell types such as breast and germ cells [117]. Understanding the role of PTEN in stem cells, and
expansion of cancer stem cells in particular, is important as loss of PTEN may drive cancer initiation and
progression through dysregulation of normal stem cell homeostasis.

Protein Phosphatase Dependent Functions
Although canonical function of PTEN is attributed to it’s the lipid phosphatase activity, its protein
phosphatase activity also contributes to its tumor suppressive properties. The first protein substrate of PTEN
was found to be FAK (Focal Adhesion Kinase) [30]. Dephosphorylation of FAK by PTEN can suppress
cell migration and invasion, as well as sensitize cells to apoptosis after detachment from the ECM
(extracellular matrix) [30, 125, 126]. While dephosphorylation of FAK inhibits directional cell migration,
PTEN dephosphorylation of Shc, a player in the MAPK pathway, has been shown to attenuate random cell
migration movements [127-129]. Since Shc is upstream in the Ras/MAPK pathway, these studies suggest
that PTEN also acts as a regulator of the MAPK pathway from Shc to endpoint effector ERK (Extracellular
Signaling Related Kinases) [128]. PTEN also inhibits cell migration and invasion phenotypes in PTEN-null
cancer cell lines by targeting protein substrates PTK6 and even itself at phosphorylation sites located in the
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C2D [130-132]. In other instances, PTEN autodephosphorylation may regulate neuronal spine density,
suggesting that autodephosphorylation has cell type specific functions [133].
PTEN has various other protein substrates which regulate processes like cell proliferation, cell
structure formation, cell differentiation, growth factor and apoptotic related signaling. Cell proliferation
was shown to be suppressed through PTEN-mediated dephosphorylation of c-Src [134]. Conditional loss
of PTEN in the lung epithelia in a mouse model demonstrated ~3 fold increase in cyclin D1 and Ki-67
staining, both hallmarks of increased cell proliferation [119]. Motile cilia formation in mice was modulated
through PTEN dephosphorylation of Dishevelled [135]. Dephosphorylation of transcription factor KLF4
regulates the differentiation of VSMCs [136]. PTEN also targets MTF-1 to upregulate its function in
response to metal and oxidative stress response [137]. PTEN can suppress insulin-mediated glucose
metabolism signaling by dephosphorylating IRS1 (insulin receptor substrate-1) or ERK [138]. Interestingly,
dephosphorylation of ERK kinases by PTEN resulted in reduced downstream phosphorylation of ETS-2.
Depletion of PTEN in mouse mammary stromal fibroblasts causes an upregulation in ETS-2
phosphorylation, which was associated with ECM remodeling, angiogenesis and innate immune infiltration
[139, 140]. Thus, the protein phosphatase activity of PTEN can regulate the MAPK pathway to modulate
growth signaling and the tumor microenvironment [138, 140]. Furthermore, PTEN protein phosphatase
activity regulates EGFR (epidermal growth factor receptor) signaling by dephosphorylating Rab7,
promoting endosomal trafficking of EGFR into lysosomes, and apoptotic signaling by releasing calcium
via dephosphorylation of inositol 1,4,5-trisphosphate receptors at the endoplasmic reticulum and
mitochondria-associated membranes [141-143]. Taken together, the protein phosphatase activity has a
variety of tumor suppressor functions, which, while critically important, remains less explored.
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Nuclear Functions
PTEN Nuclear Transport
PTEN functions in the nucleus in a phosphatase dependent and independent fashion. PTEN may
enter the nucleus as proposed by: passive diffusion, Ran GTPase/importin-11 mediated shuttling, and MVP
mediated import [67, 73, 144, 145]. PTEN ubiquitination and phosphorylation heavily modulate
nuclear/cytoplasmic shuttling as discussed below under “Post-translational regulation.” In brief,
monoubiquitination of PTEN augments nuclear import, while phosphorylation of the PTEN C-tail results
in cytoplasmic retention [10, 68, 146-148]. Nuclear exclusion of PTEN is seen in proliferating cells, while
quiescent cells have abundant nuclear PTEN, indicating that aggressive malignancies may promote PTEN
nuclear exclusion to drive oncogenesis, as demonstrated by our lab and others [10, 33, 149, 150]. Nuclear
export of PTEN is thought to be driven by acid ceramidase/sphingosine-1 phosphate/AKT signaling and
mediated by Exportin 1, also known as CRM, however this area remains less understood [151]. The nuclear
functions discussed below are integral tumor suppressor functions of PTEN.

Role of PTEN in Genome Stability and Cell Cycle
Nuclear PTEN exerts tumor suppression, mostly in a lipid phosphatase independent manner. PTEN
re-expression in PTEN-null U87MG cells decreases the PIP3 pool at the plasma membrane, but not within
the nucleus, indicating that PTEN promotes tumor suppression by other mechanisms [152]. Anchorageindependent growth is mediated by a nuclear PTEN pool that downregulates p70S6K through AMPK (AMP
activated protein kinase) [153]. Protein phosphatase active mutant PTEN G129E had a higher nuclear
distribution compared to wild-type and catalytically dead C124S [67]. Nuclear PTEN utilizes its protein
phosphatase activity to halt replication fork progression, inhibit insulin signaling and prevent cell cycle
progression [154, 155]. PTEN dephosphorylates CREB to inhibit cell proliferation and attenuate neuronal
stem cell differentiation [156, 157]. Conversely, nuclear PTEN needs its lipid phosphatase activity to
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sensitize cells to TNF-ɑ induced apoptosis [67]. Taken together, lipid and protein phosphatase functions
likely have independent tumor suppressive activities in the nucleus.
Notably, PTEN has a wide variety of phosphatase independent functions in the nucleus through its
C-terminus [158]. PTEN binds to the E3 ligase APC/C and augments its interaction with CDH1 to target
mitotic cyclins and kinases or glutaminase and PFKFB3 for degradation, promoting growth suppression
and a tumor suppressive metabolic state [56, 159]. PTEN’s interaction with topoisomerase II stabilizes the
protein so it can decatenate DNA in G2/M cell cycle phases and PTEN/CENP-C binding regulates
centromere stability [160]. Furthermore, genotoxic stress stimulates PTEN to colocalize with DNA damage
repair proteins Rad52 and γH2AX or activate AMPK-mediated autophagy [161, 162]. Thus, nuclear PTEN
utilizes PPIs via its C-terminus to assert its tumor suppressive functions such as maintenance of genome
stability and regulation of the cell cycle.

Role of PTEN in Chromatin Integrity and Transcriptional Regulation
Nuclear PTEN, via its PPIs, also influences gene transcription. PTEN interacts with E2F1 to target
and inhibit E2F1-mediated gene promoter activity, including that of E2F1, cyclin E1 and cyclin D1, which
suppresses cell proliferation [10]. PTEN, via binding to activated p53, stabilizes it, leading to enhanced p53
binding and transcription of p53-dependent genes, associates with BMI1 to derepress transcription of cell
cycle modulators p16INK4 and p14ARF, binds SRF to modulate smooth muscle cell contractile gene
transcription and interacts with AIB1 to promote its degradation, suppressing transcription of its oncogenic
targets [163-167]. PTEN can directly interact with chromatin and act as a transcription factor, as it does to
induce Rad51 expression, augmenting double stranded break repair, or repress the expression of genes
involved in transcription [160, 168]. Additionally, PTEN interactions with chromatin or chromatinassociated histone proteins modulates chromatin condensation and heterochromatin stability [169, 170].
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These PTEN functions at the chromatin attenuate the transcription of critical genes necessary for
proliferation of cancer cells.

Other Phosphatase Independent Functions
PTEN has few other phosphatase-independent functions, the most prominent being its involvement
in high molecular weight scaffolds that increase its stability and localize to the plasma membrane to
augment lipid phosphatase activity [80]. These scaffold interactions include proteins hDLG, MAGI-1,
NHERF1, and NEP and are mediated through the PTEN PDZ binding motif located at the C-terminus [80,
171, 172]. PTEN also participates in individual PPIs in a phosphatase-independent manner. Binding of
MSP58 inhibits MSP58-driven oncogenic transformation in mouse embryonic fibroblasts (MEFs) [173].
Furthermore, PTEN binds to CAV1 and prevents its interaction with β-catenin. PTEN loss frees CAV1 to
bind to β-catenin, which translocates to the nucleus to suppress the transcription of cell cycle inhibitor
p16INK4A [174]. Taken together, these scaffolding functions contribute to tumor suppression outside of
canonical PTEN phosphatase activities.

PTEN Regulation
There are several mechanisms of regulation which positively and negatively modulate PTEN
function (Figure 1.5). In the coming sections I will explore these mechanisms in detail.

Genomic Mechanisms
PTEN function and expression can be regulated at the genomic level. PTEN mutations can alter its
phosphatase activity, stability, subcellular localization or protein-protein interactions [32, 33]. Furthermore,
PTEN expression levels can be regulated via epigenetic mechanisms and association of transcriptional
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activators or repressors with regulatory gene elements [32, 33]. The next two subsections explore genomic
mechanisms of PTEN regulation in more detail.

Mutations
PTEN was initially discovered as a gene frequently mutated or deleted in advanced cancers [2325]. It is now known that sporadic PTEN mutations occur at high incidence in cancers of the breast, prostate,
endometrium, skin (melanoma) and brain (glioma) [175-177]. Additionally, PHTS diseases were shown to
have a high incidence of germline PTEN mutations, as described above in PTENopathies. An in-depth
analysis of the mutations which manifest at the protein level demonstrates that all nine exons of PTEN are
targeted for mutation. However, the C-tail of PTEN, encoded by exon nine, has a much lower susceptibility
for mutations in cancer, whereas exons five, seven and eight have the highest incidence of mutations across
multiple disease phenotypes [32, 176, 178, 179]. Furthermore, these highly susceptible regions also tend to
be highly conserved, like the active site in exon five [177]. Thus, mutations like catalytically dead C124S,
lipid phosphatase dead G129E/R and phosphatase inactive R130X are highly implicated in cancer and
PHTS. Furthermore, most clinically relevant PTEN mutations in the P-loop, TI-loop and WPD-loop are
functionally inactive [180].
Pathogenic PTEN mutations range from missense, which can either totally or partially inactivate
PTEN function, to nonsense, insertion and deletion mutants which produce truncated protein products with
decreased expression or function [32, 175, 176]. For instance, missense mutations in the catalytic motif
often alter the active site pocket in shape or chemical environment, resulting in ablation of phosphatase
activity [175, 176]. Select missense mutants arising from monoallelic mutations contain dominant negative
properties by dimerizing with and inactivating PTEN wild-type monomers [83]. Furthermore, mutants like
K13E abrogate PTM sites, contributing to aberrant subcellular localization [176]. Alternatively, nonsense
mutations in the PD or C2D often produce truncated PTEN with the active site intact; however, the stability
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of the protein product is too low to be functionally relevant in the cell [32, 75]. Interestingly, mutations
observed in patients with ASD typically do not ablate PTEN lipid phosphatase activity, while mutations
observed in cancer and PHTS patients often show PTEN lipid phosphatase activity [180]. Thus, specific
mutations contribute to different disease phenotypes through their regulation of PTEN function, expression
and subcellular localization.
Mutations within intronic sequences or at splice sites have been identified in CS and BRRS patients,
which disrupt normal PTEN mRNA splicing, resulting in exon skipping, inclusion of intronic sequences or
premature truncation [181-183]. These various mutants have different functions, subcellular localization
and stability [181-183]. For example, skipping of exon four severely reduces lipid phosphatase activity and
stability at the protein level, while skipping of exon three significantly reduces protein phosphatase activity
but enhanced the nuclear localization of the protein product [181]. Taken together, defects in splicing due
to mutations can generate functionally compromised PTEN variants that contribute to pathogenicity in
PHTS.

Epigenetic Regulation
PTEN mRNA expression, and thus protein expression, can be regulated by epigenetic mechanisms
like promoter methylation. Hypermethylation of the PTEN promoter can downregulate PTEN transcription
and mRNA levels, as demonstrated in several types of cancers, including breast, thyroid, and lung cancer
[33, 184-186]. Furthermore, promoter methylation may serve as a prognostic factor for patient survival in
cancers [187]. Alternatively, JARID1B is a histone demethylase that targets histones associated with active
genes. JARID1B activity suppresses PTEN transcription and drives proliferation of cancer cells [188].
Additionally, PTEN transcriptional repression due to histone deacetylation likely serves as another
mechanism of epigenetic regulation. Transcription factor SALL4 can associate with the histone deacetylase
complex Mi-2/NuRD to bind and deacetylate the PTEN promoter, suppressing transcription [189]. Taken
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together, epigenetic mechanisms like promoter methylation and histone deacetylation are upregulated in
many cancers to repress PTEN transcription.

Transcriptional Regulation
Additional

transcriptional

regulation

of

PTEN

is

modulated

via

transcriptional

activators/repressors, or small molecules, which activate or repress PTEN transcription. PPARγ, p53,
EGR1, IGF2, MAF1, CBF1, TET1, SPRY2 transcription factors have demonstrated the ability to enhance
PTEN transcription, in addition to the cytokine, resistin [190-198]. Select compounds, which include
resveratrol, found in red wine, indole-3-carbinol, found in cruciferous vegetables, and quercetin, found in
fruits and vegetables induce PTEN transcription through indirect mechanisms [199, 200]. PML/RARα,
BMI1, c-JUN, SLUG, SOX2, HES1, EVI1, ID1, SNAIL, NF-Κβ (induced by MKK4, IGF1 and
17β-estradiol), SMAD transcription factors (induced by TGF-β) and Sp1 (induced by OCT4) inhibit PTEN
gene transcription [106, 189, 201-212]. Notably, TNF-α stimulated NF-Kβ signaling can augment or
suppress PTEN gene transcription depending on the cellular environment [213, 214]. These mechanisms
provide insight into the negative and positive regulations of PTEN expression, specifically in a disease
context which lacks allelic loss or mutation of PTEN but exhibits deregulation of one or more of the
aforementioned proteins [32].

Non-genomic Mechanisms
In addition to genomic mechanisms, PTEN expression, function, and subcellular localization can
be modulated after transcription at the mRNA, as well as after translation at the protein level. These
mechanisms will be explored in the next two subsections.
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Post-transcriptional Regulation
Negative regulation of PTEN expression is observed at the level of PTEN mRNA, posttranscription. An abundance of small non-coding microRNAs (miRNAs) have been shown to target the
PTEN mRNA 3’ UTR (untranslated region) [32, 33]. Furthermore, miRNA targeting of the PTEN 3’ UTR
is differentially regulated in various diseases like cancer, PHTS and metabolic diseases [215, 216]. For
example, miR-19a/b and miR-21 target and deplete PTEN mRNA in multiple cancers [32, 215-220].
Additionally, there is evidence to suggest that oncogenes can upregulate miRNA expression. For instance,
Myc oncogene can induce the miR-17~92 cluster and miR-200c PTEN-targeting miRNAs in lymphoma or
nasopharyngeal carcinoma, respectively [221, 222]. Thus, PTEN post-transcriptional regulation via
miRNAs can be disease and tissue specific.
Interestingly, a PTEN pseudogene which has over 95% sequence identity to PTEN, denoted as
PTENP1, does not get translated and acts as a competing endogenous RNA [223]. Since the PTENP1 3’
UTR has high homology to PTEN, it can act as a sponge for miRNAs that target PTEN. Therefore,
expression of PTENP1 can increase PTEN levels and activity by acting as a decoy for PTEN-targeting
miRNAs [223]. Loss of PTENP1 correlates with decreased PTEN protein expression [32]. The PTENP1
gene locus also expresses PTENP1 asRNA (antisense RNA) transcripts α and β. PTENP1 asRNA α can
directly bind to and regulate the PTEN promoter, thus modulating PTEN transcription [224]. PTENP1
asRNA β can sequester the PTENP1 transcript, thus regulating PTEN protein expression indirectly [224].
Taken together, transcription of PTENP1 can positively or negatively regulate PTEN mRNA expression
levels.

Post-translational Regulation
PTEN is abundantly post-translationally modified, with modification sites spanning all four
domains (Figure 1.5) [32, 33, 215]. Eight distinct types of PTMs have been shown to target PTEN. PTMs
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affect PTEN structure, function, localization, and stability. Since these modifications can modulate PTEN
function and expression, several of these posttranslational regulation mechanisms contribute to PTEN
haploinsufficiency in disease (Figure 1.6) [32, 33, 215]. The following subsections will explore all known
PTEN post-translational modifications and their roles in PTEN protein modulation.

Figure 1.5: PTEN is Extensively Modified Post-translationally. Known PTEN modifications by eight distinct mechanisms:
Phosphorylation, Ubiquitination, SUMOylation, Oxidation, Acetylation, S-Nitrosylation, Methylation and Ribosylation. PTEN
PTMs occur across the full length of the protein, although most PTMs occur within the C2D and the C-tail. It is important to
understand the breadth by which PTEN is post-translationally modified in disease, since these PTMs regulate PTEN enzymatic
activity, structure, PPIs, and subcellular localization, resulting in overall modulation of PTEN function and stability.

Oxidation
Oxidation of PTEN forms a disulfide bond at the catalytic Cys124 residue with the adjacent Cys71
residue, inhibiting phosphatase activity (Figure 1.6) [225-231]. Inactivation via oxidation directly results in
phosphorylation and activation of AKT and downstream signaling effectors. Interestingly, thioredoxin-1,
which reduces and reactivates PTEN, has been shown to form disulfide bond with the C2D of PTEN, which
prevents its interaction with the plasma membrane and suppresses lipid phosphatase activity, adding a layer
of complexity to thioredoxin-mediated PTEN regulation [232, 233]. PTEN interaction with peroxiredoxin
I prevents PTEN oxidation [234]. Metabolism of arachidonic acid by enzymes COX-2 or ALOX5 drives
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AKT pathway stimulation through oxidation and inactivation of PTEN, although the oxidative species
targeting the cysteine residues is unknown [235]. Altogether, these studies determined that generation of
reactive oxygen species can enhance AKT pathway signaling via inactivation of PTEN through oxidation
of active site residues.
S-Nitrosylation
PTEN is S-nitrosylated at Cys83, with Cys71 and Cys124 (Figure 1.6) [236-239]. S-nitrosylation
of PTEN (SNO-PTEN) reduced its lipid phosphatase activity in vitro and decreased PTEN stability in cellbased assays via enhanced ubiquitin-mediated proteasomal degradation [236, 240]. Thus, formation of
SNO-PTEN is associated with enhanced p-AKT levels and cell survival. SNO-PTEN has been detected
during brain ischemia and during an early phase of AD known as mild cognitive impairment. Furthermore,
S-nitrosylation of PTEN has been implicated as an inactivation mechanism in cancer. Depletion of PARK2
or activation of AMPK increases SNO-PTEN levels leading to enhanced AKT signaling and tumorigenesis
[241]. SNO-PTEN generation through NOS1 also prevents excessive autophagy and promotes survival
through the PI3K/AKT pathway in nasopharyngeal carcinoma cells [240]. Taken together, S-nitrosylation
of PTEN is an inactivation mechanism that promotes cell survival via AKT/mTOR signaling in multiple
cell types.

Acetylation
Acetylation of PTEN plays multiple roles depending on the acetylation site. For example, PCAF
(P300/CBP-associated factor) driven acetylation at Lys125 and Lys128 within the catalytic cleft inactivates
PTEN phosphatase activity and upregulates AKT phosphorylation (Figure 1.6) [242, 243]. On the contrary,
acetylation at Lys163 enhances PTEN function via membrane translocation (Figure 1.6) [244]. CREB
binding protein (CBP) acetylates PTEN at lysine 402, augmenting interactions with proteins containing
PDZ domains like MAGI-2 and hDLG, which are known modulators of cell structure and polarity (Figure
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1.6) [245]. Indeed, PTEN binds MAGI/Par-3 complex and participates in the maintenance of cell shape and
polarity [82]. Therefore, it is likely that PTEN acetylation may directly regulate cell shape, behavior and
polarity. Histone deacetylases like SIRT1, HDAC6, HDAC I and HDAC II counteract PTEN acetylation
[82, 242-244, 246]. Thus, modulation of PTEN acetylation directly affects enzymatic activity, subcellular
localization and PDZ binding motif-mediated PPIs.

Methylation
Recently, PTEN has been shown to be methylated at lysine and arginine residues with distinct
functional consequences. Methylation by SMYD2 at Lys313 enhances PTEN phosphorylation at Ser380,
causing a closed/inactive conformation (Figure 1.6) [247]. On the contrary, methylation by PRMT6 at
Arg159 enhanced PTEN-mediated suppression of the PI3K pathway (Figure 1.6) [248]. PTEN contains
many conserved arginine residues which are often mutated in cancer; therefore, methylation at these
arginine sites may uncover novel mechanisms of modulating PTEN functions [248].

SUMOylation
PTEN has three known sites which are modified by small ubiquitin-related modifier, or SUMO.
Modification at Lys266 and Lys289 aid in tethering PTEN to the plasma membrane, where it can
dephosphorylate PIP3 substrate and suppress the PI3K pathway (Figure 1.6) [249, 250]. Alternatively,
SUMO modification at Lys254 targets PTEN to the nucleus (Figure 1.6) [251]. Therefore, SUMOylation
of PTEN dictates its subcellular localization.
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Ubiquitination
The role of PTEN ubiquitination at lysine residues 13, 66 and 289 regulate PTEN stability and
localization (Figure 1.6) [68, 236]. Polyubiquitination of PTEN by E3 ligases XIAP, CHIP, WWP2 and
NEDD4-1 target PTEN for proteasomal degradation [252-255]. Although the role of NEDD4-1 remains
controversial, as PTEN expression in NEDD4-1 positive or negative MEFs showed no significant
difference and PTEN was not found to interact with NEDD4-1 [256]. PTEN expression levels are inversely
correlated with high E3 ligase expression in cancer, indicating that these ligases negatively regulate PTEN
expression to promote disease progression [252, 257]. Interestingly, polyubiquitination by E3 ligase RFP
does not affect PTEN stability nor localization but suppresses its phosphatase activity [258]. PTEN
monoubiquitination of Lys289 and Lys13 modulates its subcellular localization [68]. Mutation of the
Lys289 and Lys13 residues prevents nuclear accumulation, suggesting that monoubiquitination plays a role
in PTEN nuclear import [68]. Furthermore, molecules which are not E3 ligases can regulate PTEN
ubiquitination. NEDD4-1 activators Ndfip1 and Ndfip2, as well as PTEN ribosylation via tankyrases
enhance PTEN ubiquitination [259, 260]. Contrary to E3 ligases, deubiquitylases USP13 and OTUD3
directly bind to and de-polyubiquitinate PTEN to enhance its stability, while HAUSP/USP7
de-monoubiquitinates PTEN to decrease the nuclear PTEN pool [261-263]. In brief, polyubiquitination of
PTEN promotes its proteasomal degradation, regulating PTEN protein expression levels, while
monoubiquitination promotes PTEN nuclear import, thus augmenting PTEN nuclear functions.

Phosphorylation
PTEN C-tail Phosphorylation:
Phosphorylation, the most extensive PTM of PTEN, directly regulates PTEN function,
conformation, stability and subcellular localization (Figure 1.6). PTEN is heavily phosphorylated on its
C-tail (residues 351-403). Phosphorylation of Ser380, Thr382, Thr383 and/or Ser385 by CK2 (casein kinase
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2) causes a conformational change in which the C-tail folds back on the core PD and C2D [146, 264-268].
This conformation enhances PTEN stability by occluding ubiquitination sites which target PTEN for
proteasomal degradation and proteolytic digestion by caspase-3 [146, 269]. However, this conformation
also occludes sites necessary for membrane-binding in the C2D and possibly the PD, causing cytoplasmic
retention and loss of lipid phosphatase activity at the plasma membrane [146, 265, 266, 268]. The
intramolecular C-tail/C2D interaction also prevents interactions of the PTEN PDZ binding motif with its
constituents in the PTEN-associated complex, like MAGI-2 proteins [147, 270]. Disruption of this
supramolecular complex prevents PTEN membrane recruitment and subsequent p-AKT inhibition [147].
Thus, phosphorylation at the C-tail cluster enhances stability but inactivates PTEN via cytoplasmic
retention and abrogation of PPIs.
Multiple kinases can phosphorylate one or more residues in the 380/383/383/385 cluster to regulate
PTEN function. For example, p70S6K phosphorylates PTEN at Ser380 under oxidative stress, resulting in
PTEN deubiquitylation and nuclear export, affecting PTEN nuclear functions [148]. Conversely, Ser380
phosphorylation by Plk1 (Polo-like kinase 1) augments PTEN chromatin binding during mitosis, resulting
in mitotic exit [271]. Interestingly, PTEN C-terminal interacting protein PICT-1 regulates Ser380
phosphorylation, where PICT-1 knockout significantly reduced Ser380 phosphorylation levels [272].
Ser385 is an additional Plk1 phosphorylation site on PTEN, which enhances PTEN stability by inhibiting
polyubiquitination, but excludes it from the nucleus by inhibiting PTEN monoubiquitination [273]. Plk1mediated Ser385 phosphorylation also results in PI3K pathway upregulation associated with a metabolic
state that drives the Warburg effect and tumorigenesis [273]. Taken together, phosphorylation at this cluster
via alternative kinases regulates nuclear and cytoplasmic functions.
To counteract phosphorylation at the C-tail cluster, PTEN interacting protein NDRG2 recruits
PP2A to dephosphorylate PTEN, which drives membrane recruitment and decreased p-AKT levels [274].
PTEN also has auto-dephosphorylation capabilities, which regulate its function and stability through
targeting its C-tail phosphorylated amino acid cluster [133]. Notably, use of a phosphorylation deficient
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mutant, known as PTEN-4A, which contains alanine mutations at Ser380, Thr382, Thr383 and Ser385, has
enhanced lipid phosphatase activity and preferentially localizes to the nucleus as compared to PTEN wildtype protein [10, 146, 147]. Thus, this cluster of residues modulates stability and subcellular localization.
It is also thought that phosphorylation of the C-tail at this cluster prevents PTEN dimer formation, thereby
suppressing the most active form of PTEN wild-type [83]. Additional C-tail phosphorylation sites which
regulate stability include Ser362 by GSK3β, and Ser370 by CK2 or Plk3, which can prime Thr366
phosphorylation by GSK3β or Plk3 [275-278]. Taken together, regulation of the phosphorylation of all
C-tail phosphorylation sites dictates PTEN function, localization and stability.

PTEN Phosphorylation of the Core Domains:
Phosphorylation of PTEN occurs at various sites in the C2D. Phosphorylation at Thr336 by Rak
enhances PTEN stability by abrogating polyubiquitination and subsequent proteasomal degradation by
NEDD4-1, while Tyr27 and Tyr174 phosphorylation via insulin receptor activation destabilizes PTEN
[279, 280]. PTEN phosphorylation at Thr223, Ser229, T319 and T321 by ROCK during leukocyte
chemotaxis targets PTEN to the posterior plasma membrane, contributing to directional cell migration via
its lipid phosphatase activity [281]. Tyr240 phosphorylation, possibly by FGFR2 after ionizing radiation,
promoted PTEN interaction with Ki-67 and chromatin, recruiting DNA repair molecules like Rad51 [282].
Conversely, Tyr240 phosphorylation, as well as Tyr336 and Tyr315 phosphorylation by Src destabilizes
PTEN and upregulates the PI3K pathway [283]. Although phosphorylation at Tyr240 does not affect PTEN
lipid phosphatase activity, it is associated with EGFR inhibitor resistance and shortened survival in
glioblastoma [284]. Like the C-tail phosphorylation sites, phosphorylation at select sites in the C2D
modulates stability and activity of PTEN and may serve as prognostic markers for resistance and overall
survival in patients.
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Clinical Significance of PTEN Phosphorylation:
Since phosphorylation of specific PTEN residues dictates its functional status and localization,
PTEN phosphorylation may serve as a relevant clinical marker in diseases like cancer [10, 44, 285]. For
example, PTEN phosphorylation status is associated with shorter overall survival in patients with acute
myeloid leukemia [285]. Increased phosphorylation at the C-tail cluster in >200 lung cancer patients
directly correlated with disease severity (normal, low and high grade), implicating a critical functional role
of C-tail phosphorylation in cancer progression [10, 44]. Concomitant to increased phosphorylation, there
was decreased nuclear staining of total PTEN, indicating that increased nuclear exclusion also strongly
correlated with progressively higher grade non-small lung cell lung cancer [10, 44]. A similar trend in
nuclear PTEN expression was observed in melanoma [150]. Thus, disease progression to high grade cancers
is driven by increased nuclear export or selective cytoplasmic retention, resulting in reduced PTEN
function. These results suggest that merely analyzing the PTEN gene for mutations or staining for PTEN
wild-type in patient biopsies is not representative of PTEN functional status in disease.

PTEN Restoration Therapy
Since PI3K pathway hyperactivation is widespread across most cancers, KIs (kinase inhibitors)
which target one or more effector kinases in the pathway have been used for treatment [286, 287].
Unfortunately, these therapies have met with therapy-resistance, toxicities and off-target effects [286, 287].
Therefore, various alternative approaches that “restore” PTEN function by ectopic overexpression or
indirect activation have been attempted.
Restoring PTEN can be implemented directly through gene, mRNA, or protein therapy, or
indirectly by compounds which aid in upregulating PTEN transcription. Gene therapy has been extensively
studied in multiple cancers such as small cell lung cancer, glioma and prostate, bladder, and colorectal
cancer [288-295]. These studies exemplified the ability of active PTEN to be expressed through gene
therapy in PTEN-null, PTEN-mutant or PTEN wild-type cell lines and in vivo animal models. Furthermore,
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reintroduction of wild-type PTEN suppressed and reduced tumor burden in vivo or sensitized the tumors to
additional treatment modalities [288-295]. Similar studies have been done with PTEN mRNA packaged
into nanoparticles for delivery into cells [296]. Recently, PTEN-L, a PTEN proteoform that has the ability
to be secreted and uptaken by cells has been used to validate PTEN restoration therapy. Intra-peritoneal
injection of PTEN-L in PTEN U87MG glioblastoma, MDA-MB-468 breast carcinoma, or 786-0 renal cell
carcinoma xenografted tumors showed promising results [88, 297, 298]. Genetically engineered tumorhoming neural stem cells with modified PTEN-L for enhanced secretion and cell entry was also effective
in treating glioblastoma [299]. These studies validate PTEN-L therapy as a bona fide biological therapy.
Finally, natural compounds with suggested anticancer properties have been shown to upregulate PTEN
expression levels [199, 200, 300]. Unfortunately, these mechanisms of PTEN reintroduction rely on gene
therapy or ectopic and transient PTEN expression, which are difficult to implement in the clinic [286, 297,
299, 301]. Recently, the naturally occurring indole-3-carbinol was shown to be a potent inhibitor of WWP1,
an E3 ligase which negatively regulates PTEN function by suppressing dimerization and membrane
recruitment [302]. Although indole-3-carbinol was able to reactivate PTEN in PTEN heterozygous mice,
this method remains an indirect means of reactivation. Considering these therapy gaps, novel PTEN
restoration therapy approaches that can easily be implemented in the clinic remains imperative. Therefore,
my thesis will focus on identifying potential restoration therapies suitable for patients suffering from
diseases resulting from compromised PTEN function or low levels of PTEN protein expression.

Summary
Since compromised PTEN function or hyperactivation of the PI3K signaling pathway upstream of
PTEN is common in multiple disease pathologies, PTEN is an attractive target for therapy aimed at
suppressing oncogenic PI3K pathway signaling [303]. PTEN restoration therapy has already proved
promising, as demonstrated in the section above; however, more simple modes of treatment conducive to
clinical implementation are warranted [286, 297, 301]. In the next two chapters, I explore the potential of
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small molecule compounds to directly target and activate PTEN lipid phosphatase activity, enhancing its
canonical tumor suppressor function. I use cancer as a disease model because it is the second leading cause
of death in the United States, with an estimate of 1.7 million new cases and more than 600,000 deaths in
2019 [304]. Approximately 17 million new cases will be reported and 9.5 million deaths will occur due to
cancer in 2019, resulting in an enormous health burden estimated to reach >$158 billion in the US alone in
2020 [304]. These data warrants research aimed at identifying effective therapies to alleviate patient
suffering and social cost.
In chapters 2 and 3, I identify and characterize promising small molecule compounds that directly
enhance PTEN enzymatic activity. These novel small molecules are promising therapeutic molecules in
diseases driven by compromised function or low levels of PTEN protein. In chapter 4, I have interrogated
clinically relevant PTEN mutations derived from patients with PTEN-related diseases, including cancer.
My work has discerned a novel mechanism of PTEN inactivation via protein aggregation, which will aid
in targeting inactive PTEN aggregates for better treatments. Therefore, my thesis work presented here
focuses on defining potential therapies for patients who suffer from diseases due to genomic or
non-genomic PTEN inactivation and/or a myriad of proliferative diseases associated with hyperactive PI3K
pathway signaling.

Figure 1.6: Mechanisms of PTEN Inactivation. PTEN has a multitude of inactivation mechanisms that alter PTEN structure,
function, stability, expression or subcellular localization. These mechanisms include somatic/germline mutations, histone
acetylation, generation of splice variants, PTMs, transcriptional repression, promoter methylation, RNA regulation by long
noncoding RNAs or micro RNAs and PPIs. In principle, therapeutic strategies to abrogate these PTEN inactivating mechanisms
must be sought to enhance PTEN function.
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Chapter 2: Activating PTEN via Small Molecules

Background
Current therapies to block growth signaling in various cancers include the use of KIs that target
one or more oncogenic pathway kinases [96]. The PI3K pathway is commonly upregulated in multiple
cancers due to overexpression of growth factors/receptors, gain-of-function mutation/hyperactivation of
pathway kinases or dysregulation of its pathway regulator PTEN [96]. Although KIs are effective in the
clinic, they are often met with off-target effects, causing adverse clinical outcomes in patients; therefore,
there is an unmet need for alternative approaches to develop novel therapeutic options to target the
oncogenic PI3K pathway [287].
It is now well-accepted that, unlike the Knudson’s two-hit model, PTEN follows the continuum
model of tumor suppression, whereby the extent of loss of function or expression of PTEN differs between
types of cancer (Figure 1.2) [50]. PTEN somatic or germline mutations were earlier identified as major
drivers of oncogenesis [23-25]. However, accumulating evidence over the last decade indicates that
alteration in normal PTEN protein levels or function, including PTEN protein-inactivation, is considered to
drive many cancers, which is independent of its mutational status [10, 32, 33, 44, 215]. Therefore, the
paradigm of PTEN restoration therapy via overexpression of PTEN protein in tumors has been attempted.
While this approach has proved effective in principle, limiting oncogenic potential in vitro and in vivo,
implementation of gene and protein therapy in the clinic remains challenging [294, 295, 297, 301]. The
possibility of a second approach of directly targeting and enhancing endogenous PTEN activity via small
molecules exists, which can reduce the oncogenic effects of PI3K signaling in tumors. Unfortunately, there
are no reported direct activators of PTEN. Therefore, in this chapter I use the second approach as a major
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premise, wherein I identified and elucidated a binding hotspot on PTEN protein that can be exploited for
its targeted activation. Utilizing this information, I have also identified and characterized select small
molecule compounds that targeted this hotspot, modulated PTEN lipid phosphatase activity and reduced
oncogenic potential in cancer cells.

Materials and Methods
FTMap Analysis
The FTMap computational map server (http://ftmap.bu.edu, Boston University) was utilized to
perform FTMap analysis for PTEN tumor suppressor protein (PBD 1D5R). The PTEN structure was
uploaded to the servers and analyzed per the documentation [305]. Utilizing the visualization software
PyMol (V1.7.4, Shrödinger), the output was inspected for potential ligand binding hot spots.

γ-AApeptide Synthesis
Fifty non-natural peptidomimetics mimicking bioactive peptides were synthesized from Nacylated-N-aminoethyl amino acid building blocks, synthesized as previously described [7, 306, 307]. The
building block harboring the R2 side chain was attached to a chloro-trityl resin. The sequential addition of
R3 and R1 side chains occurred after deprotection steps. After cleavage of this intermediate from the solid
phase, the R4 group was added to the C-terminus, completing synthesis (Patent Application No. 62/460,324
(USPTO); USF Ref. No. 17A011PR). γ-AAPeptides were purified as previously described [7]. Purity of γAAPeptides was verified by High Pressure Liquid Chromatography (HPLC) and Nuclear Magnetic
Resonance (NMR) spectroscopy analysis [7].
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Lipid Phosphatase Assays
Microtiter-plate Screening
PTEN lipid phosphatase activity was measured using a Malachite Green (MG) screening assay
[308]. Pure PTEN protein produced in SF9 insect cells (Cayman Chemical, Ann Arbor, MI) was used
because it maintains all post-translational modifications; therefore, it is a physiologically and functionally
more relevant protein that mimics human PTEN functions in vivo. For the MG titration assays with
γ-AAPeptides, 16.67ng of pure recombinant PTEN protein was incubated with 50mM Tris HCl, pH 8.0,
100mM NaCl, 5mM DTT and increasing amount of indicated γ-AAPeptide (0, 0.25, 0.50, 1, 2, and 5μM)
for 1 hour at 37°C in a 96-well microtiter plate. Then, water soluble diC8-PI(3,4,5)P3 substrate (Echelon
Biosciences, Salt Lake City, UT) was added in each well to a final concentration of 54nM and the reaction
continued for additional 60 minutes at 37°C. To stop the reaction, 195μL MG reagent (Echelon Biosciences,
Salt Lake City, UT) was added to each well and allowed to incubate for additional 20 min at room
temperature to allow for green color development. Absorbance was measured at 620nm and phosphate
released was calculated from a standard curve. Assays were performed in quadruplets, at least twice, and
reported as mean ± S.E.

Enzyme Kinetics
Similar to the γ-AAPeptide titration assay, a MG dose-response assay was performed using PTEN
substrate PIP3 in the absence or presence of γ-AAPeptide. 16.67ng of pure recombinant PTEN protein was
incubated with 50mM Tris HCl, pH 8.0, 100mM NaCl, 5mM DTT and 1μM γ-AAPeptide #43 for 1 hour
at 37°C in a 96-well microtiter plate. Then, diC8-PI(3,4,5)P3 substrate was added yielding a select range
of final concentrations (0, 20, 40, 60, 80, 100, and 120μM). The reaction continued for additional 60 minutes
at 37°C. To stop the reaction, 195μL MG reagent was added to each well and allowed to incubate for
additional 20 min at room temperature to allow for green color development. Absorbance was measured at
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620nm and phosphate released was calculated from a standard curve. Assays were performed in triplicates,
performed six times, and reported as mean ± S.E. The standard curve was generated by titrating the
phosphate standard (Echelon Biosciences, Salt Lake City, UT) in the sub saturating range of
0-2000ρmol/well. Kinetic parameters such as Vmax, Khalf, and h values were calculated using the Allosteric
Sigmoidal function in GraphPad Prism 6 (San Diego, California).

Cancer Cell Culture Maintenance
A549 cells (ATCC® CRM-CCl-185TM, Manassas, VA) and PC3 cells (ATCC® CRL-1435TM,
Manassas, VA) were cultured in F12K media (Thermo Fisher, Waltham, MA) supplemented with 10%
Fetal Bovine Serum (FBS), Antibiotic-antimycotic solution (final concentration 200 units/mL penicillin G,
Table 2.1: List of Primary Antibodies

Primary Antibody

Catalog #

Concentration

Company

p-AKT Ser473 (D9E) XP
(rabbit, monoclonal)

4060

1:2000

Cell Signaling Technologies, Danvers,
MA

AKT (rabbit, polyclonal)

9272

1:1000

Cell Signaling Technologies, Danvers,
MA

p-P70S6K Thr389 (108D2)
(rabbit, monoclonal)

9234

1:2000

Cell Signaling Technologies, Danvers,
MA

P70S6K (49D7) (rabbit,
monoclonal)

2708

1:1000

Cell Signaling Technologies, Danvers,
MA

p-PTEN
Ser380/Thr382/383 (rabbit,
polyclonal)

9554

1:2000

Cell Signaling Technologies, Danvers,
MA

PTEN (rabbit, monoclonal)

9559

1:1000

Cell Signaling Technologies, Danvers,
MA

β-actin (mouse,
monoclonal)

A2228

1:1000

Sigma-Aldrich, St. Louis, MO
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200 µg/mL streptomycin sulfate and 0.5 µg/mL amphotericin B, Sigma Aldrich, St. Louis, MO) and
Plasmocin (1.25 µg/mL, Invitrogen, San Diego, CA). Cells were maintained in a 5% CO2 humidified
incubator at 37°C. OVCAR3 cells (ATCC® HTB-161TM, Manassas, VA) were cultured in RPMI-1640
media supplemented with 10% FBS, Antibiotic-antimycotic solution (final concentration 200 units/mL
penicillin G, 200 µg/mL streptomycin sulfate and 0.5 µg/mL amphotericin B, Sigma Aldrich, St. Louis,
MO) and Plasmocin (1.25 µg/mL, Invitrogen, San Diego, CA). Cells were maintained in a 5% CO2
humidified incubator at 37°C.

Protein Isolation and Immuno-blotting
For treatment with γ-AAPeptides, cells were grown to 50-60% confluency in 6-well plates, treated
with indicated amount of γ-AAPeptide and allowed to incubate for 6 hours at 5% CO2 and 37°C. After 6
hours, media was aspirated and cells were lysed in ice cold Lysis Buffer (25 mM Tris•HCl pH 7.4, 150 mM
NaCl, 1% NP-40, 1 mM EDTA, 5% glycerol) supplemented with 100X protease inhibitor cocktail (Sigma
Aldrich, St. Louis, MO), phosphatase inhibitor cocktail (final concentration 10mM sodium azide, 10mM
NaF, 4mM sodium orthovanadate, 10mM sodium-molybdate dehydrate, 4mM sodium-tartrate dibasic
dehydrate, 5mM EDTA disodium dehydrate, 2mM imidazole), 1mM DTT and 1mM PMSF. Samples were
sonicated at 10% amplitude using a digital sonifier (Branson Ultrasonics, Dabury, CT), centrifuged at
14,000 rpm for 10 minutes and the supernatant was collected. Protein concentration was determined using
Bradford Dye Reagent (BioRad, Hercules, CA). The remaining supernatant was boiled in 100μL of 2X or
4X Laemmli Buffer containing 5% β-mercaptoethanol (Sigma Aldrich, St. Louis, MO) and subjected to
SDS-PAGE gel analysis, followed by immunoblotting. 20μg of total cellular proteins obtained from cell
extract were separated on a 12% SDS-PAGE gel and electro-blotted to nitrocellulose membranes (0.45 μm;
GE Healthcare, Pittsburgh, PA). Blots were blocked with 5% nonfat dry milk or bovine serum albumin in
TBST buffer (10 mM Tris, pH 8,150 mM NaCl, 0.1% Tween 20) and incubated with indicated primary
antibodies (Table 2.1). Peroxidase conjugated mouse or rabbit secondary antibodies were used, dependent
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upon the primary antibody, at dilution of 1:10,000 (Jackson ImmunoResearch, West Grove, PA). Blots
were developed by chemiluminescence (Thermo Fisher Scientific, Waltham, MA) and developed on a
Chemidoc MP System (BioRad, Hercules, CA). Quantitative Densitometric analysis on the immunoblots
are reported as mean ± S.E. (*p-value of ≤0.05 was considered to be significant).

Cell Proliferation Assay
Cell proliferation studies were performed using A549 cells and the Cell Counting Kit-8 (Dojindo
Molecular Technologies, Rockville, MD). Cells were plated in a 96-well plate with a cell density of 9000
cells/well and cultured in F12K medium as described above. Cells were treated with indicated amount of
γ-AAPeptide, diluted in F12K media, for 24 hours. After 24 hours, final cell numbers were assessed as a
function of absorbance at 450nm of reduced WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4- nitrophenyl)-5(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt) [14]. Values were reported as the mean fold change
in the number of cells ± S.E. (*p-value of ≤0.05 was considered as significant; n=6).

Cell Migration Assay via ECIS
Migration assays were performed on the ECIS (Electric Cell Substrate Impedance Sensing) Z
instrument (Applied Biophysics, Troy, NY). Briefly, A549 cells were grown on electric cell substrate
impedance sensing 8-well plate arrays (8W1E; Applied Biophysics, Troy, NY) in F12K media as described
above. Confluent cells were treated with media containing γ-AAPeptide at desired concentration for 12
hours prior to wounding. Cells were wounded using an elevated field pulse of 1400 mA at 32,000 Hz
applied for 20 seconds, producing a uniform circular lesion of 250 mm in size, and wound closure was
tracked until healing. The impedance (Z) was measured at 32000 Hz, normalized to its value at the initiation
of data acquisition, and plotted as a function of time. Assays were performed in triplicate and reported as
the mean normalized resistance ± S.E. (*p-value of ≤0.05 was considered as significant).

43

Cell Cycle Analysis via Flow Cytometry
Cell cycle analysis was performed on A549 cells treated with indicated amount of γ-AAPeptide at
50-60% confluency for 24 hours. Subsequently, cells were trypsinized and centrifuged at 2,000 rpm for 10
minutes. Media and trypsin were aspirated and cells were washed twice with PBS and spun at 2,000 rpm
for 10 minutes at 4°C after each wash. Cells were then stained with trypan blue (Thermo Fisher Scientific,
Waltham, MA) and counted using a hemocytometer. Cells were resuspended in Phosphate Buffered Saline
(PBS) at a density of 2 X 106 cells/mL. Cells suspended in 1 mL PBS were fixed in 3 mL ice cold absolute
ethanol for 1 hour at 4°C. After fixing, cells were washed twice with PBS and spun at 3,000 rpm for 10
minutes at 4°C after each wash. 1 mL of Propidium Iodide (PI) staining solution (3.8mM sodium citrate,
40μg/mL PI and PBS to volume) was added to each cell pellet, along with 50μL of RNase A (Qiagen,
Hilden, Germany) at a concentration of 10μg/mL. Cells were incubated at 37°C for 20 minutes and stored
at 4°C until analyzed by flow cytometry. Assays were performed in triplicate, performed twice, and reported
as mean ± S.E. (p value of ≤0.05 was considered to be significant).

Results
Identifying a PTEN Primary Binding Hotspot
Lee et al. crystallized the PTEN Phosphatase Domain (PD) and C2 Domain (C2D) by removing
the intrinsically disordered N-terminal and C-terminal tails, as well as an internal 24 amino acid loop in the
C2D (PDB 1D5R) (Figure 2.1) [26]. Notably, this truncated protein retains lipid phosphatase activity,
similar to the PTEN wild-type protein [26]. To define where small molecules may likely target PTEN, I
performed computational mapping of most probable small molecule binding surfaces on the available
PTEN crystal structure, utilizing FTMap analysis [305]. The primary binding hot spot was revealed to be
at the interface of the PD and C2D (Figure 2.2), specifically at the pα6 helix (amino acid residues 170-185)
highlighted in purple in Figure 2.1. A secondary consensus sight was located at the cα1 helix (amino acid
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residues 275-281) (Figure 2.2), highlighted in blue in Figure 2.1. This PD/C2D interface consists of mostly
hydrophobic and aromatic residues, supplemented with a network of nine hydrogen bonds that preserve the
structural integrity and function of the interface [26]. Therefore, targeting the PD/C2D interface has a high
likelihood of influencing PTEN lipid phosphatase activity.
To test the above concept, a synthetic ɑ-helical peptide mimicking the pɑ6 helix (amino acid
residues 170-184), which is known to engage in productive and dynamic interaction at the PD/C2D
interface (Figure 2.3A), was generated to ascertain its influence on PTEN activity utilizing the in vitro MG
phosphatase assay. Indeed, titration with a synthetic ɑ-helical peptide mimicking the pɑ6 helix enhanced
full length PTEN wild-type enzyme activity as detected by the MG assay (Figure 2.3B).

Figure 2.1: Overview of PTEN Structure. (A) Cartoon representation of domains in PTEN. PBM: PIP2 Binding Module; PD:
Phosphatase Domain: C2D: C2 Domain; C-tail: flexible C-terminal; PDZ-BD: PDZ Binding Domain. (B) PTEN crystal structure
ID5R with domains and structures.
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Figure 2.2: PTEN PD/C2D Interface is a Small Molecule Binding Hotspot. FTMap analysis revealed a binding hot spot on
PTEN crystal structure PDB 1D5R to be located at the interface between the PD and C2D (pα6 helix: amino acids 170-185 and
cα1 helix: amino acids 275-281). All 16 standard probes aggregated near the PD/C2D interface.

Figure 2.3: PTEN PD/C2D Interface is Suitable for Targeting with Small Molecules. (A) Representation of the location of the
pɑ6 helix and the synthesized amino acid sequence. (B) The synthetic pɑ6 helix demonstrated dose-dependent activation of PTEN
lipid phosphatase function in a Malachite Green assay, n=4. Values reported as mean ± SE.
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γ-AAPeptides Enhance PTEN Lipid Phosphatase Activity
With a primary binding hotspot identified, 51 non-natural peptidomimetics, known as
γ-AAPeptides, were synthesized from the previously described N-acylated-N-aminoethyl amino acid
building block [7, 306]. γ-AAPeptides have high propensity for increased chemical diversification,
bioactivity, prolonged intracellular retention, and ability to abrogate protein-protein interactions, making
them ideal candidates to target the PD/C2D interface [309]. Briefly, the building block, already containing
the R2 side chain, underwent de-protection before addition of the R3 and R1 side chains. After cleavage of
this intermediate from the solid phase, the R4 group was appended to the C-terminus, completing synthesis
(Figure 2.4). Select γ-AAPeptides described below were purified and verified by HPLC and NMR
spectroscopy, respectively (Table A1 and Figure A1) [7].

Figure 2.4: γ-AAPeptide Synthesis. γ-AAPeptides were synthesized directly from the N-acylated-N-aminoethyl amino acid
building block harboring the R2 side chain. Structurally and chemically diverse R1, R3 and R4 side chains are appended to create
the final structure.

The MG assay was used to screen 51 γ-AAPeptides at a 1μM concentration and found that 33
γ-AAPeptides increased PTEN activity (Figure 2.5A). Strikingly, 19 of 51 γ-AAPeptides contained an
adamantyl side group at position R3, of which 18 enhanced PTEN activity (Figure 2.5B). Further analysis
identified 10 γ-AAPeptides to be promising in a MG titration assay, with γ-AAPeptide #43 as the most
potent activator (Figure 2.5C and Table 2.2). Therefore, all further analysis was performed with
γ-AAPeptide #43.
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Figure 2.5: Select γ-AAPeptides Enhanced PTEN Lipid Phosphatase Activity. (A) 51 γ-AAPeptides were screened for changes
in PTEN lipid phosphatase activity at 1μM using Malachite Green assay, n=4. Values reported as mean ± SE. (B) Flow chart
representing γ-AAPeptide structure function relationship analysis. From 51 γ-AAPeptides, 19 contained an adamantyl side chain
and 18 were shown to enhance PTEN activity (66% of all activators). (C) 10 select γ-AAPeptides were titrated and measured for
changes in PTEN lipid phosphatase activity using Malachite Green assay, n=4. Values reported as mean ± SE.
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Table 2.2: Structures of Select γ-AAPeptides which Enhanced PTEN Lipid Phosphatase Activity.
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Since these γ-AAPeptides were designed to bind at the PD/C2D interface, which is a site that is
distinct from the active binding site of PTEN, γ-AAPeptide #43 likely enhances PTEN lipid phosphatase
activity via indirect conformational modulation in PTEN. To this point, I utilized the MG assay to generate
a PI(3,4,5)P3 substrate dose-response curve in the absence or presence of 1μM γ-AAPeptide #43. PTEN
activity in the absence of activator demonstrated a sigmoidal curve with increased PI(3,4,5)P3 substrate
(Figure 2.6), suggesting inherent allostery. Indeed, the Hill coefficient was h=1.852, Vmax was calculated
as 61.57 pmol phosphate released/min, and Khalf was calculated to be 55.78μM. Addition of 1μM
γ-AAPeptide #43 shifted the curve to the left and significantly increased the Vmax of PTEN to 70.34pmol
phosphate/min, reflecting the effect of γ-AAPeptide #43 binding to the PD/C2D interface (Figure 2.6).
Although Khalf (54.18μM) and h (1.717) changed slightly, the values were not calculated to be significantly
different from the PTEN alone curve.

Figure 2.6: γ-AAPeptide #43 Enhances PTEN Activity. Increasing PIP3 concentration in the presence of PTEN alone produces
a sigmoidal curve with a calculated Vmax= 61.57 pmol phosphate/min, Khalf= 55.78μM, and h=1.852. PTEN protein pre-incubated
with γ-AAPeptide #43 prior to PIP3 addition also produced a sigmoidal curve which is shifted to the right. The Vmax of the curve
significantly increased to 70.34 pmol phosphate/min (t-test, *p-value≤0.05), with a Khalf= 54.18μM and h=1.717.

A Select γ-AAPeptide Reduces Oncogenic Signaling in Cancer Cells
Since γ-AAPeptide #43 caused the most prominent increase in PTEN lipid phosphatase activity in
vitro, I tested it’s effects in attenuating oncogenic potential of a lung cancer cell line, A549, which has
normal PTEN protein expression but hyperactive KRAS signaling due to KRAS mutation. Treatment of
A549 cells with γ-AAPeptide #43 for 6 hours demonstrated a significant decrease in the phosphorylated,
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active form of AKT (pAKT Ser473) and P70S6K, (p-P70S6K Thr389), indicating inhibition of canonical
PI3K signaling (Figure 2.7A). In contrast, γ-AAPeptide #43 did not significantly alter the phosphorylation
at the PTEN C-tail amino acid cluster (Ser380, Thr382, Thr383, Ser385) (Figure 2.7A). PI3K pathway
inhibition after γ-AAPeptide #43 treatment was observed in another cell line with normal PTEN protein
expression: ovarian cancer cell line OVCAR3. Treatment with γ-AAPeptide #43 significantly decreased
both p-AKT and p-S6K levels (Figure 2.7B).

Figure 2.7: A Select γ-AAPeptide Antagonized PI3K Pathway Signaling in Cancer Cell Lines. (A) Immuno-blot analysis
revealed a significant decrease in phosphorylated and activated PI3K/AKT/S6K pathway effectors, p-AKT (Ser473) and p-P70
S6K (Thr389), in A549 cells treated with 40μM #43 for 6 hours. Quantitative densitometric analyses of blots for each component
is shown below, n=4 (*p-value ≤0.05; n.s.= not significant). (B) Immuno-blot analysis revealed a significant decrease in
phosphorylated and activated PI3K/AKT/S6K pathway effectors, p-AKT (Ser473), p-P70 S6K (Thr389) and p-PTEN (Ser380,
Thr382, Thr383) in OVCAR3 cells treated with 40μM γ-AA Peptide #43 for 6 hours. Quantitative densitometric analyses of blots
for each component is shown below, n=3 (*p-value ≤0.05).

A Select γ-AAPeptide Inhibits Tumorigenic Features in Lung Cancer Cells
Enhancing PTEN expression or function in cancer cells is known to suppress cell proliferation and
cell migration, and inhibit cell cycle progression [32, 33]. Since γ-AAPeptide #43 can augment endogenous
PTEN function in two distinct cancer cell lines to dampen PI3K pathway signaling, I hypothesized that #43
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would likely modulate other oncogenic properties of cancer cells, including cell proliferation, migration
and cell cycle progression. To test this hypothesis, I treated A549 cells with γ-AAPeptide #43 and assessed
its effects on cell proliferation, migration and alteration in cell cycle. Indeed, 24 hours of treatment with
γ-AAPeptide #43 suppressed cell proliferation in a dose-dependent manner (Figure 2.8A). Likewise, cell
migration studies using the ECIS method demonstrated that γ-AAPeptide #43 significantly inhibited the
rate of A549 cell migration (Figure 2.8B). PTEN inhibits cell proliferation by inducing cell cycle arrest at
the G1 and G2/M transition phases [310]. Treatment of A549 cells with γ-AAPeptide #43 for 24 hours
arrested cells in the G1 phase, as determined by the increase in cell population in the G1 phase and decrease
in cell population in the S phase (Figure 2.8C). Notably, γ-AAPeptide #43 had a negligible increase in the
sub-G1 cell population (Figure 2.8C), suggesting that it is not cytotoxic at the concentration of
γ-AAPeptide #43 assessed in this assay [311]. Taken together, γ-AAPeptide #43 inhibited well-established
oncogenic properties of A549 cells, including PI3K signaling, cell proliferation, cell migration and cell
cycle progression.

Figure 2.8: A Select γ-AAPeptide Inhibits Oncogenic Potential of A549 Lung Cancer Cells. (A) Dose-dependent inhibition
of cell proliferation was observed in cells treated with γ-AAPeptide #43 for 24 hours. Cells were plated at 9000 cells/well, n=6
(*p-value ≤0.05). (B) Continuous impedance sensing measurements revealed a significant decrease in rate of wound closure for
cells treated with 30μM γ-AAPeptide #43, 12 hours prior to wounding, as compared to cells treated with vehicle, n=3 (p-value of
≤0.05 was considered to be significant). (C) Cell cycle analysis of cells treated with 40μM γ-AAPeptide #43 for 24 hours increased
G1 cell population and decreased S phase cell population, n=3 (*p-value ≤0.05).

Conclusion
The lipid phosphatase activity of PTEN is crucial for its function as a potent tumor suppressor [31].
As the master regulator of the PI3K pathway, reduction in PTEN expression or function, or hyperactivation
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of the PI3K pathway, heightens oncogenic potential of cells and drive tumorigenesis [96, 303, 312]. Since
therapeutic resistance and toxicities are common in patients undergoing chemotherapy or KI treatment, the
need for novel and alternative adjunctive therapies can reduce the doses of standard therapies, and thus
morbidity observed in the clinic [96, 286, 287, 303]. PTEN restoration therapy has proved promising;
however, direct and targeted activation of PTEN has not been attempted. In this chapter, I have
demonstrated targeted activation of PTEN lipid phosphatase activity using a class of peptidomimetics
known as γ-AAPeptides. Their cell penetration efficiency and high intra-cellular retention makes them
efficient therapeutic molecules. I was able to identify a single lead γ-AAPeptide that increased PTEN
activity in vitro, likely binding to the PD/C2D interface, modulating PTEN structure and enhancing its
activity. This γ-AAPeptide likely activated endogenous cellular PTEN, reducing the PI3K signaling and
decreasing cell proliferation, migration and cell cycle progression in lung cancer cells. Since this
γ-AAPeptide also decreased PI3K pathway activation in another PTEN containing cell line, OVCAR3,
these results suggest that γ-AAPeptides have the potential to be used as a treatment for cancer patients that
harbor varying amounts of PTEN wild-type protein. In the next chapter, I will elucidate the binding
interactions of this promising γ-AAPeptide with PTEN protein to determine its allosteric mechanism of
activation.
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CHAPTER 3: Elucidation of γ-AAPeptide Mediated Enhancement of PTEN Activity

Background
Both PTEN lipid and protein phosphatase activities are dependent upon the active catalytic site
located entirely within the PD [26]. As detailed in Chapter 1, the pɑ4 helix contains the catalytic cysteine
residue responsible for dephosphorylation of lipid and protein substrates. The remainder of the active site
is composed of the WPD-loop, which stabilizes substrate binding for dephosphorylation, and the TI-loop,
which is necessary to accommodate large phospholipid substrates [26]. γ-AAPeptides were identified to
target the PD/C2D interface, which is directly adjacent to the active site, to influence PTEN activity.
Notably, PTEN enzymatic activity is dependent upon the integrity of the PD/C2D interface, and I have
shown that competitive binding at this interface can enhance PTEN activity in vitro. Since I have identified
γ-AAPeptides with a common adamantyl functional group, which have the ability to either activate or
inhibit PTEN function, it is likely that differences in binding affinity and orientation modulates PTEN
enzymatic activity. Therefore, in this chapter, I have performed molecular docking and molecular dynamic
simulation studies to elucidate how γ-AAPeptides may bind to the PTEN PD/C2D interface and influence
PIP3 catalysis in the active site.
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Materials and Methods
Molecular Docking
Rigid Docking with DOCK
PTEN crystal structure 1D5R was used for rigid body docking to screen for potential ligand binding
using the program DOCK 3.5.54 [313, 314]. The binding pocket was resolved from FTMap analysis and
was designated as amino acid residues 170-185, 278 and 279 of PTEN. These residues were used to
generate matching spheres, which were chemically labeled for matching based on ionization states and
hydrogen bonding of protein residues in the nearby vicinity. The test set of γ-AAPeptides were docked into
the binding pocket, ranked based upon score, and visually inspected with the visualization software PyMol
for chemical complementarity and spatial positioning.

Induced Fit Docking with Schrodinger
All flexible ligand/flexible receptor docking studies were performed using Schrödinger’s Induced
Fit Docking module [315, 316]. In our first set of docking studies, γ-AAPeptide ligands #43 (activator) and
#42 (inhibitor) were prepared using LigPrep 2.3 to produce all 3D structures with corresponding
stereochemistry, and Epik, which generated protonation states at a pH of 7.0 ± 2. Additionally, Epik was
used to prepare the protonation states of PTEN 1D5R at pH 7.0 ± 2 [317]. Propka was used to optimize all
hydrogen bonds within the crystals and OPLS3 force field was used for atom minimization [318]. The
prepared γ-AAPeptide ligands were docked into our proposed binding site, as determined by FTMap
analysis (residues 170-185, 278, 279). γ-AAPeptides #43 and #42 were initially docked into the binding
site using GlideSP (Glide Standard Precision) [319, 320]. This binding site, as well as relevant PTEN active
site residues (91-94, 123-130, 163-166), were “trimmed” (mutated to alanine, then later back-mutated to
their original identities) to promote induced flexibility. Furthermore, residues within 10Å of the binding
site were subject to energy minimization. After initial placement, Schrödinger’s Prime side-chain prediction
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is used to predict new orientations for all “trimmed” residues. Finally, GlideXP (Glide eXtra Precision) is
then used to “re-place” the ligand in its initially predicted location and determine the final top scoring
binding modes [321].
The top scoring PTEN-complexed γ-AAPeptide #43 and #42 structures were then used as starting
structures in the second set of docking studies, where PTEN substrate PIP3 was docked into the active site
of PTEN (residues 91-94, 123-130, 163-166). To simulate PIP3 docking into an apo-PTEN active site, a
“dummy” water molecule was first docked at the γ-AAPeptide binding site using the same above-mentioned
protocol. This was to ensure that apo-PTEN underwent the same trimming/refinement process as
γ-AAPeptide-bound PTEN structures prior to PIP3 active site docking. All residues within 10Å of the active
site, with the exception of the γ-AAPeptide binding site residues (170-185, 278, 279) were subject to
structural and energetic refinement. In order to preserve, any conformational changes in the active site
structure produced by γ-AAPeptide or water molecule binding, trimming was not employed in these
dockings. Glide XP was used to generate the top scoring binding modes of PIP3 in the active site.

Intrinsic Disorder Analysis
Intrinsic disorder profiles for the full-length human PTEN (UniProt ID: P60484) were generated
by PONDR® VLXT [322], PONDR® VL3 [323], PONDR® VSL2 [323, 324], PONDR® FIT [325],
IUPred_short and IUPred_long [326]. PONDR® VLXT is one of the first-generation disorder predictors.
Although its accuracy is not too high, this predictor is known to have high sensitivity to local sequence
peculiarities and can be used for identifying disorder-based interaction sites [322, 327-329]. In fact, because
it was trained on the limited set of then available proteins with experimentally validated intrinsically
disordered status, PONDR® VLXT may underestimate the occurrence of long disordered regions in
proteins. PONDR® VL3 was specifically designed to accurately predict long disordered regions [323].
PONDR® VSL2 is one of the more accurate stand-alone disorder predictors [330, 331]. PONDR® FIT is
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a metapredictor of intrinsic disorder that is known to be moderately more accurate than each of the
component predictors [325]. After obtaining an average disorder score by each predictor, all predictorspecific average scores were averaged again to generate an average per-protein intrinsic disorder score. Use
of consensus for evaluation of intrinsic disorder is motivated by empirical observations that this approach
usually increases the predictive performance compared to the use of a single predictor [330-332].

Molecular Dynamics Simulations
PTEN crystals structure 1D5R and all simulations for γ-AAPeptide #43, #42 and apo complexes
were run using the CHARMM (Chemistry at HARvard Macromolecular Mechanics) biomolecular
modeling program [333]. The online CHARMM interface, CHARMMing, was used to prepare all structures
for simulation, as explained here [334]. 1D5R protein structure was treated with CHARMM (C36) force
field and all ligand topology and parameters were determined using the CHARMM generalized forcefield
(CGenFF) available through the ParamChem web-interface [335]. Each protein-ligand complex (herein
referred to as protein system) was solvated in a 91.565 Å x 91.565 Å x 91.565 Å cubic box using 23,029
TIP3P water molecules [336], long range conditions were modeled using periodic boundary conditions.
Loose/short (50 step) Steepest Descent (SD) minimization protocol was used to minimize bad initial
contacts. The systems were subsequentially neutralized with the addition of 0.15M KCl salt. Following
neutralization, 10 steps of SD minimization and 25 steps of Adopted Basis Newton-Raphson (ABNR)
minimization was performed to alleviate steric clashing between protein, solvent, and ion atoms. Domain
Decomposition (DOMDEC) and Graphical Processing Unit (GPU) compatible CHARMM versions were
used to heat each system from 110.5K to 310K over a 400 picosecond (ps) timeframe, with a time step of
1 femtosecond (fs), and then allowed to equilibrate under isothermal-isobaric conditions (NpT ensemble)
for 20 nanosecond (ns). After initial equilibration, each system was simulated under NpT conditions for
140ns. The SHAKE algorithm constrained all covalent bonds to hydrogen atoms. Long range electrostatic
interactions were evaluated using Particle Mesh Ewald (PME) (k=0.34, order of B-spline interpolation=6)
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and dispersion-type interactions were modeled using Lennard-Jones potential with a switching function
between 8-12Å from the central atom and a 12Å cut-off, both of these methods were used in conjunction
with periodic boundary conditions [337].
Results
Select γ-AAPeptides Target Unique Residues in the PD/C2D Interface
Exploratory Study via Rigid Docking
To delineate the molecular mechanism by which γ-AAPeptides may bind and activate PTEN,
molecular docking studies were performed to determine the binding of γ-AAPeptide #43 with PTEN
protein. DOCK 3.5.54 [313] software was used, targeting amino acid residues identified within the FTMap
analysis binding hotspot (170-185, 278 and 279) on PTEN crystal structure PDB 1D5R. γ-AAPeptide #43
oriented productively within the PD/C2D interface, where the R3 adamantyl side chain inserted into the
cleft, which contains multiple aromatic residues (Y176, Y177, Y180, F279) (Figure 3.1). This non-polar
binding pocket also accommodated aromatic side chains R2 and R4, while the aliphatic R1 side chains
protruded out of the binding pocket towards bulk solvent (Figure 3.1). Overall, rigid docking suggests that
activator γ-AAPeptide #43 likely makes significant and favorable contacts with the suspected PTEN
PD/C2D binding interface.

Figure 3.1: Rigid Docking Demonstrates Potential γ-AAPeptide #43-PTEN Interaction. γ-AAPeptide #43 docked into PTEN
1D5R using DOCK 3.5.54. Docking pose is in a plausible orientation within the hydrophobic/nonpolar PD/C2D interface.
Visualized in PyMol.
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Validation via Induced Fit Docking
Since proteins utilize their inherent flexibility to achieve best binding, I utilized the induced fit
approach, which accounts for flexibility in the binding pocket upon γ-AAPeptide binding. Shrödinger’s
Glide module was employed to dock γ-AAPeptide #43 to PTEN 1D5R. Additionally, the screening analysis
discussed in Chapter 2 highlighted that only one γ-AAPeptide containing an adamantyl ring decreases
PTEN enzymatic activity, γ-AAPeptide #42. Titration of γ-AAPeptide #42 in a MG assay shows a dosedependent decrease in PTEN lipid phosphatase activity (Figure A2). Since this inhibitor is highly similar
in structure to the adamantyl containing activator γ-AAPeptide #43, I posited that γ-AAPeptide #42 makes
distinct interactions at the PD/C2D interface from that of γ-AAPeptide #43, which may accounts for the
functional differences (i.e. inhibition of PTEN activity by #42 binding) in PTEN lipid phosphatase activity
between the two γ-AAPeptides.
As outlined in the methods, the γ-AAPeptide binding site residues (170-185, 278, 279) were
trimmed to open the binding pocket, and all residues within 10Å of the binding site were subject to

Figure 3.2: Adamantyl Containing γ-AAPeptides Have a High Binding Affinity for the PD/C2D Interface. Induced Fit
Docking (IFD) was utilized to simulate protein flexibility upon γ-AAPeptide binding and obtain predicted binding energies of each
interaction. (A) γ-AAPeptide #43 docked into the PTEN PD/C2D interface in 1D5R with a binding energy of -13.427kcal/mol.
Hydrogen bonding interactions are observed between the γ-AAPeptide R1 aliphatic group and D324 and T319 in the C2D.
Additionally, the γ-AAPeptide backbone interacts with R173 in the PD. (B) γ-AAPeptide #42 docked into the PTEN PD/C2D
interface in 1D5R with a binding energy of -11.596kcal/mol. Hydrogen bonding occurs between the aliphatic R1 group and residues
D324 and T319 in the C2D. A potential base stacking interaction exists between the hexafluorobenzene and T180.
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refinement. Docking of γ-AAPeptide #43 and #42 to PTEN structure 1D5R revealed low energy binding
modes of -13.427kcal/mol and -11.596kcal/mol, respectively (Figure 3.2). Both binding poses demonstrate
extensive interactions of the aromatic ring structures of the R2-4 side chains with aromatic PTEN residues
Y176, Y180, F278 and F279, yielding overall favorable binding modes. γ-AAPeptide #43 makes hydrogen
bonding interactions with residues in the PD and C2D (R173, D324 and T319), while γ-AAPeptide #42
makes hydrogen bonds only within the C2D (D324, T319 and N276) (Figure 3.2). Additionally, there is a
potential base stacking interaction between Y180 and the hexafluorobenzene group at the R4 position of
γ-AAPeptide #42 (Figure 3.2B). Interestingly, the R3 adamantyl groups on each γ-AAPeptide are located
at different locations within the binding pocket (Figure 3.2). Thus, each γ-AAPeptide has a distinct binding
pose within the PD/C2D interface.

γ-AAPeptide Binding Alters PIP3 Binding Affinity and Orientation
Since γ-AAPeptide #43 and #42 have opposing effects on PTEN lipid phosphatase activity in vitro,
but are predicted to bind to the same interface, I posited that binding of each γ-AAPeptide has differential
effects on PIP3 binding in the PTEN active site. To test this hypothesis, PIP3 was docked into the active
site of apo-, #43 bound-, and #42 bound-PTEN 1D5R. Indeed, PIP3 binding affinity and orientation varied
based on the bound γ-AAPeptide (Figure 3.3).
When PIP3 was docked into the active site of PTEN 1D5R, it gave a binding score of
-9.972kcal/mol (Figure 3.3A). Furthermore, the 3’ phosphate is 5.2Å from the catalytic C124 residue,
therefore the binding pose is within nucleophilic attack distance, conducive for catalysis (Figure 3.3A).
Strikingly, when PIP3 is docked into the active site with γ-AAPeptide #43 bound to the PD/C2D interface,
the PIP3 active site binding affinity increased, with a binding score of -14.180kcal/mol, and the 3’
phosphate group is closer to the catalytic C124 residue by more than 1Å, at a distance of 4.1Å (Figure
3.3B). In contrast, when PIP3 is docked into the active site with γ-AAPeptide #42 bound to the PD/C2D
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interface, the PIP3 active site binding affinity is decreased by 2.56 kcal/mol as compared to the #43-bound
PTEN. Furthermore, 3’ phosphate group is not within range of the catalytic C124 residue, therefore is not
in range for hydrolysis (Figure 3.3C). These finding indicate that γ-AAPeptides #43 and #42 binding
differentially modulates PIP3 active site binding affinity, orientation and catalysis.

Figure 3.3: γ-AAPeptide Binding Influences PIP3 Active Site Binding and Orientation. (A) PIP3 docked into the apo-PTEN
1D5R active site with a binding energy of -9.972kcal/mol. The 3’ phosphate group is positioned 5.2Å away from the catalytic
C124. (B) PIP3 docked into γ-AAPeptide #43-bound PTEN 1D5R with a binding energy of -14.180kcal/mol, a higher binding
affinity than PIP3 docked into apo-PTEN. The 3’ phosphate group is positioned 4.1Å away from the catalytic C124, closer than
the PIP3 3’ phosphate in apo-PTEN. (C) PIP3 docked into γ-AAPeptide #42-bound PTEN 1D5R with a binding energy of
-11.621kcal/mol, a higher binding affinity than PIP3 docked into apo-PTEN, but lower than PIP3 docked into #43-bound PTEN.
The 3’ phosphate group is positioned 11.6Å away from the catalytic C124, a position not within the nucleophilic attack distance.

To validate that PD/C2D is indeed the major site from where the γ-AAPeptides modulate PTEN
catalytic activity, I systematically mutated critical amino acids lining the PD/C2D interface. Interestingly,
these mutations drastically altered γ-AAPeptide #43 and PIP3 active site binding. Alanine mutations were
generated within the interface at residues Y176, Y177, Y180, F279, D324 and γ-AAPeptide #43 was docked
into the interface. Each individual mutation decreased the binding affinity, as determined by an increase in
the binding score (Table 3.1). Furthermore, PIP3 was docked into the active site of these mutant PTEN
structures in the absence or presence of γ-AAPeptide #43. In the absence of γ-AAPeptide #43 (apo-PTEN),
the F278A mutation allowed PIP3 binding in the active site, albeit in an improper orientation so the 3’
phosphatase is not within distance of the catalytic C124 residue, indicating that this residue may be
necessary for productive PIP3 binding in wild-type PTEN (Table 3.2). All other alanine mutations allowed
for proper PIP3 binding and orientation in apo-PTEN (Table 3.2). Interestingly, docking of PIP3 into the
active site of γ-AAPeptide #43-bound mutant PTEN either abrogated PIP3 binding or resulted in an
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unproductive binding orientation where the 3’ phosphate was not in range of the catalytic cysteine residue
(Table 3.2).
Table 3.1: Mutations in PTEN 1D5R PD/C2D Interface Alters γ-AAPeptide Binding Affinity. Mutations in PD/C2D interface
residues decrease the binding affinity (an increase in binding score) of γ-AAPeptide #43 for the interface.

PTEN (1D5R)

#43 binding (kcal/mol)

WT

-13.427

Y176A

-13.023

Y177A

-13.404

Y180A

-13.134

F278A

-11.704

D324A

-12.653

Table 3.2: Mutations in PTEN 1D5R PD/C2D Interface Disrupts γ-AAPeptide-induced Effects on PIP3 Binding. Mutations at
the PD/C2D interface alter the binding affinity for PIP3 in the active site in the presence or absence of γ-AAPeptide. Notably, the
F278A mutations does not produce a binding pose where the 3’ phosphatase is within attacking distance of the catalytic C124 residue.
Docking γ-AAPeptide #43 to the mutated PD/C2D interface disrupts effective PIP3 active site binding by producing an incorrect
active site orientation (3’displaced: 3’ phosphatase is not within range of the catalytic C124 residue) or abolishing PIP3 binding
entirely (No binding).

PTEN (1D5R)

PIP3 – apo (kcal/mol)

PIP3 - #43 (kcal/mol)

WT

-9.972

-14.180

Y180A

-11.18

3’ displaced

F278A

3’ displaced

3’displaced

Y177A

-10.412

No binding

Y176A

-12.1

No binding

D324A

-11.252

3’ displaced
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Identifying Regions of PTEN that Induce Allostery
Although these γ-AAPeptides bind at a distant region from the catalytic site, they alter PTEN
activity significantly. It is plausible that such binding induces an allosteric effect, which can, via positive
coupling, augment the function of the catalytic site of PTEN, particularly facilitated by intrinsically
disordered regions (IDRs) in enzymes [338]. Figure 3.4 represents computational analysis that identifies
intrinsic disorder in human PTEN wild-type. The positions of α-helices pα6 and cα1, where these
γ-AAPeptides likely bind, are indicated by the shaded areas. Although both helices are located within
mostly ordered regions of the protein due to the high content of aromatic residues, they occupy a unique
position in close proximity to the highly disordered loops, such as the TI-loop (amino acid residues 161169) and the non-crystallizable loop in the C2D (amino acid residues 286-309), being positioned right at
the edge of the sharp "disorder-to-order" or "order-to-disorder" transitions. It is likely that such positioning
of binding sites should significantly affect mobility of these neighboring loops when a γ-AAPeptide is
bound. Furthermore, it is also likely that the γ-AAPeptides binding can affect the dynamics of the P-loop
indirectly, via the TI-loop, which may influence PIP3 active site binding and orientation.

Figure 3.4: γ-AAPeptides Bind PTEN at Regions Adjacent to Intrinsically Disordered Loops. Intrinsic disorder propensity of
PTEN evaluated by several well-established disorder predictors. Cyan dash-dot-dotted lines show the mean disorder propensity
calculated by averaging disorder profiles of individual predictors. Intrinsic disorder propensity above 0.5 indicates intrinsically
disordered residues. The gray and green shaded areas are where γ-AAPeptides are predicted to bind. The green shaded area is
directly adjacent to the intrinsically disordered loop in the C2D that is deleted from the crystal structure. The peak of intrinsic
disorder next to the gray shaded region is the TI-loop within the active site of PTEN.
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γ-AAPeptide Binding Alters Active Site Conformation
Since both γ-AAPeptides #43 and #42 stabilize the PD/C2D interface and the active site, but have
differential effects on PTEN lipid phosphatase activity, it is plausible that each γ-AAPeptide stabilizes the
active site residues in different conformations to regulate PIP3 binding and orientation. To test this
hypothesis, I overlaid the three active sites (apo-PTEN, #43-bound PTEN and #42-bound PTEN) after PIP3
binding via the IFD protocol. Comparison of the orientation of residues across the three active sites of
PTEN revealed a set of select residues in distinct positions (Figure 3.5). For example, residues C124, K125,
K163, I168 and P169 exhibit similar conformations in the absence and presence of γ-AAPeptide binding
(Figure 3.5). Conversely, K128, V166 and T167 positions show variation in the absence or presence of each
γ-AAPeptides (Figure 3.5). D92 and R130 orientations in apo-PTEN and γ-AAPeptide #43-bound PTEN
are in the same conformation, while the R130 and D92 orientations in γ-AAPeptide #42-bound PTEN differ
(Figure 3.5A). Alternatively, γ-AAPeptide #43 or #42 binding locked residues H93, R161, D162 and K164
in the same conformation, differing from apo-PTEN (Figure 3.5B). Thus, these overlaid structures show

Figure 3.5: Binding of γ-AAPeptides to the PD/C2D Interface Changes Active Site Residue Conformations. After PIP3 was
docked into the active site using the IFD protocol, the PIP3 molecules were removed and the active sites of apo-PTEN, γ-AAPeptide
#43-bound PTEN and γ-AAPeptide #42-bound PTEN were overlaid in PyMol. (A) Overlaid PTEN structures highlighting the
conformations of select residues from the P-loop (C124, K125 and K128) and the WPD-loop (D92 and H93). (B) Overlaid PTEN
structures highlighting the conformations of select residues from the TI-loop. Select active site residues do not have significant
changes in their conformations upon γ-AAPeptide binding, such as C124, K125 and K163. Conversely, the remainder of the
highlighted residues seem to adopt alternative conformations in comparison to apo-PTEN, likely due to γ-AAPeptide binding.
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differential displacement of active site residue conformations in the presence or absence of these
γ-AAPeptides.

γ-AAPeptide Binding Stabilizes PTEN Protein Structure
To determine the effects of γ-AAPeptide binding on PTEN structure and active site residue
orientation, molecular dynamics (MD) simulations were performed over a 140ns timeframe utilizing PTEN
1D5R structure. The γ-AAPeptide binding site (BS), the PIP3 BS and the TI-loop in apo-PTEN are highly
flexible with RMSD values between ~15-22Å (Figure 3.6A). However, upon γ-AAPeptide #43 or #42
binding, the γ-AAPeptide BS, PIP3 BS and the TI-loop alone all become much more rigid structures,
decreasing the RMSD values by 10-15Å (Figure 3.6B-C).
Since γ-AAPeptides #43 and #42 have differential effects on PTEN lipid phosphatase activity in
vitro and stabilize PTEN as determined by MD analysis, it is possible that γ-AAPeptide binding induces
conformational changes in the active site. In order to determine if γ-AAPeptide #43 or #42 binding can
stabilize the active site residues in distinct orientations, the dihedral angles of the active site binding pocket
were analyzed (residues 91-94, 123-130 and 161-169). γ-AAPeptide #43 or #42 binding showed no distinct
differences in the dihedral angle orientations and fluctuations in residues E91, D92, H93, H123, T160,
R161, K163, V166, and I168 as compared to apo-PTEN protein (Figure A3). In contrast, both γ-AAPeptides
induce similar dihedral angle orientations and fluctuations in residues K128, G129, D162 and K164 as
compared to apo-PTEN, likely indicating a structural change induced by general γ-AAPeptide binding
(Figure 3.7). Individually, each γ-AAPeptide can produce distinct residue conformations as compared to
γ-AAPeptide-bound or apo-PTEN. For example, binding of γ-AAPeptide #43 results in similar dihedral
angle orientations and fluctuations in N94 and K125 as compared to apo-PTEN; however, γ-AAPeptide
#42 binding produces different dihedral angles in the select bonds of these residues (Figure 3.8A-B). In
contrast, γ-AAPeptide #42 binding does not alter the dihedral angles of residue T167 as compared to apo-
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PTEN, while γ-AAPeptide #43 binding produces a distinct and altered dihedral angle signature (Figure
3.8C). Lastly, dihedral angle analysis of residues C124, A126, G127, R130 and G165 shows distinct
signatures between apo-PTEN, γ-AAPeptide #43-bound PTEN and γ-AAPeptide #42-bound PTEN (Figure
3.8D-H).

Figure 3.6: γ-AAPeptide Binding to the PD/C2D Interface Stabilizes the Domain Interface and Active Site Pocket. Molecular
dynamic simulations were run over a 140ns timeframe. (A) The PTEN 1D5R γ-AAPeptide binding site (BS), PIP3 BS and TI-loop
fluctuate with an RMSD value between 15-20Å over the course of the simulation. (B) γ-AAPeptide #43 binding significantly
decreases the RMSD values of the γ-AAPeptide binding site (BS), PIP3 BS and TI-loop in PTEN 1D5R. The RMSD values are
below 5Å for all sites over the course of the simulation, a decrease in ≥10Å compared to apo-PTEN. (C) γ-AAPeptide #42 binding
significantly decreases the RMSD values of the γ-AAPeptide binding site (BS), PIP3 BS and TI-loop in PTEN 1D5R. The RMSD
values are below 5Å for all sites over the course of the simulation, a decrease in ≥10Å compared to apo-PTEN.
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Figure 3.7: Overall Conformational Changes in PTEN Active Site Residues Following γ-AAPeptide Binding. Dihedral angle
analysis of the active site residues in apo-PTEN, γ-AAPeptide #43-bound PTEN and γ-AAPeptide #42-bound PTEN revealed that
despite differences in overall γ-AAPeptide structure, they can induce similar changes in specific dihedral angles of select residues
as compared to apo-PTEN. (A) The Psi angle in K128 is mostly stabilized at 50° in γ-AAPeptide bound structures (i, iii) while it
flips between 150° and -150° in apo-PTEN (ii). (B) Both Phi and Psi angles in G129 are stabilized in similar positions in
γ-AAPeptide bound PTEN structures (i, iii) while the angles consistently fluctuate in apo-PTEN (ii). (C) The Chi1 angles in
γ-AAPeptide bound PTEN structures flip between 50° and -50° in D162 (i, iii) while the angle is stabilized at -50° in apo-PTEN
(ii). (D) The Psi angle in K164 flips between approximately -25° and 125° in γ-AAPeptide bound PTEN structures (i, iii) while it
is mostly stabilized at 125° in apo-PTEN (ii). All other dihedral angles and their fluctuations in A-D remain consistent throughout
all three PTEN structures. (Phi: black, Psi: blue, Chi1: green, Chi2: magenta, Chi3: red, Chi4, cyan).
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Figure 3.8: Select γ-AAPeptide Binding Induces Selective Conformational Changes in Active Site Residues. (A) The
fluctuations in Phi, Psi and Chi1 angles in N94 are similar between apo-PTEN and γ-AAPeptide bound PTEN structures. In
γ-AAPeptide #42-bound PTEN, the Chi2 angle fluctuates between 0-100° (iii) while the fluctuations in apo-PTEN and
γ-AAPeptide #43-bound PTEN range from -50-0° (i, iii). (B) While Psi flips between -50° and 150° in K125 in apo-PTEN
and γ-AAPeptide #43-bound PTEN structures, Psi is stabilized at approximately -50° in γ-AAPeptide #42 bound PTEN (iii).
(C) Psi in T167 is mostly stabilized at approximately -25° in apo-PTEN and γ-AAPeptide #42-bound PTEN structures (ii,
iii) while it flips between -25° and 125° in γ-AAPeptide #43-bound PTEN (i). Additionally, Chi1 in γ-AAPeptide #43-bound
PTEN fluctuates more than in apo-PTEN and γ-AAPeptide #42-bound PTEN. (D) The Phi and Psi angles of C124 between
γ-AAPeptide #43-bound PTEN and apo-PTEN are similar in comparison to γ-AAPeptide #42-bound PTEN, while the Chi1
angles are mostly similar in their fluctuations between γ-AAPeptide #43-bound PTEN and γ-AAPeptide #42-bound PTEN.
(E) The Phi and Psi angles in A126 are stabilized in different positions between all three structures. (F) The G127 Psi angles
differ between all three structures. Phi in apo-PTEN flips between -75° and 75° (ii) while it is stabilized at 75° and -75°,
respectively, in γ-AAPeptide #43- and γ-AAPeptide #42-bound PTEN (i, iii). (G) Chi3 in R130 apo-PTEN flips between
50° and -75° (ii) while γ-AAPeptide #43- and γ-AAPeptide #42-bound Chi3 is stabilized at -75° and approximately 50°,
respectively (i, iii). (H) The Phi angle in G165 is similar between γ-AAPeptide #43-bound PTEN and γ-AAPeptide #42bound PTEN (i, iii) as compared to control (ii). Psi fluctuates greatly between all three structures, with no identifiable pattern
between any of the PTEN structures. All other dihedral angles and their fluctuations in A-H remain consistent throughout all
three PTEN structures. (Phi: black, Psi: blue, Chi1: green, Chi2: magenta, Chi3: red, Chi4, cyan, Chi5: yellow).
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Figure 3.8 (continued). (A) The fluctuations in Phi, Psi and Chi1 angles in N94 are similar between apo-PTEN and γAAPeptide bound PTEN structures. In γ-AAPeptide #42-bound PTEN, the Chi2 angle fluctuates between 0-100° (iii) while
the fluctuations in apo-PTEN and γ-AAPeptide #43-bound PTEN range from -50-0° (i, iii). (B) While Psi flips between -50°
and 150° in K125 in apo-PTEN and γ-AAPeptide #43-bound PTEN structures, Psi is stabilized at approximately -50° in γAAPeptide #42 bound PTEN (iii). (C) Psi in T167 is mostly stabilized at approximately -25° in apo-PTEN and γ-AAPeptide
#42-bound PTEN structures (ii, iii) while it flips between -25° and 125° in γ-AAPeptide #43-bound PTEN (i). Additionally,
Chi1 in
γ-AAPeptide #43-bound PTEN fluctuates more than in apo-PTEN and γ-AAPeptide #42-bound
PTEN. (D) The Phi and Psi angles of C124 between γ-AAPeptide #43-bound PTEN and apo-PTEN are similar in comparison
to γ-AAPeptide #42-bound PTEN, while the Chi1 angles are mostly similar in their fluctuations between γ-AAPeptide #43bound PTEN and
γ-AAPeptide #42-bound PTEN. (E) The Phi and Psi angles in A126 are stabilized in
different positions between all three structures. (F) The G127 Psi angles differ between all three structures. Phi in apo-PTEN
flips between -75° and 75° (ii) while it is stabilized at 75° and -75°, respectively, in γ-AAPeptide #43- and γ-AAPeptide #42bound PTEN (i, iii). (G) Chi3 in R130 apo-PTEN flips between 50° and -75° (ii) while γ-AAPeptide #43- and γ-AAPeptide
#42-bound Chi3 is stabilized at -75° and approximately 50°, respectively (i, iii). (H) The Phi angle in G165 is similar
between γ-AAPeptide #43-bound PTEN and γ-AAPeptide #42-bound PTEN (i, iii) as compared to control (ii). Psi fluctuates
greatly between all three structures, with no identifiable pattern between any of the PTEN structures. All other dihedral angles
and their fluctuations in A-H remain consistent throughout all three PTEN structures. (Phi: black, Psi: blue, Chi1: green,
Chi2: magenta, Chi3: red, Chi4, cyan, Chi5: yellow).
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Conformational Changes in R130 Dictate PIP3 Active Site Binding and Orientation
Interestingly, amongst of all the active site residues, R130 has a distinct profile in the Chi3 dihedral
angle. In apo-PTEN, the Chi3 dihedral angle flips between 50° and -50° while the γ-AAPeptide #43-bound
PTEN stabilizes Chi3 around -50° and γ-AAPeptide #42-bound PTEN stabilizes Chi3 around 50° (Figure
3.8). Since each γ-AAPeptide stabilizes Chi3 at two distinct angles, where apo-PTEN fluctuates between
the two angles, I posited that the R130 orientation may dictate proper PIP3 binding in the active site. To
test this hypothesis, I first utilized the IFD γ-AAPeptide #43-bound PTEN structure after PIP3 was docked
into the active site and changed the orientation of R130 to mimic the γ-AAPeptide #42-bound PTEN
structure. PIP3 was docked into the altered active site with a lower binding affinity (indicated by an
increased binding score) and produced an improper orientation where the 3’ phosphate group was not within
attacking distance from C124 residue (Figure 3.9A). Conversely, I utilized the IFD γ-AAPeptide #42-bound
PTEN structure after PIP3 was docked into the active site and changed the orientation of R130 to mimic
the γ-AAPeptide #43-bound PTEN structure. PIP3 was docked into the altered active site with a higher
binding affinity (indicated by a lower binding score). However, despite this maneuver, the orientation was

Figure 3.9: R130 Contributes to Productive PIP3 Binding and Orientation. (A) After PIP3 was docked into the active site of
γ-AAPeptide #43-bound PTEN via the IFD protocol (binding score: -14.180kcal/mol), the PIP3 molecule was removed and R130
was placed in an alternate conformation which mimicked the conformation found in γ-AAPeptide #42-bound PTEN. PIP3 was
then docked into the active site using the IFD protocol and resulted in a binding score of -12.448kcal/mol in an orientation not
conducive for catalysis. (B) After PIP3 was docked into the active site of γ-AAPeptide #42-bound PTEN via the IFD protocol
(binding score: -11.621kcal/mol), the PIP3 molecule was removed and R130 was placed in an alternate conformation which
mimicked the conformation found in γ-AAPeptide #43-bound PTEN. PIP3 was then docked into the active site using the IFD
protocol and resulted in a binding score of -13.237kcal/mol, also in an orientation not conducive for catalysis.
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not conducive for dephosphorylation, as the 3’ phosphate was positioned away from the catalytic C124
residue (Figure 3.9B).

Conclusion
In this chapter, I employed molecular docking to support the concept that the PD/C2D interface is
a suitable region for γ-AAPeptide binding. Both γ-AAPeptide #43 and #42 make hydrogen bonding contacts
and utilize their aromatic side chains to fit into the mostly non-polar PD/C2D interface. Furthermore, IFD
simulations suggest that PIP3 binding affinity and orientation within the active site can be modulated via
γ-AAPeptide binding. Docking of PIP3 into the PTEN active site after γ -AAPeptide #43 PD/C2D interface
binding enhanced the PIP3 binding affinity and positioned the 3’ phosphate group in a more suitable
position for catalysis as compared to apo-PTEN, suggesting that γ-AAPeptide #43 binding enhances PIP3
catalysis. In contrast, PIP3 binding after γ-AAPeptide #42 PD/C2D interface binding resulted in the loss of
a productive PIP3 binding pose, which corroborates with its inhibitory effect on PIP3 catalysis observed in
vitro. Furthermore, analysis of the IFD simulations and MD simulations suggest that γ-AAPeptide binding
can induce conformational changes in active site residues, which likely accounts for differential PIP3
binding affinity and orientation in apo-PTEN, γ-AAPeptide #43-bound PTEN and γ-AAPeptide #42-bound
PTEN. Taken together, my findings suggest that γ-AAPeptide #43 and #42 can act as an allosteric activator
and an inhibitor, respectively.
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Chapter 4: Defining the Role of PTEN Aggregation Propensity in Diseases

Note to Readers: This chapter have been adopted from my accepted manuscript, “Analyzing Aggregation
Propensities of Clinically Relevant PTEN Mutants: A New Culprit in Pathogenesis of Cancer and Other
PTENopathies” published by Taylor & Francis in The Journal of Biomolecular Structure and Dynamics on June 22,
2019, available online: https://www.tandfonline.com/doi/full/10.1080/07391102.2019.1630005

Background
It is now clear that all proteins have the propensity to aggregate and form fibrils under varying
cellular milieus, favoring partially unfolded intermediate states (Figure 4.1) [339-341]. Consequently,
proteins which are not traditionally defined as amyloidogenic do undergo aggregation as evidenced in
certain cancer pathologies [342, 343]. Recently, tumor suppressor protein p53, and its mutant conformers,
were shown to undergo protein aggregation, exacerbating the cancer phenotype [343-351]. These findings
raise the possibility that inactivation of tumor suppressor proteins via aggregation may participate in cancer
and other disease pathologies.
Since aggregation of select clinically relevant p53 mutants have been demonstrated to inactivate its
function as a tumor suppressor, I posited that PTEN protein aggregation may serve as an additional
mechanism of tumor suppressor inactivation. Indeed, PTEN has structural and functional similarities to
p53, including high mutational propensity, a myriad of PTMs, multiple PPIs, IDRs and oligomerization
properties (Figure 4.2) [32, 33, 352]. PTEN is highly mutated in multiple diseases, where somatic/germline
mutations or PTEN deficiency are seen in cancer patients and patients with PHTS or other PTENopathies
[175, 353-359]. Because PTEN inhibits the oncogenic PI3K pathway, suppresses cell proliferation and
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migration, and induces apoptosis, PTEN mutations or deficiency drives disease pathology [27, 28, 32, 38,
50, 360]. PTEN mutant C124S not only ablates its function, but also exerts dominant negative effects by
dimerizing to PTEN wild-type, similar to select p53 mutants [83, 84]. Therefore, it is indeed possible that
mutations in PTEN may disrupt normal dimerization interfaces or cause abnormal PTMs, which exacerbate
aggregation propensity rather than the normal physiological dimerization. PTEN also acts as a scaffold
protein, nucleating a myriad of proteins via multiple PPIs to regulate cell structure and polarity, as well as
participating in many cellular functions like DNA repair, genomic stability, and metabolism [33, 38, 105,
107, 286]. Since domain swapping, PTMs and oligomerization/PPIs are common characteristics which
augment amyloid fibril formation, I hypothesized that PTEN has inherent aggregation potential in its wildtype state, which gets exacerbated following mutations/deletions encompassing select amino acids in
certain clinical conditions [361-363]. In this chapter, I investigate the aggregation propensity of PTEN wildtype protein and its clinically relevant mutants derived from patients with cancer, PHTS and associated
ASD/macrocephaly phenotypes.

Figure 4.1: Pathway to Protein Aggregation. Destabilization of a natively folded protein monomer, or incomplete folding of a
protein after synthesis yields a non-native, partially folded protein monomer which can take several paths. Cellular machinery can
either utilize Unfolded Protein Response (UPR), where chaperone proteins aid in folding the protein to a native state, or activate
the Endoplasmic Reticulum Associated protein Degradation (ERAD) response, which will degrade non-native protein structures.
When both responses fail, the aberrantly folded monomer are left to associate, yielding nascent oligomeric aggregates. Amorphous
aggregates lack a specific morphology, while oligomeric and annular aggregates adopt a more defined structure and are the
precursors to fibrillary aggregates. Association of oligomeric/annular aggregates generates protofilaments, which align to generate
the final amyloid fibril which is ~6-12nm in diameter and 100nm in length. All aggregate structures contain high β-sheet content
in comparison to their native protein counterparts, with amyloid fibrils having a signature cross-β pattern. The differences in
morphology and β-sheet content allow each type of aggregate to be distinguished by staining and microscopy techniques.
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Figure 4.2: p53 and PTEN Properties Significantly Overlap. Venn diagram comparison of p53 and PTEN reveals that although
these two proteins have distinct functions, they are the two most important tumor suppressor proteins whose aberrant
expression/function contribute to disease pathologies. Additionally, both proteins are involved in mechanisms that drive
aggregation processes, such as the presence of IDRs, myriad of mutations, multimerization, and localization to phase separating
membrane-less organelles. They both undergo a high-level of PTMs which affects their structure, function and overall stability.
p53 has a confirmed aggregation prone region in the wild-type monomer and several mutants have been confirmed to induce
wild-type and mutant conformer aggregation. Multiple similar features of p53 are mirrored by PTEN.

Materials and Methods
Curation of Clinically Relevant PTEN Mutations
Known somatic/germline PTEN protein mutations were curated from several publicly available,
clinically relevant patient databases: The Catalog of Somatic Mutations in Cancer (COSMIC:
https://cancer.sanger.ac.uk/cosmic), The Cancer Genome Atlas (TCGA) (TCGA Research Network:
http://cancergenome.nih.gov/.),

Simons

Foundation

Autism

Research

Initiative

(Sfari)

Gene

(https://gene.sfari.org/), cBio Portal for Cancer Genomics (https://www.cbioportal.org/), The Human Gene
Mutation Database (HGMD: http://www.hgmd.cf.ac.uk/ac/index.php) and Healthy Exosomes (HEX:
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https://www.alzforum.org/exomes/hex) [364-369]. Curation was done as follows: missense/nonsense
mutations were from all of the aforementioned databases, insertion/deletion mutations were from COSMIC,
TCGA, cBio Portal, and frameshift mutations were from COSMIC and Sfari Gene. Once compiled, the
duplications were removed leaving 1,523 distinct mutations, at the cDNA level, for analysis.

TANGO Analysis of Wild-Type and Clinically Relevant PTEN Mutations
Each mutated PTEN sequence along with wild-type PTEN was formatted in a plain text document
as an input file and run through the TANGO algorithm [370]. The website for TANGO (http://tango.crg.es/)
provides explicit instructions on input file format, where information for the analysis of each sequence was
specified as follows: tango Name nt="N" ct="N" ph="7" te="310.15" io="0.1" tf="0" seq="sequence”).
The specifications nt and ct represent capping of the N-terminus or C-terminus, respectively (Y= Yes,
N= No). The pH (ph), temperature (te; in Kelvin), ionic concentrations (io; in Molar units) and organic
solvent (tf; in Molar units) were selected to approximate cellular conditions. The PTEN wild-type or PTEN
mutant sequences were uploaded to TANGO in full. Multiple sequences were provided in the input files,
with one sequence and its corresponding running conditions to a line. A single output file in plain text
formatting was provided for each mutant after the TANGO run, which were compiled into excel
spreadsheets for further analysis. A short linear region is considered to be aggregation-prone if five or more
consecutive amino acid residues have an aggregation score (also known as aggregation propensity or
TANGO score) of ≥5%. Thus, an overall aggregation score was calculated as the average value of the per
residue scores of the entire aggregation-prone region. The data, output and analysis that support the findings
of

this

study

are

openly

available

DOI: http://doi.org/10.17632/3dxhn32c78.2.
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Data

at
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Hydrophobicity Analysis of Wild-Type and Clinically Relevant PTEN Mutations
Mutant PTEN protein sequences that either increased or decreased aggregation propensity of PTEN
wild-type regions, as well as PTEN wild-type protein alone, were run through the Expasy Protscale module,
with a sliding window of three amino acids, to determine the hydrophobicity of each residue in the sequence
based on the Kyte-Doolittle Scale [371]. Each sequence in full was analyzed by the Expasy Protscale
module and the output was downloaded into the excel spreadsheets already created for each respective
sequence. The hydrophobicity score for each aggregation-prone region was calculated as the average
hydrophobicity score of each residue in the aggregation-prone region. The data, output and analysis that
support the findings of this study are openly available in Mendeley Data at reserved
DOI: http://doi.org/10.17632/3dxhn32c78.2.

Secondary Structure Analysis of Wild-Type and Clinically Relevant PTEN Mutations
The

Advanced

Protein

Secondary

Structure

Prediction

algorithm

(APSSP;

http://

imtech.res.in/raghava/apssp/) was used to predict β-sheet (E), ɑ-helix (H) and coil (C) propensity of each
residue in the sequences. Each sequence in full was analyzed by the algorithm and the output was
downloaded into an excel spreadsheet created for each respective sequence. The number of residues per
predicted structures (E, H or C) was counted for each aggregation-prone region and divided by the total
number of residues in the region to determine the contribution of a secondary structure to each aggregationprone region. Change in secondary structure propensity was calculated by subtracting the propensity of a
structure (E, H or C) in the mutant from the propensity of the same structure in wild-type. Positive values
indicated a structural gain, while negative values indicated a structural loss. All changes were reported as
the percent frequency of gained or lost structures. The data, output and analysis that support the findings of
this study are openly available in Mendeley Data at reserved DOI: http://doi.org/10.17632/3dxhn32c78.2.
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Intrinsic Disorder Analysis of Wild-Type and Clinically Relevant PTEN Mutations
The intrinsic disorder meta-analysis predictor DANN was used to determine the intrinsic disorder
propensity of each residue in the sequences [372]. Sequences were run through DANN in FASTA format
and a plain text output file was generated for each sequence. The data was respectively compiled into the
spreadsheets created for each sequence. The intrinsic disorder score for an aggregation-prone region was
calculated as the average intrinsic disorder score of each residue in the region. A score >0 represents
disorder while scores less than <0 are considered ordered. The data, output and analysis that support the
findings

of

this

study

are

openly

available

in

Mendeley

Data

at

reserved

DOI: http://doi.org/10.17632/3dxhn32c78.2.

Statistical Analysis
In order to determine changes in hydrophobicity scores in high or low scoring aggregation-prone
regions dominated by β-sheet, ɑ-helical or coil structure, hydrophobicity values were grouped into five
categories: 1. β-sheet structure (average E score of >0.5) and high aggregation potential (≥50%), n=80; 2.
β-sheet structure (average E score of >0.5) and low aggregation potential (≤50%), n=76; 3. ɑ-helical
structure (average H score of >0.5) and high aggregation potential (≥50%), n=66; 4. ɑ-helical structure
(average H score of >0.5) and low aggregation potential (≤50%), n=53; 5. Coil structure (average C score
of >0.5) for all aggregation prone regions, n=17. The Shapiro-Wilk normality test revealed that three of the
five categories were not normally distributed. Therefore, the non-parametric Kruskal-Wallis test was used
to determine if there were significant differences between the mean ranks differences of hydrophobicity
scores in each category, *p≤0.05. The data, output and analysis that support the findings of this study are
openly available in Mendeley Data at reserved DOI: http://doi.org/10.17632/3dxhn32c78.2.
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Results
PTEN Contains Five Aggregation-Prone Regions
The aggregation predictor TANGO successfully predicted an aggregation-prone region present in
wild-type p53, validating its utility for analysis of PTEN protein and its mutants [343, 350]. Full-length
human PTEN wild-type protein was run through the TANGO algorithm under conditions approximating
the cellular milieu. Five regions in PTEN protein were predicted to be prone to aggregation, including the

Figure 4.3: Putative Aggregation-Prone Regions of PTEN. (A) Schematic of full-length PTEN wild-type protein with the colors
depicting the various domains and critical amino acid sequence stretches. PTEN has an N-terminal PIP2 Binding Module
(aa residues 1-6), a Phosphatase Domain (aa residues 7-185), a C2 Domain (aa residues 186-350) and an intrinsically disordered
C-terminal tail (aa residues 351-403). (B) Aggregation propensity was determined using the algorithm TANGO, providing
physiological conditions (pH 7, 0.1M ionic strength, temperature: 310.15 Kelvin, 0% organic solvent). Five aggregation prone
regions were revealed in PTEN. The regions are differentially highlighted in the PDB 1D5R crystal structure. Accessibility of the
aggregation-prone regions are shown for PTEN as a monomer and as a dimer. Under dephosphorylated conditions, multiple
monomers of PTEN associate at the surfaces of the Phosphatase Domains, while the C-tails of each monomer interact with the
opposing monomers Phosphatase Domain, creating a dimer. This mechanism is known as domain swapping, which is thought to
precede aggregation as it enhances intermolecular interactions between monomers. Since PTEN dimers also have exposed
aggregation-prone regions, aggregation of PTEN wild-type/mutant homo- and hetero-dimers is possible. (C) Protein aggregation
analysis utilizing TANGO revealed five regions of PTEN to have high aggregation propensity. The cβ1 strand has the lowest
aggregation propensity of the 5 regions, at 22%. The residues of the pɑ4 helix (magenta) and the cβ6/cɑ1residues (red) have a peak
propensity of ~40-55%, while the pɑ6 helix (orange) has a peak aggregation propensity of ~55-65%. The cβ7 strand (purple) has
the highest peak aggregation propensity between 80-85%.
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pɑ4 helix (residues 133-140), pɑ6 helix (residues 174-182), cβ1 strand (residues 191-195), cβ6 strand/cɑ1
helix (residues 271-280) and cβ7 strand (residues 315-321) (Figure 4.3). The PTEN cβ7 strand had the
highest aggregation propensity of ~85%, whereas the pɑ4, pɑ6 and cβ6 strand/cɑ1 helix had a predicted
aggregation propensity range between ~50-60% and the cβ1 strand had a predicted aggregation of ~22%
(Figure 4.3C). These aggregation-prone regions are rich in hydrophobic residues (33-100%), poor in polar
(20-66%) or charged residues (0-10%) and are exclusively located within the structured Phosphatase
Domain (PD) and C2 Domain (C2D) of PTEN. Notably, the pɑ4 helix is buried within the core of the PD,
while the other four aggregation sites are exposed to the surface (pɑ6 helix, cβ1 strand, cβ7 strand and cβ6
strand/cɑ1 helix). In summary, PTEN has five putative aggregation-prone regions with distinct physicochemical properties.

Alternative Translational PTEN Proteoforms Have a Distinct Aggregation-Prone Region
The four additional PTEN proteoforms generated via alternative translation were identified to have
increased aggregation propensity compared to wild-type PTEN protein in my analysis (Figure 4.4). PTEN
translational proteoforms L, M, N and O are all produced from alternative initiation codons upstream of the
canonical initiation codon for PTEN wild-type [85]. These N-terminally extended PTEN conformers retain
catalytic phosphatase activity and are diffuse in the cytoplasm, like PTEN wild-type [85]. TANGO analysis
revealed that each translational variant contains a peptide sequence, “LSSFFF,” twelve residues upstream
of the canonical first residue in PTEN, which has a predicted aggregation propensity of ~7-8% (Figure 4.4).
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Figure 4.4: PTEN Alternative Translational Proteoforms Have an Aggregation-Prone Region. Four PTEN proteoforms
(PTEN-L, -M, -N, -O) are generated by alternative translational initiation codons upstream of the canonical AUG start. Each
N-terminal extension contains a unique sequence “LSSFFF” located 12 amino acids upstream of the first amino acid in PTEN
wild-type protein is also aggregation prone.

Curation of Clinically Relevant PTEN Mutations and Their Aggregation Propensities
To examine whether mutations in PTEN influences its aggregation potential, 1,523 known
somatic/germline PTEN protein mutations were identified for curation from several publicly available,
clinically relevant patient databases. Together, these databases comprehensively covered patients with
PTEN-related diseases, including several malignancies/cancer, PHTS, autism spectrum disorders (ASD)
and other neurological disorders/macrocephaly. The databases include COSMIC, TCGA (TCGA Research
Network: http://cancergenome.nih.gov/.), Sfari Gene, cBio Portal, HGMD and HEX [364-369]. Of the
1,523 PTEN mutations analyzed, 91 were insertions/deletions, 880 were missense/nonsense and 601 were
frameshift mutations. Interestingly, 49 of the 601 frameshift mutations produced truncated PTEN protein
with no de novo frame-shifted sequence, like the product of a nonsense mutation. Herein, I redefined these
Table 4.1: PTEN Mutations that Change Aggregation Propensity Compared to PTEN Wild-Type.
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49 mutants and all nonsense mutants as truncations (Table 4.1). Of the 1,523 collective mutations, 274
mutants were predicted to increase aggregation propensity (increased aggregation score and/or increased
length of the aggregation-prone region) and 119 were predicted to decrease aggregation propensity
(decreased aggregation score and/or decreased length of aggregation-prone region) of PTEN wild-type
protein at the mutated residue and/or at the surrounding residues (Table 4.1 and Supplement S2-S3: DOI:
http://doi.org/10.17632/3dxhn32c78.2). Notably, 448 mutants removed one or more aggregation-prone
regions of PTEN in the resulting protein, but did not increase or decrease the aggregation propensity at the
location of the mutation (Supplement S4: DOI: http://doi.org/10.17632/3dxhn32c78.2). In my subsequent
analysis, I focused on mutants that are predicted to increase or decrease the aggregation propensity
at/around the location of the mutation.

Figure 4.5: Select Mutations in PTEN Wild-Type Protein Increase Aggregation Propensity. (A) Representation of the
distribution of the 89 missense/truncation mutations that increase aggregation propensity in PTEN wild-type protein.
(B) Distribution of the 11 insertion/deletion mutations that increase PTEN wild-type aggregation propensity. Boxed amino acids
represent the wild-type residue, numbers represent the amino acid location within wild-type PTEN, and colored amino acids
represent the mutation. Deletion= Del, Insertion= Ins, Duplication= Dup, truncations represented by a red asterisk. Figure not
drawn to scale.

Mutations that Increase Hydrophobicity Enhance Aggregation Propensity of PTEN are Frequent
Mutation of a polar or charged residue to a more hydrophobic residue within or adjacent to
aggregation-prone regions, or highly hydrophobic regions, drastically increased the local predicted
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aggregation propensity of aggregation-prone and non-aggregation-prone regions in PTEN. Of the PTEN
mutants that increased aggregation propensity, approximately 75% of the missense mutants had replaced
the wild-type residue to a hydrophobic residue, while only ~18% and ~7% were mutated to a polar or
charged residue, respectively (Figure 4.5A). All deletion mutations removed one or more charged residue(s)
from the PTEN sequence, and three out of the four insertion mutations inserted one or more hydrophobic
residues into the PTEN sequence (Figure 4.5B).
The frequency difference in various amino acid mutations in PTEN mutants that increased or
decreased aggregation propensity revealed a mutational preference of chemical character. Indeed,
missense/insertion mutations to a hydrophobic residue were more prevalent for mutants that increase
aggregation propensity, as compared to mutants that decrease aggregation propensity (Figure 4.6). Whereas
mutation to a polar or charged residue was more specific to mutants that decreased aggregation propensity
(Figure 4.6). Notably, mutation to lysine or arginine was selective only to mutants that decreased
aggregation propensity, while mutation to tryptophan, phenylalanine or valine was selective only to mutants
that increased aggregation propensity (Figure 4.6).

Figure 4.6: Increased PTEN Aggregation Propensity is Dominated by Hydrophobic Mutations. The frequency of mutation
to each amino acid residue was calculated for missense/truncation/insertion/deletion mutants that increased aggregation propensity
(n=91) and decreased aggregation propensity (n=68). The frequency values for mutants that decrease aggregation propensity was
subtracted from that of mutants which increase aggregation propensity. Negative values indicate a higher mutation frequency in
mutants that decrease aggregation propensity, while positive values represent higher mutation frequency in mutants that increase
aggregation propensity. Blue asterisks indicate amino acids that are specific only to mutants that decrease aggregation (Lysine [K],
Arginine [R]) while red asterisks indicate amino acids that are specific only to mutants that increase aggregation propensity
(Tryptophan [W], Phenylalanine [F], Valine [V]). Mutations to hydrophobic amino acids are much more frequent among PTEN
mutants that increase aggregation propensity of PTEN wild-type, demonstrating the strong influence of hydrophobic character on
aggregation potential.
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Frameshift Mutations in PTEN Severely Affect its Aggregation Potential
Of the 553 PTEN frameshift mutations, 174 mutants exhibited increased aggregation propensity
(Table 4.1), with three mutants demonstrating two aggregation-prone regions in the novel frame-shifted
sequence. Interestingly, 70 aggregation-prone regions occurred at the junction between the wild-type and
frame-shifted sequence, while 37 PTEN frameshift mutations only enhanced the aggregation propensity of
an already aggregation-prone region of PTEN wild-type. The other 108 mutants increased aggregation
propensity after the start of the frameshift, within the novel sequence. Approximately 52% of the
aggregation-prone frameshift mutations have an aggregation propensity of ≥80% (Figure 4.7), indicating
that these frameshift mutations are likely to severely effect PTEN structure and induce aggregation.
Conversely, only 20 frameshift mutants decreased aggregation propensity of an aggregation-prone region
in PTEN wild-type protein (Table 4.1).

Figure 4.7: PTEN Frameshift Mutations Drastically Increase Aggregation Propensity. Of the 552 PTEN frameshift mutations
curated, 174 revealed increase aggregation propensity at or downstream of the frameshift mutation. Each frameshift mutation is
represented as a node. The color of the node indicates the average percent aggregation propensity of 5 consecutive residues with
the highest propensity within the total aggregating region (green: 5-20%; beige: 20-40%; yellow: 40-60%; orange 60-80%; red:
80-100%). A majority of the frameshift mutations (52%) have an aggregation propensity of 80%, indicating that these mutants
likely impact PTEN structure and aggregation propensity.
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Aggregation Propensity is Associated with Highly Ordered Structures
Herein, I interrogated the structural propensities of the PTEN mutants that changed aggregation
propensity. First, it was noted that mutants that increased or decreased aggregation propensity of PTEN
wild-type protein had distinct changes in their secondary structures. Mutations that increase aggregation
propensity tend to increase β-sheet character, as compared to mutants that decrease aggregation propensity,
which predominantly gain coil character (Figure 4.8A). Conversely, when one structure is gained, another
is lost. Thus, mutants that increased aggregation propensity predominantly lost their coil secondary
structure, while mutants that decreased aggregation propensity mostly lost β-sheet or ɑ-helical character
(Figure 4.8A). Overall, β-sheet structure is more frequently observed in mutants that increased aggregation
propensity, while mutants that decreased aggregation propensity lose more ordered structures (ɑ-helix and
β-sheet) to become less structured coils.
Second, a highly accurate intrinsic disorder meta-predictor, DANN, was used to generate the
intrinsic disorder scores for each residue of each PTEN mutant conformer and the average disorder score
was calculated for the aggregation-prone region [372]. DANN predictions revealed that PTEN mutants
which increased aggregation propensity are highly structured, with only 1.4% (4 out of 277 aggregationprone regions) of aggregation-prone regions predicted to be disordered (Figure 4.8B). Conversely, select
mutations which ablated aggregation potential in aggregation-prone regions demonstrated intrinsic disorder
propensity, while mutations causing decreased, albeit prevalent, aggregation propensity remained highly
structured (Figure 4.8B).
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Figure 4.8: PTEN Mutants that Increase Aggregation Propensity Favor Ordered Structures. (A) Of the 274 PTEN mutants
with increased aggregation propensity, 136 changed the aggregation propensity of one or more wild-type residues. The difference
in structural propensity of β-sheets (E), α-helices (H) and coiled-coils (C) was calculated (mutant – wild-type) and the regions
which gained or lost a structure was determined. In total, there were 45 different structural losses among the mutants (one mutant
can lose one or more of the three structures), yielding 43 structural gains (one mutant can gain one or more of the three structures).
There is a high tendency for mutants which increase aggregation propensity to cause a shift from a coiled-coil structure (lost) to a
β-sheet (gained). Of the 119 mutants that decreased aggregation propensity of PTEN wild-type, there were 66 structural losses and
68 structural gains. Mutants that decrease aggregation propensity have a much higher tendency to lose more ordered structures like
β-sheets and α-helices and adopt a less ordered coiled-coil structure. (B) Intrinsic disorder analysis using the algorithm DANN
shows that mutation-induced increase in aggregation potential falls in highly structured regions of PTEN. Only 1.4% of
aggregation-prone regions (4/277) are intrinsically disordered. n=277. PTEN mutants which decrease aggregation propensity of
PTEN wild-type can increase intrinsic disorder propensity. Only select mutants which have 0% aggregation propensity are
intrinsically disordered, while aggregation-prone regions in mutants that retain some degree of aggregation potential remain
ordered structures. n= 119. DANN scores and TANGO scores were calculated as the average score of all residues in the aggregation
prone region. DANN score values greater than 0 indicate disordered regions, values less than 0 indicate ordered regions.

Contribution of Structural and Chemical Properties to PTEN Conformer Aggregation
Since structural and chemical properties have a great influence over protein aggregation, PTEN
mutants that increase or decrease aggregation potential were analyzed for changes in two critical factors
that drive protein aggregation, i.e.

3D structural alterations and chemical characteristics such as
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hydrophobicity. To define the physico-chemical properties that render a select number of PTEN mutants
aggregation-prone to varying degrees (TANGO score above 5%), the degree of hydrophobicity within three
distinct secondary structures was analyzed. Advanced Protein Secondary Structure Prediction was utilized
to predict structural propensity, which included extended β-sheet (E), ɑ-helical (H) or coil (C) regions.
Notably, PTEN aggregation-prone regions in pathogenic mutants are fairly split between β-sheet and ɑhelical structures, with 156 and 151 aggregation-prone structures, respectively. Only 17 mutants were
dominated by a coil structure. Therefore, mutants dominated by β-sheets and ɑ-helices were then split into
high scoring (≥50% aggregation score) and low scoring aggregation (<50% aggregation score) and all coil
structures were grouped together. Analysis of the distribution of hydrophobicity scores (using the KyteDoolittle [KD] prediction available through ProtScale) revealed that regions with high aggregation potential

Figure 4.9: Both Hydrophobicity and Secondary Structure Influence the Degree of Aggregation Propensity. Distribution of
hydrophobicity scores of high and low scoring aggregating regions in PTEN mutants, based on their dominant structure (average
structural propensity of >0.5). Mutants that increased and decreased PTEN wild-type aggregation propensity were considered in
the analysis, under the condition that they contained an aggregation-prone region (5 consecutive residues of 5% or more
aggregation score). β-sheet structures are shown in dark and light red, ɑ-helical structures are shown in dark and light blue and
coiled-coil structures are shown in green. Since only several aggregation prone-regions were dominated by coiled-coil structure,
these aggregation-prone regions were not separated into high/low aggregating categories in order to keep a larger sample size
suitable for statistical analysis. A Kruskal-Wallis test revealed that PTEN mutants with high aggregation propensity and dominant
β-sheet characteristic have a significantly higher hydrophobicity score, as compared to low aggregation scoring mutants with
β-sheet characteristics and all aggregating mutants with ɑ-helical or coiled-coil structure (*p<0.05). High scoring β-sheet
structures, n=80; low scoring β-sheet structures, n=76; high scoring ɑ-helical structures, n=66; low scoring ɑ-helical structures,
n=53; coiled-coil structures, n=17. Hydrophobicity score is based off the Kyte-Doolittle index.

86

and β-sheet character had a higher hydrophobicity score, as compared to β-sheet structures with low
aggregation potential and all ɑ-helical and coil aggregation-prone regions (Figure 4.9).

Conclusion
The role of protein aggregation in cancer as a means to inactivate tumor suppressor functions has
recently emerged, with p53 protein as the most well-known example. Like p53, PTEN is a highly mutated
tumor suppressor protein with multiple intrinsic properties which can augment aggregation when altered
[352]. However, until now, the aggregation potential of PTEN has not been interrogated. In this chapter, I
elucidated five putative aggregation-prone regions in full-length human PTEN wild-type protein.
Additionally, I identified >270 mutants which increase the aggregation propensity of PTEN wild-type.
Consistent with studies on bona fide amyloidogenic proteins, PTEN mutants with high aggregation
potential demonstrated tendencies for high hydrophobicity and ordered regions of the protein, with a
tendency for β-sheet formation. My analysis suggests that PTEN mutants found in cancer, and other
PTENopathies, may drive disease progression via aggregation. Ultimately, validation of PTEN aggregation
in vivo will likely catalyze the development of novel therapeutics targeting PTEN protein aggregation in
multiple diseases.

87

Chapter 5: Discussion
Current therapies for diseases, including cancer, associated with hyperactive PI3K pathway
signaling largely rely on a myriad of kinase inhibitors that target multiple kinases driving the PI3K cascade.
However, these kinase inhibitor therapies cause off-target effects associated with varying toxicities and
therapy-resistance, warranting the need for novel therapy approaches [287]. To fill this therapy gap,
enhancing intracellular PTEN activity represents a novel alternative therapeutic paradigm to mitigate
pathogenic PI3K signaling or compromised PTEN levels or function. [303]. PTEN mutations driving
multiple diseases and cancer is well established [4, 8, 33]. However, it is increasingly becoming clear that
reduction in PTEN function or expression due to non-genomic PTEN inactivation (i.e. transcriptional,
post-transcriptional and post-translational mechanisms) is a major driver in disease initiation and
progression across multiple tissue types [32, 33]. Thus, my thesis is based on the premise that enhancing
the intracellular enzymatic activity and function of residual PTEN protein in such diseases is potentially a
novel therapeutic strategy.
Recently, PTEN restoration therapy has proved to successfully suppress tumorigenic features in
cancer cell lines and preclinical studies, limiting or resolving tumor burden in these models [88, 288-295,
297, 298]. Thus, re-activation or enhancement of endogenous PTEN activity/function is an attractive
alternative or adjunctive therapy to existing standard chemotherapies and kinase inhibitors. While
restoration of endogenous intracellular PTEN level holds promise as a future clinical therapy; delivery
modes for PTEN gene or protein for therapy remain challenging in the clinic. To this end, my work has
focused on developing small molecules that enhance PTEN activity in cells with residual PTEN expression
and hyperactive PI3K pathway signaling. I have successfully identified one lead small molecule that
directly targets PTEN protein and enhances its lipid phosphatase activity in biochemical and cell-based
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assays. To my knowledge, this strategy is the first of its kind that reduces oncogenic potential of cancer
cells by directly enhancing PTEN enzymatic activity.
To develop small molecules that enhance PTEN activity, I first utilized FTMap analysis to identify
a small molecule binding hotspot on PTEN at the interface of the PD/C2D. Targeting this region in vitro
using a synthesized peptide which competitively binds to the interface enhanced PTEN lipid phosphatase
activity in a biochemical in vitro microtiter plate assay. I then identified a select small molecule
peptidomimetic, a γ-AAPeptide subclass containing an adamantyl ring, which enhanced PTEN enzymatic
activity in vitro and suppressed PI3K pathway signaling in A549 lung cancer and OVCAR3 ovarian cancer
cells. Moreover, treatment with this promising peptidomimetic, γ-AAPeptide #43, decreased cell
proliferation, migration and cell cycle progression, inhibiting the oncogenic potential of lung cancer cells
harboring wild-type PTEN protein. Taken together, these results indicate that γ-AAPeptide #43 directly
enhances PTEN lipid phosphatase activity in vitro and likely targets endogenous PTEN in cell-based assays.
Notably, all γ-AAPeptides containing an adamantyl side chain were able to enhance PTEN lipid
phosphatase activity in vitro, with the exception of γ-AAPeptide #42. These in vitro studies suggest that
these select γ-AAPeptides rely on an adamantyl containing side chain for specific binding while additional
functional groups modulate their effects on PTEN function.
Since both FTMap analysis and titration with a synthetic helical peptide mimicking the pɑ6 helix
implicated the PD/C2D interface as a probable small molecule binding hotspot, I hypothesized that
γ-AAPeptides target the PD/C2D interface and elicit their modulatory effects on PTEN activity. To test this
hypothesis, molecular docking studies were employed to determine the binding affinity of γ-AAPeptides
for this interface. IFD predicted favorable binding of both activator γ-AAPeptide #43 and inhibitor
γ-AAPeptide #42, suggesting that γ-AAPeptides harboring aromatic and adamantyl side chain(s) are
suitable to directly target this interdomain region. Secondary IFD docking analysis using the PTEN
substrate, PIP3, revealed that prior binding of activator γ-AAPeptide #43 at the PD/C2D interface could
enhance PIP3 active site binding, with a productive orientation that would allow for catalytic 3’ phosphate
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dephosphorylation. In contrast, prior binding with inhibitor γ-AAPeptide #42 resulted in increased affinity
for PIP3 active site binding; however, the binding did not place the 3’ phosphate within an ideal distance
for nucleophilic attack by the catalytic cysteine residue. These docking results corroborate well with my in
vitro studies, highlighting the differential effects of γ-AAPeptides on PIP3 hydrolysis.
Furthermore, MD simulations suggest that select γ-AAPeptide binding can stabilize PTEN active
site residues, which likely accounts for differential PIP3 binding and orientation in the active site. IFD
analysis of γ-AAPeptide #43 and #42 PD/C2D interface binding demonstrated that each γ-AAPeptide
makes distinct contacts within the PD/C2D domain interface; therefore, it is likely that these differential
interactions modulate their enhancement or inhibitory effects on PTEN lipid phosphatase activity. Taken
together, γ-AAPeptides are suitable small molecule peptidomimetics to target PTEN protein for therapeutic
purposes. Furthermore, I have identified the first small molecule which directly regulates PTEN lipid
phosphatase activity, likely through allosteric regulation of the PTEN active site conformation.
PTEN enzymatic activity has been showed to be modulated by allosteric mechanisms in multiple
fashions. A recent study has demonstrated the ability of select mutations, especially in the PD and C2D, to
alter PTEN core structure, translating to the active site and functionally abrogating enzymatic activity [373].
In addition, PTEN is allosterically activated by binding to PIP2 at the N-terminal PIP2 binding module [58,
62-64]. PIP2 binding at the PIP2 binding motif, distinct from the active site, results in conformation changes
in PTEN and enhanced PIP3 hydrolysis [65]. My PTEN enzyme kinetics studies are consistent with the
notion of allostery. Thus, the use of small molecules, like γ-AAPeptide #43, to induce conformational
changes in PTEN which allosterically enhance phosphatase activity is plausible. Herein, my work
exemplifies the benefits of targeting PTEN wild-type to enhance catalytic activity as a means to counteract
PI3K pathway hyperactivation.
In addition to non-genomic mechanisms which suppress PTEN wild-type function, mutationinduced PTEN inactivation is observed in almost all types of cancers and with high frequency in prostate,
brain, skin and endometrial cancers, as well as in patients with PHTS [4, 12, 13, 52]. Since PTEN is a
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frequently mutated tumor suppressor protein like p53, with shared structural commonalities like IDRs,
PTMs, and oligomerization properties [32, 33, 352], I hypothesized that similar mechanisms that drive p53
inactivation observed in diseases may exist for certain select PTEN mutants. To this end, I derived more
than 1,500 clinically relevant PTEN mutants from various patient databases and interrogated PTEN
inactivation mechanisms, focusing to aggregation, as seen with select p53 mutants. These p53 mutants are
observed to aggregate in vitro, in cancer cell lines and in patient biopsies, ultimately inactivating
endogenous p53 tumor suppressor functions, accelerating the cancer phenotype [343-351]. Since the
aggregation propensity of PTEN wild-type or mutant PTEN has not been characterized, I tested the
hypothesis that select clinically relevant PTEN mutations found in patients may functionally inactive
endogenous intracellular PTEN by driving aggregation.
Indeed, my studies revealed that protein aggregation is a novel potential mechanism of inactivation
for PTEN mutants that may drive disease pathogenesis in cancer and PHTS. I searched publicly available
patient databases for known PTEN missense, nonsense, insertion/deletion and frameshift mutations and
used online algorithms to predict each mutant’s aggregation propensity by TANGO, hydrophobicity by
Expasy’s Protscale KD index and secondary structure of PTEN and its mutants utilizing APSSP. I first
identified five regions of predicted aggregation in the PTEN wild-type core domains. Furthermore, my
analysis revealed >270 distinct PTEN mutations in patients with increased aggregation propensity
compared to PTEN wild-type protein. Aggregation prone regions induced by mutations are largely evenly
split between β-sheet and α-helical structures; however, there is a significant trend towards increased
hydrophobicity following a mutation in PTEN. Further analysis revealed that high aggregation scoring
mutants with dominant β-sheet characteristics have an increased hydrophobicity score as compared to other
high/low aggregation scoring structures. Thus, my work indicates that future verification of PTEN mutant
aggregation in vivo is warranted to define aggregation as a bona fide inactivation mechanism that may be
pathogenic for select PTEN mutants. Furthermore, my analysis will also aid in the generation of small
molecules which can target the specific physico-chemical properties of PTEN mutants, resulting in the
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dissolution of PTEN aggregates, freeing endogenous PTEN for functional re-activation as a disease
treatment.
In summary, my work highlights the critical utility of small molecules in PTEN restoration therapy.
Enhancing endogenous PTEN wild-type activity via γ-AAPeptide #43 antagonized PI3K pathway signaling
and suppressed oncogenic features of tumor progression. This therapy would be most beneficial for cancer
patients with hyperactive PI3K pathway signaling resulting from an aberration in PI3K pathway kinases,
or reduced PTEN expression driven by non-genomic mechanisms. Additionally, targeted re-activation of
PTEN mutants remains an important avenue of therapy in patients with cancers or PHTS, where a PTEN
mutation drives disease pathology. Future assessment of mutant PTEN aggregation-induced functional
inactivation will aid in the development of clinically relevant small molecules that target pathogenic PTEN
aggregates for dissolution, generating free, active PTEN molecules for restoration of PTEN function.
Notably, γ-AAPeptides have been shown to disrupt Aβ amyloid found in the brains of patients with
Alzheimer’s, indicating γ-AAPeptides can be generated to target protein aggregates for dissolution [309].
Thus, small molecule based PTEN restoration therapy provides a novel alternative or adjunctive therapy
that can be used to develop a personalized clinical rationale for treating multiple diseases, including a
myriad of malignancies driven by compromised PTEN activity/function and/or hyperactive PI3K pathway
signaling.
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Appendix A: Supplementary Data

Table A1: HPLC purities and retention time of compounds. γ-AAPeptides 11, 12, 14, 39, and 43 were analyzed following our
previous report [7].

Compound Name

Purity (based on analytical HPLC) (%)

Retention Time (min)

5

98.04

23.59

8

97.92

24.55

9

98.16

26.11

10

99.75

29.39

40

96.01

27.40

109

Figure A1: 1H-NMR data of select γ-AAPeptides. (A) γ-AAPeptide #5. 1H-NMR (500 MHz, d6-DMSO) δ 10.17 (d, J = 19.0
Hz, 0.4H), 9.96 (d, J = 19.0 Hz, 0.6H), 8.60 (d, J = 8.5 Hz, 0.4H), 8.49 (d, J = 8.5 Hz, 0.3H), 8.37 (t, J = 8.0 Hz, 0.4H), 8.01‒8.13
(m, 4H), 7.92‒7.96 (m, 1H), 7.76–7.83 (m, 4H), 7.63–7.67 (m, 0.5H), 7.48–7.58 (m, 4H), 7.15‒7.33 (m, 5H), 4.11–4.52 (m, 3H),
3.51–3.80 (m, 4.2H), 3.19‒3.29 (m, 0.8H), 2.98 (d, J = 13.5 Hz, 0.6H), 2.72–2.88 (m, 2.4H), 2.53–2.68 (m, 2.7H), 2.18‒2.27 (m,
0.7H), 2.08‒2.14 (m, 0.8H), 1.86–2.01 (m, 3.6H), 1.51‒1.69 (m, 14.5H), 1.15–1.45 (m, 3.3H), 0.89‒0.98 (m, 0.5H), 0.72‒0.78 (m,
0.4H). HRMS (ESI) C39H52N5O3 [M+H]+ calc’d = 638.4065; found = 638.4086. (B) γ-AAPeptide #8. 1H-NMR (500 MHz, d6DMSO) δ 8.63 (d, J = 8.0 Hz, 0.7H), 8.54 (t, J = 5.0 Hz, 0.4H), 8.36 (d, J = 8.5 Hz, 1.7H), 8.28 (t, J = 5.0 Hz, 0.6H), 8.10‒8.14
(m, 1.6H), 7.99‒8.05 (m, 0.8H), 7.93 (d, J = 6.5 Hz, 1H), 7.67‒7.72 (m, 1H), 7.51‒7.62 (m, 4.4H), 7.16‒7.30 (m, 5.8H), 6.52 (s,
0.8H), 5.27‒6.36 (m, 1.5H), 4.10‒4.18 (m, 1H), 4.01 (dd, J = 14.5, 7.5 Hz, 1H), 3.94 (t, J = 8.5 Hz, 1H), 3.71‒3.79 (m, 0.7H),
3.58‒3.67 (m, 1.2H), 2.88‒3.16 (m, 2.7H), 2.67‒2.76 (m, 4H), 2.62 (s, 0.5H), 2.35 (s, 0.5H), 2.14‒2.17 (m, 0.6H), 1.98 (s, 1.8H),
1.87 (brs, 2H), 1.80 (brs, 2H), 1.72‒1.77 (m, 1H), 1.44‒1.66 (m, 16H), 1.23 (br, 1.8H), 1.16 (t, J = 7.0 Hz, 2.5H), HRMS (ESI)
C44H56N5O3 [M+H]+ calc’d = 702.4378; found = 702.4396. (C) γ-AAPeptide #9. 1H-NMR (500 MHz, d6-DMSO) δ 8.48 (d, J
= 8.5 Hz, 0.4H), 8.25 (d, J = 8.5 Hz, 0.5H), 8.15 (d, J = 8.5 Hz, 0.5H), 8.05 (d, J = 8.5 Hz, 0.6 H), 7.93–7.99 (m, 4.8H), 7.83–7.90
(m, 3H), 7.69–7.72 (m, 3H), 7.48–7.57 (m, 4.2H), 4.36–7.43 (m, 3.6H), 7.25–7.28 (m, 1H), 7.07–7.21 (m, 5H), 4.91¬–5.31 (m,
4.3H), 4.14–4.37 (m, 2.5H), 3.97–4.06 (m, 1H), 3.27–3.34 (m, 1.5H), 2.91 (td, J = 14.0, 4.0 Hz, 0.4H), 2.70–2.82 (m, 1.5H), 2.62–
2.68 (m, 1.4H), 2.54–2.58 (m, 1.4H), 2.33 (d, J = 13.0 Hz, 0.6H), 1.90 (s, 1.7H), 1.70–1.87 (m, 3H), 1.56–1.66 (m, 8.4H), 1.49–
1.52 (m, 0.9H), 1.38–1.46 (m, 6.1H), 1.26–1.34 (m, 1.5H), 1.13–1.24 (m, 1.3H), 1.02–1.09 (m, 0.5H), 0.94–1.00 (m, 0.5H), 0.81–
0.92 (m, 0.2H), 0.66–0.73 (m, 0.2H). HRMS (ESI) C51H62N5O3 [M+H]+ calc’d = 792.4847; found = 792.4878. (D) γ-AAPeptide
#10. 1H-NMR (500 MHz, d6-DMSO) δ 8.48 (dd, J = 15.5, 8.5 Hz, 0.7H), 8.29 (d, J = 8.0 Hz, 0.3H), 8.24 (d, J = 8.0 Hz, 0.3H),
8.13 (d, J = 8.5 Hz, 0.3H), 7.99–8.02 (m, 2H), 7.94–7.97 (m, 2.5H), 7.87–7.92 (m, 1.5H), 7.80–7.84 (m, 2.2H), 7.68–7.73 (m,
3.3H), 7.55–7.60 (m, 1H), 7.50–7.53 (m, 0.8H), 7.44–7.50 (m, 0.6H), 7.32–7.41 (m, 1.2H), 7.27–7.30 (m, 2H), 7.20–7.24 (m,
1.6H), 7.08–7.18 (m, 1.5H), 5.06–5.22 (m, 1.7H), 4.73–4.96 (m, 1.8H), 4.62 (d, J = 15.5 Hz, 0.3H), 4.40 (d, J = 16.0 Hz, 0.3H),
4.30 (td, J = 18.5, 6.0 Hz, 0.8H), 3.99–4.24 (m, 2H), 3.27–3.35 (m, 2H), 3.07–3.15 (m, 0.6H), 2.87–2.91 (m, 0.4H), 2.57–2.83 (m,
4H), 2.28–2.36 (m, 1H), 1.03 (t, J = 6.0 Hz, 1H), 1.88 (brd, 1H), 1.71–1.82 (m, 2.3H), 1.54–1.67 (m, 10H), 1.13–1.48 (m, 5H),
0.96–1.10 (m, 1.3H). HRMS (ESI) C49H58F6N5O3 [M+H]+ calc’d = 878.4438; found = 878.4469. (E) γ-AAPeptide #40. 1HNMR (500 MHz, d6-DMSO) δ 10.89 (d, J = 2.0 Hz, 0.5H), 10.75 (d, J = 2.0 Hz, 0.3H), 8.61 (t, J = 5.5 Hz, 0.4H), 8.48 (d, J =
8.5Hz, 0.4H), 8.30 (t, J = 6.0 Hz, 0.5H), 8.24 (d, J = 8.5 Hz, 0.3H), 8.05–8.10 (m, 2.7H), 2.93–7.96 (m, 1.8H), 7.82–7.88 (m, 1.2H),
7.58–7.68 (m, 3H), 7.50–7.57 (m, 2.4H), 7.40–7.47 (m, 2H), 7.30–7.37 (m, 1H), 7.18–7.22 (m, 0.6H), 7.02–7.10 (m, 1H), 6.97–
6.70 (m, 0.6H), 6.93 (t, J = 7.5 Hz, 0.5H), 4.76 (d, J = 5.5 Hz, 0.6H), 4.72 (d, J = 6.0 Hz, 1H), 4.27–4.33 (m, 0.7H), 4.07–4.16 (m,
1H), 3.87 (d, J = 16.0 Hz, 0.6H), 3.62–3.67 (m, 1.7H), 3.07–3.15 (m, 1.8H), 2.96 (dd, J = 14.5, 4.0 Hz, 1H), 2.81 (d, J = 7.5 Hz,
1H), 2.60–2.64 (m, 1.4H), 2.35 (t, J = 2.0 Hz, 0.5H), 1.84–1.93 (m, 3H), 1.67–1.76 (m, 3H), 1.38–1.62 (m, 12.8H), 1.22–1.33 (m,
4H), 1.09–1.17 (m, 1.6H), 0.97–1.05 (m, 0.9H), 0.76–0.95 (m, 0.8H). HRMS (ESI) C42H55N6O3 [M+H]+ calc’d = 691.4330;
found = 691.4357.
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Figure A1 (continued). (A) γ-AAPeptide #5. 1H-NMR (500 MHz, d6-DMSO) δ 10.17 (d, J = 19.0 Hz, 0.4H), 9.96 (d, J = 19.0
Hz, 0.6H), 8.60 (d, J = 8.5 Hz, 0.4H), 8.49 (d, J = 8.5 Hz, 0.3H), 8.37 (t, J = 8.0 Hz, 0.4H), 8.01‒8.13 (m, 4H), 7.92‒7.96 (m, 1H),
7.76–7.83 (m, 4H), 7.63–7.67 (m, 0.5H), 7.48–7.58 (m, 4H), 7.15‒7.33 (m, 5H), 4.11–4.52 (m, 3H), 3.51–3.80 (m, 4.2H), 3.19‒
3.29 (m, 0.8H), 2.98 (d, J = 13.5 Hz, 0.6H), 2.72–2.88 (m, 2.4H), 2.53–2.68 (m, 2.7H), 2.18‒2.27 (m, 0.7H), 2.08‒2.14 (m, 0.8H),
1.86–2.01 (m, 3.6H), 1.51‒1.69 (m, 14.5H), 1.15–1.45 (m, 3.3H), 0.89‒0.98 (m, 0.5H), 0.72‒0.78 (m, 0.4H). HRMS (ESI)
C39H52N5O3 [M+H]+ calc’d = 638.4065; found = 638.4086. (B) γ-AAPeptide #8. 1H-NMR (500 MHz, d6-DMSO) δ 8.63 (d, J
= 8.0 Hz, 0.7H), 8.54 (t, J = 5.0 Hz, 0.4H), 8.36 (d, J = 8.5 Hz, 1.7H), 8.28 (t, J = 5.0 Hz, 0.6H), 8.10‒8.14 (m, 1.6H), 7.99‒8.05
(m, 0.8H), 7.93 (d, J = 6.5 Hz, 1H), 7.67‒7.72 (m, 1H), 7.51‒7.62 (m, 4.4H), 7.16‒7.30 (m, 5.8H), 6.52 (s, 0.8H), 5.27‒6.36 (m,
1.5H), 4.10‒4.18 (m, 1H), 4.01 (dd, J = 14.5, 7.5 Hz, 1H), 3.94 (t, J = 8.5 Hz, 1H), 3.71‒3.79 (m, 0.7H), 3.58‒3.67 (m, 1.2H),
2.88‒3.16 (m, 2.7H), 2.67‒2.76 (m, 4H), 2.62 (s, 0.5H), 2.35 (s, 0.5H), 2.14‒2.17 (m, 0.6H), 1.98 (s, 1.8H), 1.87 (brs, 2H), 1.80
(brs, 2H), 1.72‒1.77 (m, 1H), 1.44‒1.66 (m, 16H), 1.23 (br, 1.8H), 1.16 (t, J = 7.0 Hz, 2.5H), HRMS (ESI) C44H56N5O3 [M+H]+
calc’d = 702.4378; found = 702.4396. (C) γ-AAPeptide #9. 1H-NMR (500 MHz, d6-DMSO) δ 8.48 (d, J = 8.5 Hz, 0.4H), 8.25 (d,
J = 8.5 Hz, 0.5H), 8.15 (d, J = 8.5 Hz, 0.5H), 8.05 (d, J = 8.5 Hz, 0.6 H), 7.93–7.99 (m, 4.8H), 7.83–7.90 (m, 3H), 7.69–7.72 (m,
3H), 7.48–7.57 (m, 4.2H), 4.36–7.43 (m, 3.6H), 7.25–7.28 (m, 1H), 7.07–7.21 (m, 5H), 4.91¬–5.31 (m, 4.3H), 4.14–4.37 (m,
2.5H), 3.97–4.06 (m, 1H), 3.27–3.34 (m, 1.5H), 2.91 (td, J = 14.0, 4.0 Hz, 0.4H), 2.70–2.82 (m, 1.5H), 2.62–2.68 (m, 1.4H), 2.54–
2.58 (m, 1.4H), 2.33 (d, J = 13.0 Hz, 0.6H), 1.90 (s, 1.7H), 1.70–1.87 (m, 3H), 1.56–1.66 (m, 8.4H), 1.49–1.52 (m, 0.9H), 1.38–
1.46 (m, 6.1H), 1.26–1.34 (m, 1.5H), 1.13–1.24 (m, 1.3H), 1.02–1.09 (m, 0.5H), 0.94–1.00 (m, 0.5H), 0.81–0.92 (m, 0.2H), 0.66–
0.73 (m, 0.2H). HRMS (ESI) C51H62N5O3 [M+H]+ calc’d = 792.4847; found = 792.4878. (D) γ-AAPeptide #10. 1H-NMR (500
MHz, d6-DMSO) δ 8.48 (dd, J = 15.5, 8.5 Hz, 0.7H), 8.29 (d, J = 8.0 Hz, 0.3H), 8.24 (d, J = 8.0 Hz, 0.3H), 8.13 (d, J = 8.5 Hz,
0.3H), 7.99–8.02 (m, 2H), 7.94–7.97 (m, 2.5H), 7.87–7.92 (m, 1.5H), 7.80–7.84 (m, 2.2H), 7.68–7.73 (m, 3.3H), 7.55–7.60 (m,
1H), 7.50–7.53 (m, 0.8H), 7.44–7.50 (m, 0.6H), 7.32–7.41 (m, 1.2H), 7.27–7.30 (m, 2H), 7.20–7.24 (m, 1.6H), 7.08–7.18 (m,
1.5H), 5.06–5.22 (m, 1.7H), 4.73–4.96 (m, 1.8H), 4.62 (d, J = 15.5 Hz, 0.3H), 4.40 (d, J = 16.0 Hz, 0.3H), 4.30 (td, J = 18.5, 6.0
Hz, 0.8H), 3.99–4.24 (m, 2H), 3.27–3.35 (m, 2H), 3.07–3.15 (m, 0.6H), 2.87–2.91 (m, 0.4H), 2.57–2.83 (m, 4H), 2.28–2.36 (m,
1H), 1.03 (t, J = 6.0 Hz, 1H), 1.88 (brd, 1H), 1.71–1.82 (m, 2.3H), 1.54–1.67 (m, 10H), 1.13–1.48 (m, 5H), 0.96–1.10 (m, 1.3H).
HRMS (ESI) C49H58F6N5O3 [M+H]+ calc’d = 878.4438; found = 878.4469. (E) γ-AAPeptide #40. 1H-NMR (500 MHz, d6DMSO) δ 10.89 (d, J = 2.0 Hz, 0.5H), 10.75 (d, J = 2.0 Hz, 0.3H), 8.61 (t, J = 5.5 Hz, 0.4H), 8.48 (d, J = 8.5Hz, 0.4H), 8.30 (t, J =
6.0 Hz, 0.5H), 8.24 (d, J = 8.5 Hz, 0.3H), 8.05–8.10 (m, 2.7H), 2.93–7.96 (m, 1.8H), 7.82–7.88 (m, 1.2H), 7.58–7.68 (m, 3H),
7.50–7.57 (m, 2.4H), 7.40–7.47 (m, 2H), 7.30–7.37 (m, 1H), 7.18–7.22 (m, 0.6H), 7.02–7.10 (m, 1H), 6.97–6.70 (m, 0.6H), 6.93
(t, J = 7.5 Hz, 0.5H), 4.76 (d, J = 5.5 Hz, 0.6H), 4.72 (d, J = 6.0 Hz, 1H), 4.27–4.33 (m, 0.7H), 4.07–4.16 (m, 1H), 3.87 (d, J = 16.0
Hz, 0.6H), 3.62–3.67 (m, 1.7H), 3.07–3.15 (m, 1.8H), 2.96 (dd, J = 14.5, 4.0 Hz, 1H), 2.81 (d, J = 7.5 Hz, 1H), 2.60–2.64 (m,
1.4H), 2.35 (t, J = 2.0 Hz, 0.5H), 1.84–1.93 (m, 3H), 1.67–1.76 (m, 3H), 1.38–1.62 (m, 12.8H), 1.22–1.33 (m, 4H), 1.09–1.17 (m,
1.6H), 0.97–1.05 (m, 0.9H), 0.76–0.95 (m, 0.8H). HRMS (ESI) C42H55N6O3 [M+H]+ calc’d = 691.4330; found = 691.4357.
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Figure A1 (continued). (A) γ-AAPeptide #5. 1H-NMR (500 MHz, d6-DMSO) δ 10.17 (d, J = 19.0 Hz, 0.4H), 9.96 (d, J = 19.0
Hz, 0.6H), 8.60 (d, J = 8.5 Hz, 0.4H), 8.49 (d, J = 8.5 Hz, 0.3H), 8.37 (t, J = 8.0 Hz, 0.4H), 8.01‒8.13 (m, 4H), 7.92‒7.96 (m,
1H), 7.76–7.83 (m, 4H), 7.63–7.67 (m, 0.5H), 7.48–7.58 (m, 4H), 7.15‒7.33 (m, 5H), 4.11–4.52 (m, 3H), 3.51–3.80 (m, 4.2H),
3.19‒3.29 (m, 0.8H), 2.98 (d, J = 13.5 Hz, 0.6H), 2.72–2.88 (m, 2.4H), 2.53–2.68 (m, 2.7H), 2.18‒2.27 (m, 0.7H), 2.08‒2.14 (m,
0.8H), 1.86–2.01 (m, 3.6H), 1.51‒1.69 (m, 14.5H), 1.15–1.45 (m, 3.3H), 0.89‒0.98 (m, 0.5H), 0.72‒0.78 (m, 0.4H). HRMS
(ESI) C39H52N5O3 [M+H]+ calc’d = 638.4065; found = 638.4086. (B) γ-AAPeptide #8. 1H-NMR (500 MHz, d6-DMSO) δ
8.63 (d, J = 8.0 Hz, 0.7H), 8.54 (t, J = 5.0 Hz, 0.4H), 8.36 (d, J = 8.5 Hz, 1.7H), 8.28 (t, J = 5.0 Hz, 0.6H), 8.10‒8.14 (m, 1.6H),
7.99‒8.05 (m, 0.8H), 7.93 (d, J = 6.5 Hz, 1H), 7.67‒7.72 (m, 1H), 7.51‒7.62 (m, 4.4H), 7.16‒7.30 (m, 5.8H), 6.52 (s, 0.8H),
5.27‒6.36 (m, 1.5H), 4.10‒4.18 (m, 1H), 4.01 (dd, J = 14.5, 7.5 Hz, 1H), 3.94 (t, J = 8.5 Hz, 1H), 3.71‒3.79 (m, 0.7H), 3.58‒3.67
(m, 1.2H), 2.88‒3.16 (m, 2.7H), 2.67‒2.76 (m, 4H), 2.62 (s, 0.5H), 2.35 (s, 0.5H), 2.14‒2.17 (m, 0.6H), 1.98 (s, 1.8H), 1.87 (brs,
2H), 1.80 (brs, 2H), 1.72‒1.77 (m, 1H), 1.44‒1.66 (m, 16H), 1.23 (br, 1.8H), 1.16 (t, J = 7.0 Hz, 2.5H), HRMS (ESI)
C44H56N5O3 [M+H]+ calc’d = 702.4378; found = 702.4396. (C) γ-AAPeptide #9. 1H-NMR (500 MHz, d6-DMSO) δ 8.48 (d, J
= 8.5 Hz, 0.4H), 8.25 (d, J = 8.5 Hz, 0.5H), 8.15 (d, J = 8.5 Hz, 0.5H), 8.05 (d, J = 8.5 Hz, 0.6 H), 7.93–7.99 (m, 4.8H), 7.83–
7.90 (m, 3H), 7.69–7.72 (m, 3H), 7.48–7.57 (m, 4.2H), 4.36–7.43 (m, 3.6H), 7.25–7.28 (m, 1H), 7.07–7.21 (m, 5H), 4.91¬–5.31
(m, 4.3H), 4.14–4.37 (m, 2.5H), 3.97–4.06 (m, 1H), 3.27–3.34 (m, 1.5H), 2.91 (td, J = 14.0, 4.0 Hz, 0.4H), 2.70–2.82 (m, 1.5H),
2.62–2.68 (m, 1.4H), 2.54–2.58 (m, 1.4H), 2.33 (d, J = 13.0 Hz, 0.6H), 1.90 (s, 1.7H), 1.70–1.87 (m, 3H), 1.56–1.66 (m, 8.4H),
1.49–1.52 (m, 0.9H), 1.38–1.46 (m, 6.1H), 1.26–1.34 (m, 1.5H), 1.13–1.24 (m, 1.3H), 1.02–1.09 (m, 0.5H), 0.94–1.00 (m, 0.5H),
0.81–0.92 (m, 0.2H), 0.66–0.73 (m, 0.2H). HRMS (ESI) C51H62N5O3 [M+H]+ calc’d = 792.4847; found = 792.4878. (D) γAAPeptide #10. 1H-NMR (500 MHz, d6-DMSO) δ 8.48 (dd, J = 15.5, 8.5 Hz, 0.7H), 8.29 (d, J = 8.0 Hz, 0.3H), 8.24 (d, J = 8.0
Hz, 0.3H), 8.13 (d, J = 8.5 Hz, 0.3H), 7.99–8.02 (m, 2H), 7.94–7.97 (m, 2.5H), 7.87–7.92 (m, 1.5H), 7.80–7.84 (m, 2.2H), 7.68–
7.73 (m, 3.3H), 7.55–7.60 (m, 1H), 7.50–7.53 (m, 0.8H), 7.44–7.50 (m, 0.6H), 7.32–7.41 (m, 1.2H), 7.27–7.30 (m, 2H), 7.20–
7.24 (m, 1.6H), 7.08–7.18 (m, 1.5H), 5.06–5.22 (m, 1.7H), 4.73–4.96 (m, 1.8H), 4.62 (d, J = 15.5 Hz, 0.3H), 4.40 (d, J = 16.0
Hz, 0.3H), 4.30 (td, J = 18.5, 6.0 Hz, 0.8H), 3.99–4.24 (m, 2H), 3.27–3.35 (m, 2H), 3.07–3.15 (m, 0.6H), 2.87–2.91 (m, 0.4H),
2.57–2.83 (m, 4H), 2.28–2.36 (m, 1H), 1.03 (t, J = 6.0 Hz, 1H), 1.88 (brd, 1H), 1.71–1.82 (m, 2.3H), 1.54–1.67 (m, 10H), 1.13–
1.48 (m, 5H), 0.96–1.10 (m, 1.3H). HRMS (ESI) C49H58F6N5O3 [M+H]+ calc’d = 878.4438; found = 878.4469. (E) γAAPeptide #40. 1H-NMR (500 MHz, d6-DMSO) δ 10.89 (d, J = 2.0 Hz, 0.5H), 10.75 (d, J = 2.0 Hz, 0.3H), 8.61 (t, J = 5.5 Hz,
0.4H), 8.48 (d, J = 8.5Hz, 0.4H), 8.30 (t, J = 6.0 Hz, 0.5H), 8.24 (d, J = 8.5 Hz, 0.3H), 8.05–8.10 (m, 2.7H), 2.93–7.96 (m, 1.8H),
7.82–7.88 (m, 1.2H), 7.58–7.68 (m, 3H), 7.50–7.57 (m, 2.4H), 7.40–7.47 (m, 2H), 7.30–7.37 (m, 1H), 7.18–7.22 (m, 0.6H),
7.02–7.10 (m, 1H), 6.97–6.70 (m, 0.6H), 6.93 (t, J = 7.5 Hz, 0.5H), 4.76 (d, J = 5.5 Hz, 0.6H), 4.72 (d, J = 6.0 Hz, 1H), 4.27–
4.33 (m, 0.7H), 4.07–4.16 (m, 1H), 3.87 (d, J = 16.0 Hz, 0.6H), 3.62–3.67 (m, 1.7H), 3.07–3.15 (m, 1.8H), 2.96 (dd, J = 14.5, 4.0
Hz, 1H), 2.81 (d, J = 7.5 Hz, 1H), 2.60–2.64 (m, 1.4H), 2.35 (t, J = 2.0 Hz, 0.5H), 1.84–1.93 (m, 3H), 1.67–1.76 (m, 3H), 1.38–
1.62 (m, 12.8H), 1.22–1.33 (m, 4H), 1.09–1.17 (m, 1.6H), 0.97–1.05 (m, 0.9H), 0.76–0.95 (m, 0.8H). HRMS (ESI)
C42H55N6O3 [M+H]+ calc’d = 691.4330; found = 691.4357.
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Figure A1 (continued). (A) γ-AAPeptide #5. 1H-NMR (500 MHz, d6-DMSO) δ 10.17 (d, J = 19.0 Hz, 0.4H), 9.96 (d, J = 19.0
Hz, 0.6H), 8.60 (d, J = 8.5 Hz, 0.4H), 8.49 (d, J = 8.5 Hz, 0.3H), 8.37 (t, J = 8.0 Hz, 0.4H), 8.01‒8.13 (m, 4H), 7.92‒7.96 (m, 1H),
7.76–7.83 (m, 4H), 7.63–7.67 (m, 0.5H), 7.48–7.58 (m, 4H), 7.15‒7.33 (m, 5H), 4.11–4.52 (m, 3H), 3.51–3.80 (m, 4.2H), 3.19‒
3.29 (m, 0.8H), 2.98 (d, J = 13.5 Hz, 0.6H), 2.72–2.88 (m, 2.4H), 2.53–2.68 (m, 2.7H), 2.18‒2.27 (m, 0.7H), 2.08‒2.14 (m, 0.8H),
1.86–2.01 (m, 3.6H), 1.51‒1.69 (m, 14.5H), 1.15–1.45 (m, 3.3H), 0.89‒0.98 (m, 0.5H), 0.72‒0.78 (m, 0.4H). HRMS (ESI)
C39H52N5O3 [M+H]+ calc’d = 638.4065; found = 638.4086. (B) γ-AAPeptide #8. 1H-NMR (500 MHz, d6-DMSO) δ 8.63 (d, J
= 8.0 Hz, 0.7H), 8.54 (t, J = 5.0 Hz, 0.4H), 8.36 (d, J = 8.5 Hz, 1.7H), 8.28 (t, J = 5.0 Hz, 0.6H), 8.10‒8.14 (m, 1.6H), 7.99‒8.05
(m, 0.8H), 7.93 (d, J = 6.5 Hz, 1H), 7.67‒7.72 (m, 1H), 7.51‒7.62 (m, 4.4H), 7.16‒7.30 (m, 5.8H), 6.52 (s, 0.8H), 5.27‒6.36 (m,
1.5H), 4.10‒4.18 (m, 1H), 4.01 (dd, J = 14.5, 7.5 Hz, 1H), 3.94 (t, J = 8.5 Hz, 1H), 3.71‒3.79 (m, 0.7H), 3.58‒3.67 (m, 1.2H),
2.88‒3.16 (m, 2.7H), 2.67‒2.76 (m, 4H), 2.62 (s, 0.5H), 2.35 (s, 0.5H), 2.14‒2.17 (m, 0.6H), 1.98 (s, 1.8H), 1.87 (brs, 2H), 1.80
(brs, 2H), 1.72‒1.77 (m, 1H), 1.44‒1.66 (m, 16H), 1.23 (br, 1.8H), 1.16 (t, J = 7.0 Hz, 2.5H), HRMS (ESI) C44H56N5O3 [M+H]+
calc’d = 702.4378; found = 702.4396. (C) γ-AAPeptide #9. 1H-NMR (500 MHz, d6-DMSO) δ 8.48 (d, J = 8.5 Hz, 0.4H), 8.25 (d,
J = 8.5 Hz, 0.5H), 8.15 (d, J = 8.5 Hz, 0.5H), 8.05 (d, J = 8.5 Hz, 0.6 H), 7.93–7.99 (m, 4.8H), 7.83–7.90 (m, 3H), 7.69–7.72 (m,
3H), 7.48–7.57 (m, 4.2H), 4.36–7.43 (m, 3.6H), 7.25–7.28 (m, 1H), 7.07–7.21 (m, 5H), 4.91¬–5.31 (m, 4.3H), 4.14–4.37 (m,
2.5H), 3.97–4.06 (m, 1H), 3.27–3.34 (m, 1.5H), 2.91 (td, J = 14.0, 4.0 Hz, 0.4H), 2.70–2.82 (m, 1.5H), 2.62–2.68 (m, 1.4H), 2.54–
2.58 (m, 1.4H), 2.33 (d, J = 13.0 Hz, 0.6H), 1.90 (s, 1.7H), 1.70–1.87 (m, 3H), 1.56–1.66 (m, 8.4H), 1.49–1.52 (m, 0.9H), 1.38–
1.46 (m, 6.1H), 1.26–1.34 (m, 1.5H), 1.13–1.24 (m, 1.3H), 1.02–1.09 (m, 0.5H), 0.94–1.00 (m, 0.5H), 0.81–0.92 (m, 0.2H), 0.66–
0.73 (m, 0.2H). HRMS (ESI) C51H62N5O3 [M+H]+ calc’d = 792.4847; found = 792.4878. (D) γ-AAPeptide #10. 1H-NMR (500
MHz, d6-DMSO) δ 8.48 (dd, J = 15.5, 8.5 Hz, 0.7H), 8.29 (d, J = 8.0 Hz, 0.3H), 8.24 (d, J = 8.0 Hz, 0.3H), 8.13 (d, J = 8.5 Hz,
0.3H), 7.99–8.02 (m, 2H), 7.94–7.97 (m, 2.5H), 7.87–7.92 (m, 1.5H), 7.80–7.84 (m, 2.2H), 7.68–7.73 (m, 3.3H), 7.55–7.60 (m,
1H), 7.50–7.53 (m, 0.8H), 7.44–7.50 (m, 0.6H), 7.32–7.41 (m, 1.2H), 7.27–7.30 (m, 2H), 7.20–7.24 (m, 1.6H), 7.08–7.18 (m,
1.5H), 5.06–5.22 (m, 1.7H), 4.73–4.96 (m, 1.8H), 4.62 (d, J = 15.5 Hz, 0.3H), 4.40 (d, J = 16.0 Hz, 0.3H), 4.30 (td, J = 18.5, 6.0
Hz, 0.8H), 3.99–4.24 (m, 2H), 3.27–3.35 (m, 2H), 3.07–3.15 (m, 0.6H), 2.87–2.91 (m, 0.4H), 2.57–2.83 (m, 4H), 2.28–2.36 (m,
1H), 1.03 (t, J = 6.0 Hz, 1H), 1.88 (brd, 1H), 1.71–1.82 (m, 2.3H), 1.54–1.67 (m, 10H), 1.13–1.48 (m, 5H), 0.96–1.10 (m, 1.3H).
HRMS (ESI) C49H58F6N5O3 [M+H]+ calc’d = 878.4438; found = 878.4469. (E) γ-AAPeptide #40. 1H-NMR (500 MHz, d6DMSO) δ 10.89 (d, J = 2.0 Hz, 0.5H), 10.75 (d, J = 2.0 Hz, 0.3H), 8.61 (t, J = 5.5 Hz, 0.4H), 8.48 (d, J = 8.5Hz, 0.4H), 8.30 (t, J =
6.0 Hz, 0.5H), 8.24 (d, J = 8.5 Hz, 0.3H), 8.05–8.10 (m, 2.7H), 2.93–7.96 (m, 1.8H), 7.82–7.88 (m, 1.2H), 7.58–7.68 (m, 3H),
7.50–7.57 (m, 2.4H), 7.40–7.47 (m, 2H), 7.30–7.37 (m, 1H), 7.18–7.22 (m, 0.6H), 7.02–7.10 (m, 1H), 6.97–6.70 (m, 0.6H), 6.93
(t, J = 7.5 Hz, 0.5H), 4.76 (d, J = 5.5 Hz, 0.6H), 4.72 (d, J = 6.0 Hz, 1H), 4.27–4.33 (m, 0.7H), 4.07–4.16 (m, 1H), 3.87 (d, J = 16.0
Hz, 0.6H), 3.62–3.67 (m, 1.7H), 3.07–3.15 (m, 1.8H), 2.96 (dd, J = 14.5, 4.0 Hz, 1H), 2.81 (d, J = 7.5 Hz, 1H), 2.60–2.64 (m,
1.4H), 2.35 (t, J = 2.0 Hz, 0.5H), 1.84–1.93 (m, 3H), 1.67–1.76 (m, 3H), 1.38–1.62 (m, 12.8H), 1.22–1.33 (m, 4H), 1.09–1.17 (m,
1.6H), 0.97–1.05 (m, 0.9H), 0.76–0.95 (m, 0.8H). HRMS (ESI) C42H55N6O3 [M+H]+ calc’d = 691.4330; found = 691.4357.
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Figure A1 (continued). (A) γ-AAPeptide #5. 1H-NMR (500 MHz, d6-DMSO) δ 10.17 (d, J = 19.0 Hz, 0.4H), 9.96 (d, J = 19.0
Hz, 0.6H), 8.60 (d, J = 8.5 Hz, 0.4H), 8.49 (d, J = 8.5 Hz, 0.3H), 8.37 (t, J = 8.0 Hz, 0.4H), 8.01‒8.13 (m, 4H), 7.92‒7.96 (m, 1H),
7.76–7.83 (m, 4H), 7.63–7.67 (m, 0.5H), 7.48–7.58 (m, 4H), 7.15‒7.33 (m, 5H), 4.11–4.52 (m, 3H), 3.51–3.80 (m, 4.2H), 3.19‒
3.29 (m, 0.8H), 2.98 (d, J = 13.5 Hz, 0.6H), 2.72–2.88 (m, 2.4H), 2.53–2.68 (m, 2.7H), 2.18‒2.27 (m, 0.7H), 2.08‒2.14 (m, 0.8H),
1.86–2.01 (m, 3.6H), 1.51‒1.69 (m, 14.5H), 1.15–1.45 (m, 3.3H), 0.89‒0.98 (m, 0.5H), 0.72‒0.78 (m, 0.4H). HRMS (ESI)
C39H52N5O3 [M+H]+ calc’d = 638.4065; found = 638.4086. (B) γ-AAPeptide #8. 1H-NMR (500 MHz, d6-DMSO) δ 8.63 (d, J
= 8.0 Hz, 0.7H), 8.54 (t, J = 5.0 Hz, 0.4H), 8.36 (d, J = 8.5 Hz, 1.7H), 8.28 (t, J = 5.0 Hz, 0.6H), 8.10‒8.14 (m, 1.6H), 7.99‒8.05
(m, 0.8H), 7.93 (d, J = 6.5 Hz, 1H), 7.67‒7.72 (m, 1H), 7.51‒7.62 (m, 4.4H), 7.16‒7.30 (m, 5.8H), 6.52 (s, 0.8H), 5.27‒6.36 (m,
1.5H), 4.10‒4.18 (m, 1H), 4.01 (dd, J = 14.5, 7.5 Hz, 1H), 3.94 (t, J = 8.5 Hz, 1H), 3.71‒3.79 (m, 0.7H), 3.58‒3.67 (m, 1.2H),
2.88‒3.16 (m, 2.7H), 2.67‒2.76 (m, 4H), 2.62 (s, 0.5H), 2.35 (s, 0.5H), 2.14‒2.17 (m, 0.6H), 1.98 (s, 1.8H), 1.87 (brs, 2H), 1.80
(brs, 2H), 1.72‒1.77 (m, 1H), 1.44‒1.66 (m, 16H), 1.23 (br, 1.8H), 1.16 (t, J = 7.0 Hz, 2.5H), HRMS (ESI) C44H56N5O3 [M+H]+
calc’d = 702.4378; found = 702.4396. (C) γ-AAPeptide #9. 1H-NMR (500 MHz, d6-DMSO) δ 8.48 (d, J = 8.5 Hz, 0.4H), 8.25 (d,
J = 8.5 Hz, 0.5H), 8.15 (d, J = 8.5 Hz, 0.5H), 8.05 (d, J = 8.5 Hz, 0.6 H), 7.93–7.99 (m, 4.8H), 7.83–7.90 (m, 3H), 7.69–7.72 (m,
3H), 7.48–7.57 (m, 4.2H), 4.36–7.43 (m, 3.6H), 7.25–7.28 (m, 1H), 7.07–7.21 (m, 5H), 4.91¬–5.31 (m, 4.3H), 4.14–4.37 (m,
2.5H), 3.97–4.06 (m, 1H), 3.27–3.34 (m, 1.5H), 2.91 (td, J = 14.0, 4.0 Hz, 0.4H), 2.70–2.82 (m, 1.5H), 2.62–2.68 (m, 1.4H), 2.54–
2.58 (m, 1.4H), 2.33 (d, J = 13.0 Hz, 0.6H), 1.90 (s, 1.7H), 1.70–1.87 (m, 3H), 1.56–1.66 (m, 8.4H), 1.49–1.52 (m, 0.9H), 1.38–
1.46 (m, 6.1H), 1.26–1.34 (m, 1.5H), 1.13–1.24 (m, 1.3H), 1.02–1.09 (m, 0.5H), 0.94–1.00 (m, 0.5H), 0.81–0.92 (m, 0.2H), 0.66–
0.73 (m, 0.2H). HRMS (ESI) C51H62N5O3 [M+H]+ calc’d = 792.4847; found = 792.4878. (D) γ-AAPeptide #10. 1H-NMR (500
MHz, d6-DMSO) δ 8.48 (dd, J = 15.5, 8.5 Hz, 0.7H), 8.29 (d, J = 8.0 Hz, 0.3H), 8.24 (d, J = 8.0 Hz, 0.3H), 8.13 (d, J = 8.5 Hz,
0.3H), 7.99–8.02 (m, 2H), 7.94–7.97 (m, 2.5H), 7.87–7.92 (m, 1.5H), 7.80–7.84 (m, 2.2H), 7.68–7.73 (m, 3.3H), 7.55–7.60 (m,
1H), 7.50–7.53 (m, 0.8H), 7.44–7.50 (m, 0.6H), 7.32–7.41 (m, 1.2H), 7.27–7.30 (m, 2H), 7.20–7.24 (m, 1.6H), 7.08–7.18 (m,
1.5H), 5.06–5.22 (m, 1.7H), 4.73–4.96 (m, 1.8H), 4.62 (d, J = 15.5 Hz, 0.3H), 4.40 (d, J = 16.0 Hz, 0.3H), 4.30 (td, J = 18.5, 6.0
Hz, 0.8H), 3.99–4.24 (m, 2H), 3.27–3.35 (m, 2H), 3.07–3.15 (m, 0.6H), 2.87–2.91 (m, 0.4H), 2.57–2.83 (m, 4H), 2.28–2.36 (m,
1H), 1.03 (t, J = 6.0 Hz, 1H), 1.88 (brd, 1H), 1.71–1.82 (m, 2.3H), 1.54–1.67 (m, 10H), 1.13–1.48 (m, 5H), 0.96–1.10 (m, 1.3H).
HRMS (ESI) C49H58F6N5O3 [M+H]+ calc’d = 878.4438; found = 878.4469. (E) γ-AAPeptide #40. 1H-NMR (500 MHz, d6DMSO) δ 10.89 (d, J = 2.0 Hz, 0.5H), 10.75 (d, J = 2.0 Hz, 0.3H), 8.61 (t, J = 5.5 Hz, 0.4H), 8.48 (d, J = 8.5Hz, 0.4H), 8.30 (t, J =
6.0 Hz, 0.5H), 8.24 (d, J = 8.5 Hz, 0.3H), 8.05–8.10 (m, 2.7H), 2.93–7.96 (m, 1.8H), 7.82–7.88 (m, 1.2H), 7.58–7.68 (m, 3H),
7.50–7.57 (m, 2.4H), 7.40–7.47 (m, 2H), 7.30–7.37 (m, 1H), 7.18–7.22 (m, 0.6H), 7.02–7.10 (m, 1H), 6.97–6.70 (m, 0.6H), 6.93
(t, J = 7.5 Hz, 0.5H), 4.76 (d, J = 5.5 Hz, 0.6H), 4.72 (d, J = 6.0 Hz, 1H), 4.27–4.33 (m, 0.7H), 4.07–4.16 (m, 1H), 3.87 (d, J = 16.0
Hz, 0.6H), 3.62–3.67 (m, 1.7H), 3.07–3.15 (m, 1.8H), 2.96 (dd, J = 14.5, 4.0 Hz, 1H), 2.81 (d, J = 7.5 Hz, 1H), 2.60–2.64 (m,
1.4H), 2.35 (t, J = 2.0 Hz, 0.5H), 1.84–1.93 (m, 3H), 1.67–1.76 (m, 3H), 1.38–1.62 (m, 12.8H), 1.22–1.33 (m, 4H), 1.09–1.17 (m,
1.6H), 0.97–1.05 (m, 0.9H), 0.76–0.95 (m, 0.8H). HRMS (ESI) C42H55N6O3 [M+H]+ calc’d = 691.4330; found = 691.4357.

114

Figure A2: γ-AAPeptide #42 Inhibits PTEN Lipid Phosphatase Activity. γ-AAPeptide #42 was titrated and measured for
changes in PTEN lipid phosphatase activity using Malachite Green assay, n=4. Values reported as mean ± SE.
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Figure A3: γ-AAPeptide Binding Does Not Induce Conformational Changes in Select Active Site Residues. (A-I) Molecular
dynamics simulations reveal that residues E91, D92, H93, H123, T160, R161, K163, V166, and I168 have similar fluctuations and
orientations of their dihedral angles between apo-PTEN and γ-AAPeptide-bound PTEN. (Phi: black, Psi: blue, Chi1: green, Chi2:
magenta, Chi3: red, Chi4, cyan, Chi5: yellow).
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Figure A3 (continued). (A-I) Molecular dynamics simulations reveal that residues E91, D92, H93, H123, T160, R161, K163,
V166, and I168 have similar fluctuations and orientations of their dihedral angles between apo-PTEN and γ-AAPeptide-bound
PTEN. (Phi: black, Psi: blue, Chi1: green, Chi2: magenta, Chi3: red, Chi4, cyan, Chi5: yellow).
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